<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> CONTRAFECT Corp (Form: 10-K, Received: 03/15/2016 17:33:34) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_STOCKHOLDERS_EQUITY_2 **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_3 **FIS_CERTIFICATE_OF_INCORPORATION FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_10_3 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="170">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="D109824D10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="LINE-HEIGHT:1.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:17PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:17PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:11PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Washington, DC 20549
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:17PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form 10-K
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	(Mark One)
</B>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:11PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
</B>
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	For the fiscal year ended December&nbsp;31, 2015
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	OR
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:11PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
</B>
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Commission File Number: 001-36577
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:23PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	ContraFect
	Corporation
</B>
</P>
<P STYLE="MARGIN-TOP:3PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	Delaware
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	39-2072586
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(State or other jurisdiction of
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	incorporation or organization)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(IRS Employer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Identification No.)
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	28 Wells Avenue, 3
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	rd
</SUP>
	Floor
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Yonkers, NY
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	10701
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	(Address of principal executive offices)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	(Zip Code)
</B>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Registrant&#146;s telephone number, including area code:
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(914) 207-2300
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Securities
	registered pursuant to Section&nbsp;12(b) of the Act:
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:44.80PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Title of Class
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:137.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Name of Exchange on Which Registered
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Common Stock, Par Value $0.0001 per share
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Class A warrant, exercisable for one share of common stock
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	NASDAQ Capital Market
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	NASDAQ Capital Market
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Securities registered pursuant to Section&nbsp;12(g) of the Act: None
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
	Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
	Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
	Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
	days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
	File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
	files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be
	contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form
	10-K.&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act.
	(Check one):
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;PAGE-BREAK-BEFORE:ALWAYS">
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT" ALIGN="CENTER">
<TR>
<TD WIDTH="16%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="19%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="1%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT">
<TD VALIGN="BOTTOM">
	Large&nbsp;accelerated&nbsp;filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Accelerated&nbsp;filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:9PT">
<TD VALIGN="BOTTOM">
	Non-accelerated filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;(Do not check if a smaller reporting company)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Smaller&nbsp;reporting&nbsp;company
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
	Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#168;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">
	&#120;
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of June&nbsp;30, 2015, the last business day of the registrant&#146;s most recently completed second fiscal quarter, the aggregate market
	value of the registrant&#146;s common stock held by non-affiliates of the registrant was approximately $120.0 million, based on the closing price of the registrant&#146;s common stock on the NASDAQ Capital Market on June&nbsp;30, 2015 of $5.25 per
	share.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:3%; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of March 9, 2016, there were 27,484,005 shares of Common Stock, $0.0001 par value per share, outstanding.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:9PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
<P STYLE="FONT-SIZE:4PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:1.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<A NAME="eolPage2"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TOC">
</A>
	Table of contents
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="87%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER">
<B>
	Page
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="6" ALIGN="CENTER">
<B>
	PART I
</B>
</TD>
<TD VALIGN="TOP">
<B>
	&nbsp;&nbsp;
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 1.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_1">
	Business
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item&nbsp;1A.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_2">
	Risk Factors
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 1B.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_3">
	Unresolved Staff Comments
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 2.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_4">
	Properties
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 3.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_5">
	Legal Proceedings
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 4.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_6">
	Mine Safety Disclosures
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="7">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="6" ALIGN="CENTER">
<B>
	PART II
</B>
</TD>
<TD VALIGN="TOP">
<B>
	&nbsp;&nbsp;
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 5.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_7">
	Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 6.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_8">
	Selected Financial Data
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 7.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_9">
	Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 7A.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_10">
	Quantitative and Qualitative Disclosures about Market Risk
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 8.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_11">
	Financial Statements and Supplementary Data
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 9.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_12">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 9A.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_13">
	Controls and Procedures
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 9B.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_14">
	Other Information
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	72
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="7">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="6" ALIGN="CENTER">
<B>
	PART III
</B>
</TD>
<TD VALIGN="TOP">
<B>
	&nbsp;&nbsp;
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 10.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_15">
	Directors, Executive Officers and Corporate Governance
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	73
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 11.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_16">
	Executive Compensation
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	79
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item&nbsp;12.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_17">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	87
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 13.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_18">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	90
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 14.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_19">
	Principal Accounting Fees and Services
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="7">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="6" ALIGN="CENTER">
<B>
	PART&nbsp;IV
</B>
</TD>
<TD VALIGN="TOP">
<B>
	&nbsp;&nbsp;
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Item 15.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_ROM109824_20">
	Exhibits and Financial Statement Schedules
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	93
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	i
</P>
<A NAME="eolPage3"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	References to ContraFect
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Throughout this Annual Report on Form 10-K, the &#147;Company,&#148; &#147;ContraFect,&#148; &#147;we,&#148; &#147;us,&#148; and
	&#147;our,&#148; except where the context requires otherwise, refer to ContraFect Corporation, and &#147;our board of directors&#148; refers to the board of directors of ContraFect Corporation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	All brand names or trademarks appearing in this Annual Report on Form 10-K are the property of their respective holders.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Forward Looking Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	information in this Annual Report on Form 10-K contains forward-looking statements and information within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities
	Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#147;safe harbor&#148; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future
	operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;expects&#148;, &#147;intends&#148;,
	&#147;targets&#148;, &#147;may&#148;, &#147;plans&#148;, &#147;projects&#148;, &#147;potential&#148;, &#147;will&#148;, &#147;would&#148;, &#147;could&#148; and similar expressions are intended to identify forward-looking statements, although not
	all forward-looking statements contain these identifying words. All such forward-looking statements involve significant risks and uncertainties, including, but not limited to, statements regarding:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the success, cost, timing and potential indications of our product development activities and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to advance into and through clinical development and ultimately obtain FDA approval for our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our future marketing and sales programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the rate and degree of market acceptance of our product candidates and our expectations regarding the size of the commercial markets for our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our research and development plans and ability to bring forward additional product candidates into preclinical and clinical development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the effect of competition and proprietary rights of third parties;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the availability of and our ability to obtain additional financing;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the effects of existing and future federal, state and foreign regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with third parties; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the period of time for which our existing cash and cash equivalents will enable us to fund our operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As more fully described under the heading &#147;Risk Factors&#148; contained elsewhere in this Annual Report on Form 10-K, many important
	factors affect our ability to achieve our stated objectives and to develop and commercialize any product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not
	place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without
	limitation, the risks and uncertainties set forth in our filings with the SEC. You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding
	that our actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking statements are applicable only as of the date on which they are made,
	and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	ii
</P>
<A NAME="eolPage4"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_1">
</A>
	Item&nbsp;1. Business
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment
	of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Drug-resistant infections account for two million illnesses in the United States and 700,000 deaths
	worldwide each year. We intend to address drug-resistant infections using product candidates from our lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Lysins are enzymes derived from naturally
	occurring bacteriophage which are viruses that infect bacteria. When recombinantly produced and then applied to bacteria, lysins cleave a key component of the target bacteria&#146;s peptidoglycan cell wall, which results in rapid bacterial cell
	death. Lysins kill bacteria faster than conventional antibiotics, which typically require bacterial cell division and metabolism in order to kill or stop the growth of bacteria. We believe that the properties of our lysins will make them suitable
	for targeting antibiotic-resistant organisms, such as Staphylococcus aureus (&#147;
<I>
	Staph aureus&#148;)
</I>
	which causes serious infections such as bacteremia, pneumonia and osteomyelitis. In addition, our lysins have demonstrated the ability to
	clear biofilms in animal models, and we believe they may be useful for the treatment of biofilm-related infections in prosthetic joints, indwelling devices and catheters. Beyond our lysin programs, we are exploring therapies using monoclonal
	antibodies (&#147;mAbs&#148;) designed to bind to viral targets. Our approach to antibody therapy employs a combination of multiple mAbs to either achieve greater efficacy or provide broader coverage across pathogenic strains.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In August 2015, our most advanced lysin product candidate, CF-301, was granted fast track designation for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, including endocarditis. CF-301 recently concluded a Phase 1 single ascending dose study in healthy volunteers. The study was designed as a randomized, double-blind, placebo-controlled trial in order to evaluate the safety, tolerability
	and pharmacokinetics of CF-301 alone, administered as a two hour IV infusion. As specified in the protocol, an independent data safety monitoring board (the &#147;DSMB&#148;) reviewed the safety, tolerability, and pharmacokinetic data from healthy
	volunteers dosed in all of the planned cohorts. The DSMB observed no clinical adverse safety signals associated with CF-301 in the study. We intend to pursue an initial indication for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, including
	endocarditis, caused by methicillin-resistant (&#147;MRSA&#148;) or methicillin-susceptible (&#147;MSSA&#148;)
<I>
	Staph aureus
</I>
	. We believe CF-301 may also be developed for the treatment of
<I>
	Staph aureus
</I>
	pneumonia, osteomyelitis, and
	biofilm-related infections in prosthetic joints, indwelling devices and catheters. Our second product candidate, CF-404, is a combination of three human mAbs for the treatment of life-threatening human influenza, including all seasonal and most
	pandemic varieties. We are also advancing earlier stage programs that leverage the lysin and monoclonal antibody platforms.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Strategy
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our strategy is to use our therapeutic products to achieve a leading market position in the treatment of life-threatening infectious diseases,
	including those caused by drug-resistant pathogens. We plan to pursue commercialization of therapeutic products through discovery, acquisition and development as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Advance our lead product candidate, CF-301, through clinical trials and demonstrate superiority of our therapy combined with standard-of-care (&#147;SOC&#148;) drugs over SOC alone for the treatment of
<I>
	Staph
	aureus
</I>
	bacteremia;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Advance CF-404 through preclinical studies and clinical trials for the treatment of life-threatening complicated influenza;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Advance additional product candidates from our lysin portfolio, including lysins to gram-negative bacteria;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Acquire additional foundation technologies that enable the efficient discovery of anti-infective agents; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Acquire clinical stage therapies that treat infectious diseases through unique mechanisms of action.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	1
</P>
<A NAME="eolPage5"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Indications
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Staph aureus bacteremia
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the United States (&#147;U.S.&#148;) alone there are approximately 120,000 cases annually of
<I>
	Staph aureus
</I>
	bacteremia, a bloodstream
	infection, which causes approximately 30,000 deaths.
<I>
	Staph aureus
</I>
	bacteremia can be further complicated when the infection spreads into the heart muscle, heart valves or lining of the heart, causing endocarditis. Even with current SOC
	antibiotic therapy, the resulting damage to the heart muscle or heart valves could require surgery to prevent stroke, heart failure or severe organ damage. Of further concern, drug-resistant strains of
<I>
	Staph aureus
</I>
	are now evolving additional
	resistance against SOC antibiotics, which may ultimately result in an increase in the number of cases and in mortality from
<I>
	Staph aureus
</I>
	bacteremia, including endocarditis.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Influenza
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On a global
	basis, approximately 20% of children and 5% of adults develop symptomatic influenza annually, resulting in approximately 4&nbsp;million severe cases and 375,000 deaths each year. Of further concern, despite the widespread availability of annual
	vaccines in the U.S., approximately 30 million people will contract influenza, resulting in an average of over 200,000 hospitalizations and up to 49,000 influenza-associated deaths each year in the U.S. alone.&nbsp;Because of reduced vaccine
	effectiveness against the predominant circulating influenza virus in the 2014-2015 season, approximately 40 million people contracted influenza, resulting in over 970,000 flu-associated hospitalizations. As a result of genetic drift and genetic
	shift, mutations in influenza occur each year as it circulates through the population. These mutations may result in drug-resistance of the virus and ineffectiveness of the vaccine, which causes the need for annual reformulation of the vaccine. In
	addition, influenza has multiple chromosomes, and the virus can grow in a variety of species, such as human, swine, bird, etc., which may result in novel strains of influenza entering into human circulation, as did the &#147;swine flu&#148;. These
	new viruses have the potential to cause worldwide pandemics.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage6"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Pipeline
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	With our product candidates, we intend to treat life-threatening infections, including those caused by drug resistant pathogens. Our current
	pipeline of product candidates and advanced research programs is reflected in Figure 1:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G36P78.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Lysins
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Bacteria can be divided into two groups based on structural differences of the bacteria&#146;s outermost walls:
	(a)&nbsp;&#147;gram-positive&#148; and (b)&nbsp;&#147;gram-negative&#148;. Gram-positive bacteria have an outermost cell wall of peptidoglycan (a structure consisting of sugars and amino acids), which, when exposed to a dye known as the
	&#147;Gram-stain,&#148; absorb the dye and appear dark blue or violet when viewed under a microscope. Gram-negative bacteria have an additional outer membrane that prevents the Gram-stain from penetrating the peptidoglycan and, therefore, do not
	appear dark blue or violet when viewed microscopically. The additional outer membrane also makes gram-negative bacteria harder for lysins to penetrate. However, we have discovered and have multiple research programs on lysins that kill gram-positive
	and gram-negative bacteria.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lysins are enzymes derived from naturally occurring bacteriophage, which are viruses that infect bacteria.
	When recombinantly produced and then applied to bacteria, lysins cleave a key component of the target bacteria&#146;s peptidoglycan cell wall, resulting in rapid bacterial cell death. We believe lysins are unlike conventional antibiotics, especially
	regarding their mechanism and speed of action. Conventional antibiotics require bacterial cell division and metabolism to occur in order to exert their effect (i.e., cell death or cessation of growth). Based on in vitro tests, lysins, however, are
	fundamentally different in that they kill bacteria immediately upon contact, regardless of bacterial growth and cell division.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our
	pipeline of lysins includes internally discovered lysins targeting gram-positive and gram-negative organisms, as well as lysins discovered at The Rockefeller University (&#147;Rockefeller&#148;) which are being developed by us. We were granted a
	world-wide, exclusive license under Rockefeller patent rights to discover, develop, make, have made, use, import, lease, sell and offer for sale lysin products. We acquired worldwide exclusive
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage7"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	license rights to patents for composition of matter for nine lysins from Rockefeller. Each lysin targets a specific species of bacteria, including drug-sensitive and drug-resistant forms of
<I>
	Staph aureus
</I>
	, pneumococcus, group B streptococcus, enterococcus and anthrax. Significantly, our lysins kill only the specific species of bacteria they target, which we believe will avoid the damaging side effects that often occur when
	conventional antibiotic treatments kill the body&#146;s healthy, desirable bacteria. Table 1 sets forth the lysins for which we have acquired licenses to patents from Rockefeller, the bacteria that each lysin targets and the diseases associated with
	such pathogenic bacteria.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Table 1: Lysins Licensed from The Rockefeller University
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="33%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:19.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Lysin
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Bacteria
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Disease
</B>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-301,&nbsp;CF-302
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Staphylococcus&nbsp;aureus
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Bacteremia*
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Abscesses*
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Endocarditis
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Meningitis
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Pneumonia
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-303, CF-309
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Pneumococcus
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Pneumonia*
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Bacteremia*
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Endocarditis*
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Meningitis*
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Otitis Media*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-304
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Enterococcus
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Serious&nbsp;Intestinal&nbsp;Infections
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-305
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Group B Strep
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Neonatal Meningitis*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CF-306,&nbsp;CF-307,&nbsp;
	CF-308
</FONT>
</FONT>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Bacillus Anthracis
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Anthrax*
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	*
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Indicates published data.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Lead Lysin Program: CF-301
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Market Opportunity
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We
	recently concluded a Phase 1 single ascending dose study in healthy volunteers with CF-301. CF-301 represents a first-in-class anti-bacterial therapeutic candidate. CF-301 has been granted fast track designation for the initial indication we intend
	to pursue for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, including endocarditis, caused by MRSA or MSSA. If we are able to obtain regulatory approval of CF-301 for this initial indication, we believe CF-301 can be further developed for the
	treatment of
<I>
	Staph aureus
</I>
	pneumonia, osteomyelitis, and biofilm-related infections in prosthetic joints, indwelling devices and catheters.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The issue of antibiotic-resistant bacterial infections has been widely recognized as an increasingly urgent public health threat, including by
	the World Health Organization, the Centers for Disease Control and Prevention and the Infectious Disease Society of America. Antibiotic resistance has limited the effectiveness of many existing drugs, and the discovery of new antibiotics to address
	resistance has not kept pace with the increasing incidence of difficult-to-treat microbial infections. According to the Infectious Diseases Society of America, as of 2010 the estimated cost to the U.S. healthcare system of antibiotic-resistant
	infections was approximately $21 billion to $34 billion annually, a substantial portion of which is due to increased length of hospital stays.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Staph aureus
</I>
	bacteremia is a serious bacterial infection associated with high morbidity and mortality. In the U.S. alone, there were
	approximately 120,000 cases of
<I>
	Staph aureus
</I>
	bacteremia, of which over 80,000 were reported as invasive MRSA infections in 2011. Of further concern, the incidence of infective endocarditis is increasing, with over 47,000 cases in 2011, due to
	the growth of the at-risk populations, such as adults with heart disease and prosthetic device implants, especially cardiac devices.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage8"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Potential Advantages
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our preclinical studies to date have shown that CF-301 has the following attributes:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Highly specific to, yet broadly active against Staph aureus bacteria
</I>
</B>
	. CF-301 exhibits broad activity against a wide spectrum of
<I>
	Staph aureus
</I>
	strains, including resistant strains such as MRSA,
	vancomycin-resistant
<I>
	Staph aureus
</I>
	(&#147;VRSA&#148;), and daptomycin-resistant
<I>
	Staph aureus
</I>
	(&#147;DRSA&#148;). Significantly, CF-301 specifically kills
<I>
	Staph aureus
</I>
	, which we believe will avoid the damaging side effects that
	often occur when conventional broad spectrum antibiotic treatments kill the body&#146;s healthy, desirable bacteria.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Rapid bactericidal activity
</I>
</B>
	. In vitro, CF-301 kills
<I>
	Staph aureus
</I>
	bacteria within seconds after contact. Currently, mortality from
<I>
	Staph aureus
</I>
	bacteremia remains close to 30% with treatment
	on SOC drugs. The average length of hospitalization due to
<I>
	Staph aureus
</I>
	bacteremia is 21 days and the average total cost of hospitalization is $114,000. We expect CF-301, combined with SOC antibiotics, to have the potential to improve patient
	outcomes, shorten treatment times and reduce the length of hospital stays.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Synergy with standard-of-care antibiotics.
</I>
</B>
	We have discovered a strong synergy between CF-301 and several SOC antibiotics, including daptomycin, vancomycin and oxacillin. We intend to seek approval for
	CF-301 to be used in addition to these SOC antibiotics. We believe that the use of CF-301, if approved, in addition to, rather than as a replacement for, SOC antibiotics, may help speed adoption of our product by physicians and provide the best
	outcome for patients.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Clears biofilms.
</I>
</B>
	In in vitro studies, CF-301 clears biofilms that protect bacterial infections in the body, rendering infections up to 1,000-fold more resistant to antibiotics. Infected human tissues, such
	as a heart valve in endocarditis or bone in osteomyelitis, or indwelling medical devices, such as central venous catheters, prosthetic joints and pacemakers, are common sites for biofilm formation, providing an impediment to effective treatment
	using antibiotics alone.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Minimal resistance
</I>
</B>
<I>
	.
</I>
	To date, bacteria show minimal resistance to CF-301&#146;s killing activity in vitro.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Minimal competition.
</I>
</B>
	There are only two FDA approved drugs for the treatment of MRSA bacteremia, vancomycin and daptomycin. MRSA bacteremia has shown resistance to both drugs. CF-301 works synergistically
	with both of these drugs and is intended to be used in addition to, not as a replacement for, SOC antibiotics.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Patent protection.
</I>
</B>
	Our issued composition of matter patent on CF-301 provides protection through 2032 and additional patents, if issued as we expect, could provide further protection beyond 2032.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Preclinical Data
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A key feature of lysins is their ability to target pathogenic antibiotic-resistant bacteria, as well as those that are antibiotic-sensitive.
	Table 2 sets forth our findings of CF-301&#146;s effect on
<I>
	Staph aureus
</I>
	isolates, showing that CF-301 killed all
<I>
	Staph aureus
</I>
	isolates tested, regardless of their antibiotic-resistance profile. In this experiment, we tested 250
	different drug sensitive and resistant isolates of
<I>
	Staph aureus
</I>
	. The isolates (which are classified by the particular drugs they are sensitive or resistant too) tested included MSSA, MRSA, VRSA, linezolid-resistant (&#147;LRSA&#148;) and
	daptomycin-resistant (&#147;DRSA&#148;)
<I>
	Staph aureus
</I>
	. The isolates were all analyzed to determine their sensitivity to CF-301 and SOC antibiotics as measured by the Minimum Inhibitory Concentration (&#147;MIC&#148;) value. The MIC value is
	the minimum dose of drug that is required to kill a standard amount of bacteria over a 24-hour period. Based on demonstrated MIC values, CF-301 was shown to be active against all the strains tested (&#145;+&#146;), while subsets of the
<I>
	Staph
	aureus
</I>
	strains were resistant to daptomycin, vancomycin or linezolid (&#145;&#150;&#146;).
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage9"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Table 2: In Vitro Sensitivity of Antibiotic-Sensitive and Antibiotic-Resistant Strains to
	CF-301
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Strain
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:26.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	(n=250)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	CF-301
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Daptomycin
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Vancomycin
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Linezolid
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	MRSA (120)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	MSSA (103)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	DRSA (8)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
	-
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	VRSA (14)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
	-
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	LRSA (5)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	+
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
	-
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lysins have been shown to kill bacteria upon contact and demonstrate bactericidal activity (defined as a 3-log
	drop in colony forming units (&#147;CFU&#148;) per mL) in minutes. The figure below compares the rate at which lysins kill bacteria to the rates at which SOC antibiotics kill bacteria (with all drugs being administered at 1X MIC). CF-301 reduced the
	number of
<I>
	Staph aureus
</I>
	bacteria in tests on 62 strains (20 MSSA; 42 MRSA) by 3-logs (99.9%)&nbsp;within 30 minutes. In contrast, daptomycin required six hours to achieve the same level of cell kill, while vancomycin failed to achieve a 2-log,
	or 99%, cell kill during the same six-hour test period. The rapid bactericidal activity of lysins is one of the primary reasons we believe they could be a highly desirable therapeutic option for the treatment of rapidly advancing bacterial
	infections.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 2: CF 301&#146;s Rapid Bactericidal Activity In Vitro
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G39D91.JPG" ALT="LOGO">
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	*
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The star symbols indicate the limit of detection in the plating assay.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Synergy with
	Standard-of-Care Antibiotics
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Synergy is defined as the interaction of two or more agents so that their combined effect is greater
	than the sum of their individual effects. We discovered a strong synergy between lysins and several SOC antibiotics, including daptomycin, vancomycin and oxacillin through our in vitro testing (data not shown). In these
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage10"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	preclinical tests, when used together, lysins and antibiotics offered a dual attack on pathogenic bacteria that was far greater than the sum of their individual contributions. The result was
	significantly improved killing of bacteria.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To demonstrate this synergy in vivo, we have developed animal models where CF-301 could be
	tested as single agent (monotherapy) or combined with a SOC antibiotic (combination therapy). Our Standard Bacteremia Model utilizes animals infected with 10&nbsp;million CFU of MRSA and treated 3 hours later with various doses of therapy or buffer.
	When used alone, CF-301 has potent anti-Staph activity that demonstrates a dose/response effect. Figure 3 below presents the dose/response of animals treated with various doses of CF-301 in the Standard Bacteremia Model. As pictured on the graph
	below, all mice receiving at least 0.5 mg/kg of CF-301 demonstrated at least 90% survival, whereas doses below 0.5 mg/kg resulted in lower survival rates.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 3: CF-301 Dose Response in Mice in the Standard Bacteremia Model
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G60K06.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We also developed the Drug Failure Bacteremia Model, where the bacterial infection burden (one billion CFU)
	was so high that SOC antibiotics used at their human equivalent doses as monotherapies failed to have significant cure rates. We tested daptomycin, vancomycin and oxacillin in this model (data not shown for vancomycin and oxacillin). We then
	adjusted the dose of CF-301 so that CF-301 monotherapy would also fail to have significant cure rates under these intense infection conditions. To test whether the synergy that we had observed in vitro between CF-301 and SOC antibiotics would lead
	to improved efficacy in vivo, we then treated groups of animals in the Drug Failure Bacteremia Model with the drugs as monotherapies and also in combinations to evaluate if there was an improvement in efficacy.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Figure 4 below presents the results of the combination of CF-301 and daptomycin when used in the Drug Failure Bacteremia Model. All control
	mice treated with buffer (diamonds) succumbed to bacterial infection within 18 hours. Administration of a clinical dose of daptomycin as a single agent (triangles) resulted in clinical failure, as only 17% of mice survived. When CF-301 (squares) was
	dosed as a single agent at this chosen dose, only 60% of mice survived. In contrast, when mice received the
<I>
	combination
</I>
	of CF-301 plus daptomycin (circles), 90% survived the bacterial challenge, demonstrating superiority of the combination
	therapy over the single-drug regimens.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage11"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 4: Combination Therapy of CF-301 with Daptomycin in Drug Failure Bacteremia Model
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G73W41.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have tested the combination of CF-301 with daptomycin, vancomycin and oxacillin in 30 different
	experiments (including both the Standard and Drug Failure Bacteremia Models). In each experiment, the combination therapy was shown to be superior to monotherapy with a single drug alone. As a result, we believe this provides a strong foundation on
	which to pursue clinical development of the combination of CF-301 and SOC antibiotics for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, as CF-301&#146;s first indication.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To further explore the activity of CF-301 in combination with SOC antibiotics for the treatment of life-threatening, drug-resistant
	infections, we engaged the LA Biomed Research Institute at Harbor-UCLA Medical Center (&#147;UCLA&#148;) to perform a study in their rat infective endocarditis model (&#147;IE Model&#148;). The IE Model has become a well-established experimental
	animal model and has been used for assessing possible efficacy of therapeutic agents in infective endocarditis. The primary endpoint of the IE Model is a reduction in the amount of bacteria (measured as CFUs) on the heart valve, in the kidney and in
	the spleen. Survival during the course of the treatment period was considered a secondary endpoint, as the study was not designed to see the long-term effects of the treatment on overall survival. Our study examined the activity of CF-301 alone and
	in combination with daptomycin, in UCLA&#146;s prototypical high-burden biofilm-based IE Model. Prior to running the experiment, management and the investigator agreed that the achievement of a 2-log (or 99%) decrease in the CFU in the vegetation on
	the heart valve, spleen and kidney compared to daptomycin alone would be considered a good result and the achievement of a 3-log (or 99.9%) reduction would be considered impressive. We worked directly with UCLA to design the study, and the
	description of the methods and results follows below.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Figure 5 presents the results of the combination of CF-301 alone and in combination
	with daptomycin as compared to both buffer and daptomycin alone in the IE Model. In this study, a single dose of CF-301 significantly increased the activity of daptomycin. This study was designed to mimic the planned clinical approach (single dose
	of CF-301 on top of multiple days of SOC antibiotic therapy) in a difficult to treat biofilm-based infection. In this study, a single dose of CF-301, when combined with four days of daptomycin treatment, resulted in a 3-log drop in bacterial burden
	in the cardiac vegetations and &gt;2-log drop in the kidney and spleen of infected animals relative to daptomycin treatment alone. Importantly, in the combination treatment groups 4 of 9 animals were determined to be culture negative, whereas no
	animals in any other treatment arms approached this level of disease eradication.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage12"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 5: Single Dose of CF-301 with Daptomycin in Rat Infective Endocarditis Model
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G80T71.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As a result, we believe this additional data supports our human clinical study plan to evaluate the
	combination of CF-301 and SOC antibiotics for the treatment of patients with invasive
<I>
	Staph aureus
</I>
	infections, including endocarditis, caused by MSSA or MRSA.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Impact on Antibiotic-Resistant Biofilms
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Biofilm formation is a common protective mechanism for bacteria and a key feature associated with bacterial pathogenesis. Biofilms are
	characterized by densely packed bacterial cells that grow in communities and are enclosed within a complex matrix of dead bacteria and excess cell wall components. Biofilm bacteria exhibit significant tolerance of various antimicrobial agents,
	rendering biofilm cells up to 1,000-fold less susceptible than the same bacteria grown in a planktonic, or free-floating, non-biofilm culture. Infected human tissues, such as the heart valve in endocarditis or bone in osteomyelitis, or indwelling
	medical devices, such as central venous catheters, prosthetic joints and pacemakers, are common sites for biofilm formation, providing a hurdle for effective treatment with antibiotics alone. Biofilm coating of bacterial infections in human medicine
	is estimated to occur in more than 60% of bacterial infections, costing the healthcare system billions of dollars. For this reason, novel treatment strategies and antimicrobial agents with activity toward biofilms remain a serious unmet medical need
	as there is no product currently indicated for the treatment of biofilms.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Since CF-301 disrupts the outer wall of
<I>
	Staph aureus
</I>
	by
	enzymatic lysis, we performed studies to determine if CF-301 would also disrupt biofilms. For this purpose, we cultured MRSA for 24 hours within wells of polystyrene dishes typically used for the culture of cells, at which point a dense biofilm
	formed on the dish surface. Dishes were incubated for up to 24 hours with high-dose (1,000x MIC) daptomycin, vancomycin or linezolid, or lower-dose (1xMIC)&nbsp;CF-301. After the four-hour treatment, dishes were washed and stained with a dye that
	stains the biomass of a biofilm a dark blue color. In dishes treated with CF-301, there was no visual biofilm present after two hours of treatment, whereas in dishes treated with antibiotics for up to 24 hours, the biofilm biomass remained intact
	(images shown in Figure 6 below). These findings are consistent with the inability of these antibiotics to penetrate and clear biofilm material. This demonstrated that CF-301 was at least 1,000-fold more potent than SOC antibiotics at destroying
	bacterial biofilms in vitro.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage13"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 6: Sensitivity of
</B>
<B>
<I>
	Staph Aureus
</I>
</B>
<B>
	(MRSA) Biofilms to CF-301 Versus SOC
	Antibiotics
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G33E70.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To microscopically visualize CF-301&#146;s disruption of biofilms, we inoculated MRSA onto a medically
	relevant device (a catheter) where it attached to the wall of the plastic and formed a dense 3-dimensional structure. We then treated the interior of the catheter with CF-301 at 1x MIC. At various time intervals after treatment the interior of the
	catheter was sectioned and examined by scanning electron microscopy (&#147;SEM&#148;), select images shown below in Figure 7. In the untreated catheter (left panel) the majority of MRSA cells (little circles in the pictures below) were found within
	a biofilm. However, within 30 seconds of exposure to CF-301, the dense biofilm was largely removed and only single cells were observed (middle panel). Fifteen minutes following exposure to CF-301 (right panel), the biofilm was completely stripped
	and residual MRSA cells which had been beneath the biofilm were killed, in effect, sterilizing the catheter. These images emphasize the rapid and potent activity of CF-301 against bacterial biofilms. Taken together with the lack of efficacy that
	antibiotics display against biofilms, we believe CF-301 potentially represents a new therapeutic option against what were previously untreatable biofilms.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 7: Sensitivity of
</B>
<B>
<I>
	Staph Aureus
</I>
</B>
<B>
	(MRSA) Biofilms Grown on Catheters to CF-301
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G60K99.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: Product Development
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Product development is generally accomplished in four steps, which may overlap: (1)&nbsp;preclinical activities to demonstrate consistent
	manufacturing, safety and efficacy in animals; (2)&nbsp;Phase 1 clinical trials, in healthy volunteers, to determine pharmacokinetics (&#147;PK&#148;), safety, tolerability, immunogenicity, dosing, effects in special populations, and other issues;
	(3)&nbsp;Phase 2 clinical trials in patients to determine dose, efficacy, safety, tolerability, PK and immunogenicity; and (4)&nbsp;Phase 3 clinical trials, the pivotal trials in patients to confirm efficacy and safety at the proposed commercial
	dose.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
<A NAME="eolPage14"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Non-Clinical Activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chemistry, Manufacturing and Controls
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Manufacturing of CF-301 utilizes a proprietary engineered
<I>
	E. coli
</I>
	strain that expresses the product in a recombinant manner during the
	fermentation process. This technology allows production of up to nine grams of CF-301&nbsp;per liter of fermentation broth. After fermentation, the broth containing CF-301 is separated and purified through a process containing two chromatographic
	columns. The resulting product has greater than 99% purity. The CF-301 produced by this process has been used in animal studies submitted to the IND and may be used for our planned Phase 1 and Phase 2 clinical trials.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We intend to further optimize the manufacturing process for increased purity and yield. Once completed, we plan to begin a program to
	manufacture Phase 3 material. The process will then be scaled 35-fold from the current 100 liter fermentation to 5,000 liters. This process will then be validated in a series of manufacturing batches to demonstrate consistency. In parallel to the
	validation, we intend to conduct a comparability program that demonstrates comparability between the final product used in Phase 3 and commercial manufacturing. We intend to include the results in the biologics license application (&#147;BLA&#148;)
	that we expect to submit to the FDA. Following submission, the FDA will conduct pre-approval inspections of all manufacturing facilities and determine whether it agrees that our commercial material is sufficiently comparable to our Phase 3 material.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Safety Pharmacology and Toxicology
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preclinical safety pharmacology and toxicology studies have been completed in connection with our IND application for CF-301. In these studies
	CF-301 was well tolerated in rats for a single two-hour IV administration of doses up to 25mg/kg (determined by us to be the no observable adverse effect level, or &#147;NOAEL&#148;) and that a single dose of 2.5mg/kg was not associated with any
	effects, adverse or not, and was therefore determined to be the no observable effect level (&#147;NOEL&#148;). CF-301 was also well tolerated in these studies in both rats and dogs for seven consecutive days of once daily two-hour IV infusions of up
	to 2.5mg/kg. In a non-GLP pilot study in rats, 1.0 mg/kg/day was well tolerated for up to seven consecutive days of once daily two-hour IV infusions or IV boluses. We will need to conduct a definitive dose ranging, repeat dose study in rats prior to
	initiating any clinical trial with administration of CF-301 over consecutive days.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Dose dependent adverse tissue effects were seen in
	both species at doses above 25 mg/kg/day for 1 day in the rat and above 2.5 mg/kg/day for seven-consecutive days in both the rat and the dog. The dose limiting toxicity observed was a localized inflammation surrounding certain blood vessels. In
	accordance with industry practice, we intend to study CF-301 in clinical trials at doses much lower than those that caused adverse effects in animals, and we believe these doses to be within the efficacious range of the drug.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Upon first exposure to CF-301, no hypersensitivity reaction was observed in any of our animal studies. Upon administration of a second course
	of CF-301, given two weeks after completion of the first course, hypersensitivity or hypersensitivity-like findings were observed in mice, rats and dogs. In a dedicated hypersensitivity studies in rats, findings of Type III hypersensitivity were
	observed after a two week delayed re-challenge with a second course of CF-301 and were not dose dependent. In general, Type I hypersensitivity is an allergic anaphylaxis-like response (e.g., an immediate and potentially life-threatening allergic
	reaction) and Type III hypersensitivity is a serum sickness-like response (e.g., fever, joint pain, protein in urine, vascular changes). While the nature of hypersensitivity reactions in rats may not necessarily be predictive of hypersensitivity
	reactions that may occur in humans, we have also considered the risk of hypersensitivity occurring upon first administration of CF-301 due to potential prior exposure to the active protein component of CF-301 from the environment, as it is a
	naturally occurring protein. Testing for anti-CF-301 antibodies was performed in Phase I subjects. No clinical hypersensitivity related to CF-301 was observed in subjects dosed in our Phase 1 study.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	11
</P>
<A NAME="eolPage15"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Clinical Activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Phase 1.
</I>
	We recently concluded a Phase 1 single ascending dose study in healthy volunteers. This trial was a randomized, double-blind,
	placebo-controlled trial designed to evaluate the safety, tolerability and PK of four different intravenous doses of CF-301 alone. Subjects were randomized to receive a single IV dose of CF-301 or placebo, each administered as a two hour infusion.
	As specified in the protocol, an independent data safety monitoring board (DSMB) reviewed the safety, tolerability, and pharmacokinetic data from healthy volunteers dosed in all of the planned cohorts. The DSMB observed no clinical adverse safety
	signals associated with
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CF-301
</FONT>
	in the study. No clinical hypersensitivity related to CF-301 was observed in subjects dosed in our Phase 1 study.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Phase 2.
</I>
	We expect to proceed into Phase 2 clinical trials to assess the safety, tolerability, PK, and efficacy of CF-301 plus
	standard-of-care (&#147;SOC&#148;) antibiotics. We expect any Phase 2 clinical trial to be a multicenter, double-blind, randomized study that evaluates the safety and efficacy of CF-301 plus SOC antibiotics and SOC antibiotics alone in patients with
	Staph bacteremia caused by MSSA or MRSA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Phase 3.
</I>
	If the Phase 2 results are consistent with our expectations regarding the safety
	and efficacy profile of CF-301, we expect to enter into Phase 3 clinical trials. We expect any Phase 3 clinical trial to be a global, multicenter, double-blind, randomized study that evaluates the efficacy and safety of CF-301 plus SOC antibiotics
	compared to SOC antibiotics alone among patients with bacteremia caused by MSSA or MRSA. Specific parameters for Phase 3 trials will be based on the outcomes of previously completed clinical trials and relevant guidance and precedents from
	regulatory authorities.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Lysin Discovery Platform
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We employ bioinformatics and a series of metagenomic-based techniques to clone bacteriophage lysins from bacterial, viral, and environmental
	sources. The field of metagenomics is based on the bulk extraction of DNA/RNA from environmental samples (e.g., soil, water, etc.) without prior isolation of individual microbial sources. This is useful when one considers that less than 1% of
	microbes are culturable under standard laboratory conditions. Once extracted, the metagenomic DNA can then be examined using sequence-based methods or by proprietary functional screens. These functional screens for bacteriophage lysin activity form
	the basis for our lysin discovery work.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	For the functional metagenomic work that we perform, environmental genes are expressed in a
	recombinant format in a standard host organism (i.e.,
<I>
	Escherichia coli
</I>
	) and cells are monitored for the acquisition of a desired phenotype. We can vary both the source of environmental DNA and the way we monitor for desired phenotypes to
	focus only on environmental populations enriched for bacteriophage lysins that can actively kill a pathogen of interest. We sample various DNA sources including viral, prophage, and pathogen-amplified viral metagenomics. Multiple methods for both
	DNA library construction and for functional screening are used in parallel in order to maximize lysin identification.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have also
	established additional discovery methodologies, including bioinformatics analysis of the rapidly expanding databases of bacterial genomic sequences. The highly conserved modular structure of lysins, combined with sequence homologies amongst
	different lysin classes, enable the rapid analysis of putative lysins from DNA databases. Such sequences can be readily synthesized and screened for lytic activity against any pathogen of interest.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The application of these methods enables the large scale identification of lysins, enabling the production of lysin banks specific for any
	particular pathogen. We believe the ability to rapidly identify lysins specific for any pathogen of interest, either by in vitro or in silico methods, will provide a steady pipeline of novel lysins for consideration as potential antimicrobial
	therapeutic candidates.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	12
</P>
<A NAME="eolPage16"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We intend to pursue preclinical and clinical development of additional lysins. In addition to the
	lysins we have licensed from Rockefeller and our in-house lysin discovery program, we have an active collaborative research agreement where we provide funding for the discovery of new lysins with Dr.&nbsp;Vincent Fischetti&#146;s Laboratory of
	Bacterial Pathogenesis and Immunology at Rockefeller, where we have the first right to negotiate a license to all discoveries concerning lysins through October 2016. The primary focus of our in-house and sponsored research is the discovery of lysins
	to target gram-negative bacteria.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Monoclonal Antibodies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are exploring combination therapy with mAbs that bind to target bacteria or viruses and block certain biological activities or recruit other
	parts of the immune system to destroy the pathogenic target. The strategies of our mAb program include: (1)&nbsp;targeting conserved regions of the virus or bacteria which are not prone to mutation and (b)&nbsp;targeting multiple proteins expressed
	from different genes within a bacteria or virus to prevent therapeutic escape and (c)&nbsp;combining mAbs to cover multiple strains for superior outcomes.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our antibodies are generated by genetic engineering using phage display libraries, isolated directly from human blood samples or other
	available technologies, enabling the screening of billions of human mAbs with different binding sites. Once the best monoclonal antibodies are isolated, we use protein engineering techniques to optimize important antibody attributes such as
	pharmacokinetic profile, effector function engagement, antibody format (such as Fabs and bispecifics), and manufacturing efficiency. The common properties provide for a unique ability to create a therapeutic combination of mAbs.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our Lead mAb Program: CF-404
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We
	are developing a combination of three human mAbs against influenza as a treatment for life-threatening seasonal and pandemic influenza infections, a disease that kills as many as 49,000 people annually in the U.S. alone. We expect to complete the
	required manufacturing and preclinical studies to file an IND for CF-404 in 2016. Our preclinical studies to date have shown that CF-404 may have the following attributes:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Broad activity against influenza in one combination drug.
</I>
</B>
	CF-404 exhibits broad activity against influenza strains, including the three principal strains (H1, H3 and B). By targeting a conserved region on
	the virus, we believe CF-404 bypasses the effects of seasonal change, which allows (1)&nbsp;our mAbs to cross-react and neutralize many different influenza strains; (2)&nbsp;for the production of a single therapeutic combination of only three mAbs
	covering all human seasonal and most pandemic influenza strains; and (3)&nbsp;for an immediate therapeutic effect that cannot be obtained by vaccination which typically requires weeks.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Minimal resistance potential
</I>
</B>
<I>
	.
</I>
	Our mAbs react with the principal protein, hemagglutinin, on the surface of influenza at a region referred to as the hemagglutinin stalk. Because the hemagglutinin
	stalk is genetically stable and therefore represents a conserved region of the virus, it does not vary from one season to another.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
<I>
	Minimal competition.
</I>
</B>
	There are only four approved drugs for the treatment of influenza&#151;Tamiflu, Relenza, Symmetrel and Flumadine&#151;although only Tamiflu is widely used in practice. Influenza has
	demonstrated an increasing resistance to Tamiflu, and the clinical benefit of Tamiflu is greatest when antiviral treatment is administered early, especially within 48 hours of influenza illness onset. Based on preclinical data, we believe treatment
	with our mAbs may be effective even when given 96 hours after infection.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Influenza Research
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In preclinical studies, our combination of mAbs in CF-404 cross-reacts with all strains of influenza, including the three principal strains
	(H1, H3 and B). These mAbs react with the principal protein, hemagglutinin,
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	13
</P>
<A NAME="eolPage17"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	on the surface of influenza at a region referred to as the hemagglutinin stalk which is genetically stable and does not vary from one season to another. We have produced mAbs that are reactive
	with the stalk region of hemagglutinin for the entire natural history of the H3 influenza (1968-present), H1 influenza (1918-present; seasonal and swine flu), other strains of type A influenza (including H5), and Type B influenza.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have tested our mAbs in mouse models to evaluate protection against lethal infection with influenza in &#147;proof-of-concept&#148;
	experiments. These data demonstrated that our anti-H1 (CF-401), anti-H3 (CF-402) and anti-B mAbs (CF-403) were able to protect animals from lethal challenge. Importantly, our in vivo animal studies show that treatment with our mAbs appears to
	provide greatly enhanced potency compared to treatment with other mAbs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Figure 8 below shows the results of an experiment using CF-401 in
	a mouse model of HINI influenza infection, in which body weight loss is used as a proxy of disease progression (and ultimately, death). In this figure, we also demonstrate that at equivalent dosing of 1 mg/kg, CF-401 was far superior to a
	competitor&#146;s mAb currently in clinical development. Control mice treated with buffer (diamonds) succumbed to viral infection within 9 days. Administration of a single treatment, 24 hours post-infection, of a competitor&#146;s antibody
	(triangles) resulted in clinical failure at an identical rate as the no treatment group. When CF-401 (circles) was administered as a single treatment, 24 hours post-infection, the mice appeared perfectly healthy, with weight changes identical to
	animals that did not receive challenge with influenza (squares).
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 8: Effectiveness of CF-401 in Mouse Model of Influenza
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G27E20.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As the goal of our influenza program is to produce a combination of mAbs with efficacy against all human
	seasonal strains of influenza, we have formulated a combination of three mAbs (&#147;CF-404&#148;) and tested it in animal models of disease. Figure 9 below shows how CF-404 cured mice infected with three different strains of influenza, regardless
	of the strain (H1N1, H3N2 or B). Control mice treated with buffer (triangles) all succumbed to viral infection within 7-9 days. By contrast, when we administered a single treatment of our anti-Influenza combination CF-404 (squares) 24 hours
	post-infection, the infected mice appeared perfectly healthy, with weight changes comparable to healthy mice (not pictured).
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	14
</P>
<A NAME="eolPage18"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 9: Effectiveness of CF-404 in Mouse Model
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G33Y72.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Currently, the SOC treatment for influenza is Tamiflu. Tamiflu, however, has several limitations, including
	emerging resistance. In 2009, just prior to the emergence of the pandemic H1N1 swine flu, the CDC cautioned against the use of Tamiflu for the treatment of H1N1 seasonal influenza due to nearly complete drug-resistance of the virus (in 2006 &lt;1%
	of H1N1 were resistant, by 2009 that figure jumped to &gt;98%). As previously discussed, due to the targeting of conserved regions on the hemagglutinin, we do not anticipate resistance will occur to our mAbs. The second major limitation of Tamiflu
	is its narrow time window to treat a patient and still be efficacious. The clinical benefit of Tamiflu is greatest when administered early in a patient&#146;s infection, especially within 48 hours of illness onset. To compare the time-to-treat
	windows of our mAbs to Tamiflu, H1N1 influenza-infected mice were treated with either a single administration of CF-401or a 5 day course of Tamiflu beginning 24-96 hours post infection (&#147;HPI&#148;). Figure 10 below shows the findings of that
	study, including the finding that Tamiflu treatment had to have been initiated by 24 HPI to cure mice, while treatments beginning at 48, 72 or 96 HPI resulted in 100% death by day 14. In contrast, a single treatment with CF-401 resulted in 100%
	survival when given any time up to 72 HPI and in 80% survival when given 96 HPI. This result suggests that our mAb treatment may provide effective treatment to influenza patients at later times post-infection when Tamiflu is no longer effective.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	15
</P>
<A NAME="eolPage19"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Figure 10: Our mAbs Provide Greater Therapeutic Window than Tamiflu
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Mouse Model
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/15/0001193125-16-505381_G109824G20K83.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We believe our combination for the treatment of influenza is a novel approach addressing a high unmet
	medical need (influenza causes up to 49,000 deaths per year in U.S. alone) and would offer competitive advantages to the only product widely used on the market today if successfully developed and approved.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Intellectual Property
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our goal is to
	obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the
	United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary technology through a
	combination of contractual arrangements and patents, both in the United States and abroad. However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well as that
	of our advisors, consultants and other contractors. To help protect our proprietary know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we currently rely and will in the future rely on trade secret
	protection and confidentiality agreements to protect our interests. To this end, we will require all of our employees, consultants, and other contractors (including any consultants or contractors we may retain for purposes of any of our ad hoc
	Clinical Advisory Boards) to enter into confidentiality agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions
	important to our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our lysin portfolio consists of eleven (11)&nbsp;U.S. patents, four (4)&nbsp;foreign patents and fifty-seven
	(57)&nbsp;U.S. and international patent applications that we have licensed from Rockefeller and/or developed in-house. The patents and patent applications are directed to compositions and methods for the treatment of infections caused by Group B
	Streptococci, Staphylococcus aureus, Streptococcus pneumonia, Bacillus anthracis (anthrax), Enterococcus faecalis and Enterococcus faecium. These patents will expire between 2023 and 2029. If patents are granted on our patent applications, which
	include the patent applications for CF-301, they would expire between 2032 and 2033.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	16
</P>
<A NAME="eolPage20"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our influenza patent portfolio consists of forty-one (41)&nbsp;U.S. and foreign patent
	applications, which we have licensed from Trellis and/or developed in-house. The patent applications are directed to compositions relating to influenza antibodies as well as to pharmaceutical compositions for administration to patients and to
	methods for their use in conferring passive immunity against various influenza strains and clades. If patents are granted on these patent applications they would expire between 2031 and 2036.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The U.S. patent system permits the filing of provisional and non-provisional patent applications. A non-provisional patent application is
	examined by the United States Patent and Trademark Office (&#147;USPTO&#148;), and can issue as a patent once the USPTO determines that the claimed invention meets the various standards for patentability. A provisional patent application is not
	examined or prosecuted, and automatically expires 12 months after its filing date if a non-provisional application is not filed based on the provisional application within that 12-month period. Provisional applications are often used, among other
	things, to establish a priority filing date for the subsequently filed non-provisional patent application. The term of individual patents depends upon the legal term for patents in the countries in which they are filed. In most countries in which we
	file, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#146;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays
	by the USPTO in granting a patent. Alternatively, a patent&#146;s term may be shortened if a patent is terminally disclaimed over another patent.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The term of a patent that covers an FDA-approved drug may also be eligible for patent term extension (&#147;PTE&#148;), which permits patent
	term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, permits a PTE of up to five years beyond the
	expiration of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only
	one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical
	product candidates receive FDA or other regulatory approval, we may be able to apply for or receive the benefit of PTEs on patents covering those products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	License Agreements&#151;The Rockefeller University
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have entered into the following license agreements with Rockefeller:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	On July&nbsp;12, 2011, we entered into a license agreement for the worldwide, exclusive right to a provisional patent application, upon which a non-provisional patent application has since been filed, covering the
	composition of matter for the lysin PlySS2 for the treatment and prevention of diseases caused by gram-positive bacteria (the &#147;CF-301 License&#148;). We rebranded PlySS2 as CF-301. This license gives us the right to exclusively develop, make,
	have made, use, import, lease, sell and offer for sale products that would otherwise infringe a claim of this patent application or patent.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	On June&nbsp;1, 2011, we entered into a license agreement for the exclusive rights to Rockefeller&#146;s interest in a joint patent application, which is presently pending, covering the method of delivering antibodies
	through the cell wall of a gram-positive bacteria to the periplasmic space. This intellectual property was developed as a result of the sponsored research agreement between us and Rockefeller, and was jointly discovered and filed by the two parties.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	On September&nbsp;23, 2010, we entered into a license agreement for the worldwide, exclusive right to develop, make, have made, use, import, lease and sell, and offer for sale products that would otherwise infringe a
	claim of the suite of patents and patent applications covering the composition of matter for eight individual lysin molecules for the treatment and prevention of diseases caused by gram-positive bacteria. The lysins in this suite have activity
	against Group B Streptococci, Staphylococcus aureus, Streptococcus pneumonia, Bacillus anthracis, Enterococcus faecalis and Enterococcus faecium.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	17
</P>
<A NAME="eolPage21"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In consideration for the licenses, we paid Rockefeller license initiation fees in cash and stock
	and may be required to pay an annual maintenance fee, milestone payments and royalties on net sales from products to Rockefeller. We are allowed to grant sublicenses to third parties without prior approval, subject to certain conditions and the
	payment of a certain percentage of all payments we receive from sublicensees.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Each license agreement terminates upon the later of
	(i)&nbsp;the expiration or abandonment of the last licensed patent under the license agreement to expire or become abandoned, or (ii)&nbsp;10 years after the first commercial sale of the first licensed product. Rockefeller may terminate any license
	agreement in the event of a breach of such agreement by us or if we challenge the validity or enforceability of the underlying patent rights. We may terminate any license agreement at any time on 60 days&#146; notice.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	License Agreement&#151;Trellis Bioscience LLC
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On January&nbsp;29, 2014, we entered into a license agreement with Trellis that gives us exclusive rights to all Trellis mAbs in the field of
	influenza discovered from their CellSpot platform. Particularly, the license provides us with three fully human mAbs that bind, neutralize and protect animals from all strains of H1, H3 and B influenza, and that will also cross bind, neutralize and
	protect animals from other seasonal or pandemic influenza strains that may arise (including H5N1 and H7N9). We have selected our three lead mAbs for the H1, H3, and B influenzas and are currently producing these antibodies at scale using
	manufacturing-grade expression systems and performing IND-enabling studies.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In consideration for the license, we paid Trellis licensing
	fees in cash and stock and may be required to make specified development and regulatory milestone payments and make additional payments upon the achievement of future sales and a royalty on net sales from products to Trellis. We are allowed to grant
	sublicenses to third parties.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The license agreement terminates upon the earlier of (i)&nbsp;our decision to terminate the agreement at
	will or for safety reasons, (ii)&nbsp;material breach by either party that is not cured within ninety (90)&nbsp;days, or (iii)&nbsp;either party&#146;s insolvency.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On August&nbsp;14, 2014, we amended the license agreement to include research conducted pursuant to a government grant.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Collaborative Research Agreements&#151;The Rockefeller University
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Beginning in October 2009, we entered into a research agreement with Rockefeller where we provided funding for research focused on producing
	and testing monoclonal antibodies against proteins of
<I>
	Staph aureus
</I>
	. On October&nbsp;24, 2011, we entered into a second research agreement with Rockefeller, where we provide funding for the research primarily to identify lysins, enzymes or
	small molecules that will kill gram-negative bacteria, and to identify and characterize lysins from Clostridia difficile to be engineered into gut commensal bacteria.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our current agreement runs through October&nbsp;31, 2016. Either party may terminate the agreement upon breach of the agreement, following 30
	days written notice and failure to cure such breach. Following the expiration or termination of the agreement, each party will have a non-exclusive license to use for internal research purposes all research results, including joint intellectual
	property. If Rockefeller or joint intellectual property develops from these programs, we will have the right-of-first refusal to negotiate to acquire a royalty-bearing license to utilize such intellectual property for commercial purposes.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Competition
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The pharmaceutical and
	biotechnology industries are intensely competitive. While we believe that our technology and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
	specialty pharmaceutical and biotechnology companies and academic and research organizations in developing therapies to treat diseases.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	18
</P>
<A NAME="eolPage22"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-301 is a first-in-class drug candidate and we believe will be among the first lysins to enter
	human clinical trials. We believe there is no clinical competitor to CF-301 as it was designed with at least six attributes that no single antibiotic possesses, including: (1)&nbsp;a novel mechanism of action, (2)&nbsp;specificity for a target
	bacteria (only
<I>
	Staph aureus
</I>
	), (3)&nbsp;rapid speed of action, (4)&nbsp;activity across all drug-sensitive and drug-resistant strains of the target bacteria (including MRSA, VRSA and DRSA), (5)&nbsp;the ability to eradicate biofilms, and
	(6)&nbsp;synergy with antibiotics.
<I>
	Staph aureus
</I>
	bacteremia is typically treated with oxacillin, or for MRSA strains, daptomycin and vancomycin. Vancomycin is currently a generic drug and we expect daptomycin to reach the end of its patent
	life by the time CF-301 comes to market, if approved. We do not see market competition with these drugs, as our strategy is to combine CF-301 with these drugs to aim for superiority over any one of those drugs alone. Additionally, we anticipate
	similar synergy and approach with identifiable clinical development molecules, such as Teflaro from Cerexa Inc.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Recently, iNtRon
	Biotechnology Inc., a biotechnology company located in South Korea, completed the first Phase I human clinical trial for SAL-200, an endolysin-based drug candidate for multidrug-resistant
<I>
	Staph aureus
</I>
	infections. We will continue to monitor
	the advancements of SAL-200 as data become available.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-404 is intended for the treatment of life-threatening seasonal and pandemic
	influenza infections. We believe CF-404 has competitive advantages in that it potentially addresses the short-comings of currently marketed products (Tamiflu, Relenza and Rapivab) and other products in development for the following reasons:
	(1)&nbsp;it may not be prone to drug-resistance due to targeting conserved regions of the influenza virus, (2)&nbsp;it may provide for an increased &#147;time-to-treat&#148; window compared to Tamiflu, Relenza and Rapivab, which are indicated to be
	used within 48 hours of symptom onset, and (3)&nbsp;it may provide complete coverage against all seasonal and most potential pandemic strains of human influenza without the need for annual reformulation, including influenza B.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-404 may directly or indirectly compete with other products already in development from F.
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Hoffmann-La
</FONT>
	Roche Ltd., Genentech, Inc., Crucell N.V, Vertex Pharmaceuticals Incorporated, Theraclone Sciences, Inc., Toyama Chemical Co., Ltd., Romark Laboratories, L.C., Biota Pharmaceuticals, Inc., Adamas
	Pharmaceuticals, Inc., Activaero GmbH, Far East Bio-Tec Co. Ltd, Visterra Inc., MedImmune LLC, Ansun Biopharma, Inc. and others with early stage product candidates.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing,
	preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved medicines than we do. We compete with companies that have products on the market or in development for the same indications as our product
	candidates. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting
	and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials. Smaller or early stage companies may also prove to be significant competitors, particularly through
	collaborative arrangements with large and established companies.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The key competitive factors affecting the success of all of our product
	candidates, if approved, are likely to be their efficacy, safety, convenience, price and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors
	develop and commercialize medicines that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines that we may develop. Our competitors also may obtain FDA or other regulatory
	approval for their medicines more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	19
</P>
<A NAME="eolPage23"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Manufacturing
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to
	rely, on third parties for the manufacture of our product candidates for preclinical or clinical manufacturing, testing, as well as for commercial manufacture of any products that we may commercialize. We employ the services of Fujifilm UK to supply
	the drug substance for CF-301. We do not yet have contracts to produce a commercial supply of the drug substance for CF-301; however, we intend to pursue agreements with Fujifilm UK to do so. We employ the services of CanGene to produce CF-301 in
	its final vialed drug product form. We do not have contracts for the commercial supply of CF-301. We intend to pursue agreements with third party manufacturers regarding commercial supply of vialed drug product at an appropriate future time. We may
	choose to locate second fill finish third party manufacturers to supply other world regions such as the European Union or Asia.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Sales, Marketing and
	Distribution
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not currently have an organization for the sales, marketing and distribution of pharmaceutical products. We may
	rely on licensing and co-promotion agreements with strategic partners for the commercialization of our products in the United States and other territories. If we choose to build a commercial infrastructure to support marketing in the United States,
	such commercial infrastructure could be expected to include a targeted sales force supported by sales management, internal sales support, an internal marketing group and distribution support. To develop the appropriate commercial infrastructure
	internally, we would have to invest financial and management resources, some of which would have to be deployed prior to any confirmation that any of our other products will be approved.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Research and Development Expenses
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We
	have invested $15.0 million, $8.9 million and $9.1 million in research and development expenses for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Government Regulation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The production,
	distribution, and marketing of products employing our research and intellectual property or that we may license from third parties are subject to extensive governmental regulation in the United States and in other countries. In the United States,
	our products will be regulated as biologics and subject to the Federal Food, Drug, and Cosmetic Act, as amended (the &#147;FDC Act&#148;), the Public Health Service Act, as amended (the &#147;PHSA&#148;) and the regulations of the FDA, as well as to
	other federal, state, and local statutes and regulations. These laws, and similar laws outside the United States, govern the research, development, clinical and preclinical testing, manufacture, safety, effectiveness, approval, labeling,
	distribution, sale, import, export, storage, record-keeping, reporting, advertising, and promotion and marketing of our products. Product development and approval within this regulatory framework, if successful, will require the expenditure of
	substantial resources and take years to achieve. Violations of regulatory requirements at any stage may result in various adverse consequences, including the FDA&#146;s and other health authorities&#146; delay in approving or refusal to approve a
	product and may result in enforcement actions and administrative or judicial sanctions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following provides further information on
	certain legal and regulatory requirements that have the potential to affect our operations and the future marketing of our products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	FDA Approval
	Process
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDC Act and other
	federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution,
	post-
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	20
</P>
<A NAME="eolPage24"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human
	being are subject to regulation under the FDC Act, except the section of the FDC Act which governs the approval of new drug applications (&#147;NDAs&#148;). Biological products are approved for marketing under provisions of PHSA, via a BLA. However,
	the application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company
	to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
	civil penalties, and criminal prosecution.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pharmaceutical product development for a new product or certain changes to an approved product
	in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the
	safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type,
	complexity, and novelty of the product or disease.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preclinical tests include laboratory evaluation of product chemistry, formulation, and
	toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The
	results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical tests,
	such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A 30-day waiting period after
	the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients under the supervision
	of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice (&#147;GCP&#148;), an international standard meant to protect the rights and health
	of healthy volunteers or patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the
	effectiveness criteria to be evaluated. Each protocol involving testing on healthy volunteers or patients in the U.S. and subsequent protocol amendments must be submitted to the FDA as part of the IND.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that
	the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be
	submitted to an IRB for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other conditions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clinical trials to support NDAs or BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.
	In Phase 1, the initial introduction of the drug or biologic into healthy human subjects or patients, the product is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if
	possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify
	common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	21
</P>
<A NAME="eolPage25"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical
	trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug or biologic and to provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase 3
	clinical trials to demonstrate the efficacy of the drug or biologic. A single Phase 3 trial with other confirmatory evidence may be sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a
	statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or
	ethically impossible.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA. FDA approval
	of the NDA or BLA is required before marketing of the product may begin in the United States. The NDA or BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#146;s
	pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. The submission of most NDAs and BLAs is additionally subject to a substantial application user fee, currently set at $2,374,200,
	and the manufacturer and/or sponsor under an approved NDA or BLA are also subject to annual product and establishment user fees, currently set at $114,450 per product and $585,200 per establishment. These fees are typically increased annually.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the
	agency&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs
	and BLAs. The FDA aims to review applications for standard review drug or biologic products within twelve months of the submission of the application, and the goal is to review applications for priority review drugs or biologics in eight months of
	the date of submission. Priority review can be applied to applications for drugs or biologics that are intended to treat a serious disease or condition and that, if approved, would provide a significant improvement in safety or effectiveness. The
	review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDA may also refer applications for novel drug or biologic products, or drug or biologic products that present difficult questions of
	safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the
	recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the
	facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practices (&#147;cGMPs&#148;) is satisfactory and the NDA or BLA contains data that provide
	substantial evidence that the drug or biologic is safe and effective in the indication studied.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	After the FDA evaluates the NDA or BLA
	and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in
	order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such
	resubmissions in two or six months depending on the type of information included.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	An approval letter authorizes commercial marketing of
	the drug or biologic with specific prescribing information for specific indications. As a condition of NDA or BLA approval, the FDA may require a risk evaluation and mitigation strategy (&#147;REMS&#148;), to help ensure that the benefits of the
	drug or biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	22
</P>
<A NAME="eolPage26"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	elements to assure safe use (&#147;ETASU&#148;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
	circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, product approval may require substantial post-approval testing
	and surveillance to monitor the product&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing
	processes or facilities, require submission and FDA approval of a new NDA or BLA or NDA or BLA supplement before the change can be implemented. An NDA or BLA supplement for a new indication typically requires clinical data similar to that in the
	original application, and the FDA uses the same procedures and actions in reviewing NDA or BLA supplements as it does in reviewing NDAs or BLAs.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Post-Approval Requirements
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the
	post-approval marketing and promotion of drugs and biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving
	the internet. Drugs and biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require
	post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality
	control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug and biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
	certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue
	to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory
	standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Fast Track Designation and Accelerated Approval
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDA administers a number of programs to facilitate the development, and expedite the review, of drugs or biologics that are intended for
	the treatment of serious or life-threatening diseases or conditions. For instance, a sponsor may seek the FDA&#146;s designation of its product candidate as a &#147;fast track&#148; product. Fast track products are those products intended for the
	treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address unmet medical needs for such disease or condition. Drugs that qualify as a qualified infectious disease product, or QIDP, under the
	recently enacted Generating Antibiotic Incentives Now, or GAIN Act, are also eligible for fast track designation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under the fast track
	program, the sponsor of a new drug or biologic candidate may request that the FDA designate the candidate for a specific indication as a fast track drug or biologic concurrent with, or after, the filing of the IND for the candidate. The FDA must
	determine if the drug or biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. If fast track designation is obtained, the FDA may initiate review of sections of a the marketing application
	before the application is complete. This &#147;rolling review&#148; is available if the applicant provides and the FDA approves a schedule for the remaining information. However, the FDA&#146;s time period goal for reviewing an application does not
	begin until the last section of the NDA or BLA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	23
</P>
<A NAME="eolPage27"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	believes that the designation is no longer supported by data emerging in the clinical trial process. In addition, a product candidate that receives fast track designation is eligible for more
	frequent meetings with the FDA to discuss the product&#146;s development plan and ensure collection of appropriate data needed to support approval and more frequent communications from FDA regarding such things as the design of the proposed clinical
	trials and use of biomarkers, as applicable. In August 2015, the FDA granted fast track designation to CF-301 for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, including endocarditis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In some cases, a fast track product may be approved under the accelerated approval program, which means that the approval may be made on the
	basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on
	irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement
	of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A drug or biologic candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
	Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug or
	biologic from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Breakthrough Therapy Designation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDA is required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or
	life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy
	program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if
	the drug candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Pediatric Information
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under the Pediatric Research Equity Act (&#147;PREA&#148;), NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety
	and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial
	waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Additional Controls for Biologics
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for
	products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages
	and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing
	process, the manufacturer is required to perform certain tests on each lot of the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	24
</P>
<A NAME="eolPage28"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a
	release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral
	vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs,
	after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Biosimilars
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	Biologics Price Competition and Innovation Act of 2009 (&#147;BPCIA&#148;), created an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product.
	Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological
	product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical studies, animal studies, and at least one clinical study, absent a waiver by the Secretary. A biosimilar product may be deemed
	interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the
	reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. In March 2015, the FDA approved the first biosimilar
	product in the U.S., though no interchangeable products have been approved under the BPCIA to date. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are
	manufactured, pose significant hurdles to implementation which are still being evaluated by the FDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under the BPCIA, an application for
	a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years
	from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product
	containing that company&#146;s own preclinical and clinical data from adequate and well-controlled trials to demonstrate the safety, and efficacy of their product. The first biologic product submitted under the abbreviated approval pathway that is
	determined to be interchangeable with the reference product may also enjoy a period of exclusivity. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies,
	which are governed by state pharmacy law.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Disclosure of Clinical Trial Information
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial
	information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to
	discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information
	to gain knowledge regarding the progress of development programs.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Other Domestic Regulatory Requirements
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the United States, the research, manufacturing, distribution, sale, and promotion of drug and biological products are potentially subject to
	regulation by various federal, state, and local authorities in addition to the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	25
</P>
<A NAME="eolPage29"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of the Inspector General), the United
	States Department of Justice and individual United States Attorneys&#146; offices within the Department of Justice, and state and local governments. For example, sales, marketing, and scientific/educational grant programs must comply with the
	anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or &#147;HIPAA&#148;, as amended by the Health Information Technology
	and Clinical Health Act, or &#147;HITECH&#148;, and similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act
	of 1992, each as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to
	federal and state consumer protection, unfair competition, and other laws, and violations of these laws may result in imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to
	restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program Anti-Kickback Statute prohibits, among other things, knowingly
	and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or
	other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. In addition, a person or
	entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations of the Anti-Kickback Statute are punishable by imprisonment, criminal fines, civil monetary penalties
	and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and
	safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal
	government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they
	report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the
	product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which
	apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HIPAA also created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to
	execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare
	offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
	Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers.
	The Patient Protection and Affordable Care Act, as amended by the Health Care
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	26
</P>
<A NAME="eolPage30"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes new reporting requirements on drug manufacturers for payments made by them to physicians
	and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or
	up to an aggregate of $1 million per year for &#147;knowing failures&#148;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Drug
	manufacturers are required to submit reports to the government by the 90th day of each calendar year. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the
	tracking and reporting of gifts, compensation and other remuneration to physicians.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may also be subject to data privacy and security
	regulation by both the federal government and the states in which we conduct our business. HIPAA, HITECH, and their respective implementing regulations, including the final omnibus rule published on January&nbsp;25, 2013, imposes specified
	requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to &#147;business associates,&#148;
	defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and
	criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
	HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in
	significant ways, thus complicating compliance efforts.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Moreover, ContraFect is now, and in the future may become, subject to additional
	federal, state, and local laws, regulations, and policies relating to safe working conditions, laboratory practices, the experimental use of animals, and/or the use, storage, handling, transportation, and disposal of human tissue, waste, and
	hazardous substances, including radioactive and toxic materials and infectious disease agents used in conjunction with our research work.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Physician Drug Samples
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The
	Prescription Drug Marketing Act, or the PDMA, imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program
	meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	New Legislation and Regulations
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing
	the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and
	our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations changed or what the effect of such changes, if any, may be.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Foreign Regulation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to regulations in the United States, we may become subject to widely varying foreign regulations, which may be quite different from
	those of the FDA, governing clinical trials, manufacture, product
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	27
</P>
<A NAME="eolPage31"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	registration and approval, and pharmaceutical sales. Whether or not FDA approval has been obtained, we must obtain a separate approval for a product by the comparable regulatory authorities of
	foreign countries prior to the commencement of product marketing in these countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. In certain countries, regulatory
	authorities also establish pricing and reimbursement criteria. In addition, under current United States law, there are restrictions on the export of products not approved by the FDA, depending on the country involved and the status of the product in
	that country.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Pharmaceutical Coverage, Pricing and Reimbursement
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our ability to commercialize our product candidates successfully will depend in part on the extent to which the United States and foreign
	governmental authorities, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. In many of the markets where we would commercialize a product
	following regulatory approval, the prices of pharmaceutical products are subject to direct price controls (by law) and to drug reimbursement programs with varying price control mechanisms. Public and private health care payors control costs and
	influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others
	within a therapeutic class. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered. In particular, many public and private health care payors limit
	reimbursement and coverage to the uses of a drug that are either approved by the FDA or that are supported by other appropriate evidence (for example, published medical literature) and appear in a recognized drug compendium. Drug compendia are
	publications that summarize the available medical evidence for particular drug products and identify which uses of a drug are supported or not supported by the available evidence, whether or not such uses have been approved by the FDA.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Healthcare Reform
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the United States,
	there have been a number of legislative and regulatory changes to the healthcare system in ways that could affect our future revenues and profitability and the future revenues and profitability of our potential customers. For example, the Medicare
	Prescription Drug, Improvement, and Modernization Act of 2003 (the &#147;MMA&#148;) revised the payment methodologies for many drugs, which resulted in reduced reimbursement to providers. Additionally, the MMA created an outpatient prescription drug
	benefit which became effective on January&nbsp;1, 2006. This benefit is administered by private pharmacy benefit managers and other managed care organizations and is putting increased pressure on the pharmaceutical industry to reduce prices.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In March 2010, the Affordable Care Act was passed, which substantially changes the way health care is financed by both governmental and
	private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates
	owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program
	and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and a new Medicare Part D coverage gap discount program, in
	which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered
	under Medicare Part D.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, other legislative changes have been proposed and adopted in the United States since the Health Care
	Reform Law was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	28
</P>
<A NAME="eolPage32"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic
	reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal year, which went into effect in April 2013, due to subsequent legislative amendments to the statute, and will remain
	in effect through 2025 unless additional Congressional action is taken.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If additional state and federal healthcare reform measures are
	adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, we could expect such measures to result in reduced demand for our product candidates or additional pricing
	pressures.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Segment Reporting
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are
	engaged solely in the discovery and development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. Accordingly, we have determined that we operate in one operating segment.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Scientific Advisors
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have
	assembled a world-class scientific advisory board that includes renowned experts in infectious diseases. These advisors work in close collaboration with our scientists to identify new research directions and accelerate our infectious disease
	programs. Our scientific advisory board is led by Dr.&nbsp;Vincent&nbsp;A. Fischetti, the founder of our lysin technology.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="32%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="65%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Primary Affiliation
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Vincent A. Fischetti, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	The Rockefeller University, Laboratory of Bacterial Pathogenesis and Immunology
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Daniel Capon, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Blood Systems Research Institute
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Adolfo Garcia-Sastre, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Mount Sinai School of Medicine, Department of Microbiology; Global Health &amp; Emerging Pathogens Institute
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Peter Palese, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Mount Sinai School of Medicine, Department of Microbiology
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Leon G. Smith, M.D., M.A.C.P.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Formerly, Saint Michael&#146;s Medical Center, New Jersey
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Employees
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of March 9, 2016, we had 31 full-time employees, including 9 employees with M.D. or Ph.D. degrees. Of these full-time employees, 15
	employees are engaged in research and development activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Corporate Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We were
	incorporated under the laws of the State of Delaware in March 2008. Our executive offices are located at 28 Wells Avenue, 3rd Floor, Yonkers, NY 10701, and our telephone number is (914)&nbsp;207-2300. Our website address is www.contrafect.com.
	References to our website are inactive textual references only and the content of our website should not be deemed incorporated by reference into this Form 10-K.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Available Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our Annual Reports
	on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to these reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge
	on our website located at www.contrafect.com as soon as reasonably practicable after they are filed with or furnished to the Securities and Exchange Commission (the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	29
</P>
<A NAME="eolPage33"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;SEC&#148;). These reports are also available at the SEC&#146;s Internet website at www.sec.gov. The public may also read and copy any materials filed with the SEC at the SEC&#146;s Public
	Reference Room at 100 F Street, N.E., Washington D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics, Whistleblower Policy and the charters of the Audit
	Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.contrafect.com, under &#147;Corporate Governance&#148; and are available in print to any person who requests copies by contacting us
	by calling (914)&nbsp;
	207-2300 or by writing to ContraFect Corporation, Attn: General Counsel, 28 Wells Avenue, 3rd Floor, Yonkers, NY 10701.
</P>
</EFX_BUSINESS>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_2">
</A>
	Item&nbsp;1A.
	Risk Factors
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	You should carefully consider the following risk factors, as well as the other information in this report, and in our
	other public filings. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or
	indirectly, cause the Company&#146;s actual results of operations and financial condition to vary materially from past, or from anticipated future, results of operations and financial condition. Any of these factors, in whole or in part, could
	materially and adversely affect the Company&#146;s business, financial condition, results of operations and common stock price. Other factors may exist that we do not consider significant based on information that is currently available. In
	addition, new risks may emerge at any time, and we cannot predict those risks or estimate the extent to which they may affect us. Past financial performance should not be considered to be a reliable indicator of future performance, and investors
	should not use historical trends to anticipate results or trends in future periods.
</I>
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to Our Financial Position and
	Need for Additional Capital
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have incurred significant losses since our inception and do not expect to generate revenue for at least the next
	several years. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We
	are a clinical-stage biopharmaceutical company with no approved products, and we have not generated any revenue from product sales to date. To date, we have focused exclusively on developing our product candidates and have funded our operations
	primarily through public sale of units and private sales of common stock, convertible preferred stock and issuances of convertible debt to our investors. We have not yet demonstrated an ability to overcome many of the risks and uncertainties
	frequently encountered by companies in the pharmaceutical industry, and you should analyze our company in light of such risks and uncertainties.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Since inception, we have incurred significant operating losses. Our net loss was $25.1 million for the year ended December&nbsp;31, 2015. We
	have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. The net losses we incur may fluctuate significantly
	from quarter to quarter and year to year.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We anticipate that our expenses will increase substantially in connection with commencing
	clinical trials for any of our product candidates. Our expenses will increase if and as we:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seek to discover or develop additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seek marketing approvals for any of our product candidates that successfully complete clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	in-license or acquire other products and technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	maintain, expand and protect our intellectual property portfolio;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	30
</P>
<A NAME="eolPage34"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	hire additional clinical, quality control and scientific personnel; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our recurring losses from operations could raise substantial doubt regarding our ability to continue as a going concern.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We currently operate with limited resources. We believe that our cash, cash equivalents and marketable securities balance of $32.9 million as
	of December 31, 2015 will be sufficient to fund our projected operations into the first half of 2017. Depending on the level of cash used in or generated from operations, additional capital may be required to sustain operations. We have incurred
	significant losses since our inception and have never generated revenue or profit, and it is possible we will never generate revenue or profit. Meaningful revenues will likely not be available until and unless any future product candidates are
	approved by the FDA or comparable regulatory agencies in other countries and successfully marketed, either by us or a partner, an outcome which may not occur. There is no assurance that other financing will be available when needed to allow us to
	continue as a going concern. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations. If we are unable to continue as
	a going concern, you could lose all or part of your investment in our Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We currently have no source of product revenue and have not yet
	generated any revenues from product sales.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To date, we have not completed the development of any products and have not generated
	any revenues from product sales. Our ability to generate revenue from product sales and achieve profitability will depend upon our ability to successfully commercialize products, including any of our current product candidates, or other product
	candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for these product candidates, we may never generate revenues that are significant enough to achieve profitability. Our
	ability to generate revenue from product sales from our current or future product candidates also depends on a number of additional factors, including our ability to:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	successfully complete development activities, including the necessary clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	complete and submit BLAs to the FDA, and obtain regulatory approval for indications for which there is a commercial market;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	complete and submit applications to, and obtain approval from, foreign regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	set a commercially viable price for our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	develop a commercial organization capable of sales, marketing and distribution for any products we intend to sell ourselves in the markets which we choose to commercialize on our own;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	find suitable distribution partners to help us market, sell and distribute our products in other markets; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtain coverage and adequate reimbursement from third parties, including government and private payors.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, because of the numerous risks and uncertainties associated with product development, including that any of our product candidates
	may not advance through development or achieve the desired endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we
	are able to complete the development and regulatory process for any product candidates, we anticipate incurring significant costs associated with commercializing these products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if we are able to generate revenues from the sale of our products, we may not become profitable. If we do achieve profitability, we may
	not be able to sustain or increase profitability on a quarterly or annual basis. Our
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	31
</P>
<A NAME="eolPage35"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital to expand our business or continue our operations. A decline in the
	value of our company could also cause you to lose all or part of your investment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have a need for substantial additional funding. If we are
	unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the clinical development of CF-301
	and commence the clinical development of CF-404, make acquisitions of new products and technologies and, possibly, acquire and develop other product candidates. Accordingly, we will need to obtain substantial additional funding in connection with
	our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our future capital requirements will depend on many factors, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the complexity, timing and results of our clinical trials of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs, timing and outcome of regulatory review of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs of developing our product candidates for additional indications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to establish scientific or business collaborations on favorable terms, if at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs of preparing, filing and prosecuting patent or other intellectual property applications, maintaining and protecting our intellectual property rights and defending against intellectual property-related claims;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the extent to which we in-license or acquire other products and technologies; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the scope, progress, results and costs of product development for our product candidates.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Conducting clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the
	necessary data or results to obtain marketing approval and achieve product sales. In addition, if approved, CF-301, CF-404 or any other product candidate that we develop may not achieve commercial success. Accordingly, we may need to continue to
	rely on additional financing to achieve our business objectives. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future
	operating plans. Adequate additional financing may not be available to us on acceptable terms, or at all.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Raising additional capital may cause
	dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Until such time, if ever, as we can generate substantial product revenues, we may finance our cash needs through a combination of equity
	offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity
	or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve
	agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
	parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	32
</P>
<A NAME="eolPage36"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights
	to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our short operating history may make it
	difficult for you to evaluate the success of our business to date and to assess our future viability.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We were incorporated in
	2008 and commenced active research operations in 2010. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital and acquiring and developing CF-301, CF-404 and other potential products. We
	have not yet demonstrated our ability to successfully complete Phase 2 or Phase 3 clinical trials, obtain marketing approval, manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing
	activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to
	transition from a company with a product development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	The timing of the milestone and royalty payments we are required to make under certain agreements, including to Rockefeller and Trellis, is uncertain
	and could adversely affect our cash flows and results of operations.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are party to certain agreements, including with
	Rockefeller and Trellis, pursuant to which we have acquired licenses to certain patents and patent applications and other intellectual property related to a series of compounds, including CF-301 and CF-404, to develop and commercialize therapeutics.
	Under our agreements with Rockefeller and Trellis, we have obligations to achieve diligence minimums and to make payments upon achievement of specified development and regulatory milestones. We will also make additional payments upon the achievement
	of future sales milestones and for royalties on future net sales.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The timing of milestone payments under our licenses and sponsored
	research agreements is subject to factors relating to the clinical and regulatory development and commercialization of products, many of which are beyond our control. We may become obligated to make a milestone payment when we do not have the cash
	on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization and marketing efforts or seek funds to meet these obligations on terms unfavorable to us.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under Section&nbsp;382 and related provisions of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), if a corporation
	undergoes an &#147;ownership change&#148; (generally defined as a greater than 50% change (by value) in its equity ownership over a three year period), the corporation&#146;s ability to use its pre-change net operating loss carryforwards and other
	pre-change tax attributes to offset its post-change income may be limited. As a result of our past transactions, we may have experienced an &#147;ownership change.&#148; At this time, we have not completed a study to assess whether an ownership
	change under Section&nbsp;382 of the Code has occurred, or whether there have been multiple ownership changes since our formation, due to the costs and complexities associated with such a study. We may also experience ownership changes in the future
	as a result of subsequent shifts in our stock ownership. Thus, our ability to utilize carryforwards of our net operating losses and other tax attributes to reduce future tax liabilities may be substantially restricted. Further, U.S. tax laws limit
	the time during which these carryforwards may be applied against future taxes. Therefore, we may not be able to take full advantage of these carryforwards for federal or state tax purposes. As of December&nbsp;31, 2015, we had federal and state net
	operating loss carryforwards of approximately $91.6 million and $96.1 million, respectively, and federal research and development credits of approximately $1.5 million, the use of which could be limited or eliminated by virtue of one or more
	&#147;ownership changes.&#148;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	33
</P>
<A NAME="eolPage37"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are heavily dependent on the success of our leading product candidates, CF-301 and CF-404. The approval process of the FDA and comparable
	foreign regulatory authorities is lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for CF-301, CF-404 or any other product candidate our business will be substantially harmed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our near-term business prospects are substantially dependent on our ability to develop and commercialize CF-301 and CF-404. We
	cannot market or sell CF-301, CF-404 or any other product candidate in the United States without FDA approval, but this approval, if ever issued, is at least several years away. To commercialize CF-301, CF-404 or any other product candidate outside
	of the United States, we will need applicable foreign regulatory approvals. The clinical development of CF-301, CF-404 or any other product candidate is susceptible to the inherent risks of any drug development program, including a failure to
	achieve efficacy across a broad population of patients, the potential occurrence of severe adverse events and the risks that the FDA or any applicable foreign regulatory authority will determine that a drug product is not approvable.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The process required to obtain approval for commercialization from the FDA and similar foreign authorities is unpredictable, and typically
	takes many years even after the commencement of clinical trials, depending on numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to obtain regulatory approval may change during the course
	of a product&#146;s clinical development. We may fail to obtain regulatory approval for CF-301, CF-404 or any other product candidate for many reasons, including the following:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we may not be able to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that CF-301, CF-404 or any other product candidate is safe and effective for any indication;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the results of clinical trials may not meet the level of clinical or statistical significance required for approval by the FDA or comparable foreign regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we may not be able to demonstrate that CF-301, CF-404 or any other product candidate&#146;s clinical and other benefits outweigh its safety risks;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or comparable foreign regulatory authorities may identify deficiencies in data generated at our clinical trial sites;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or comparable foreign regulatory authorities may identify deficiencies in the clinical practices of the third-party contract research organizations (&#147;CROs&#148;) we use for clinical trials; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or comparable foreign regulatory authorities may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or our collaborators enter into agreements for
	clinical and commercial supplies.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This lengthy approval process as well as the unpredictability of future clinical trial
	results may prevent us from obtaining regulatory approval to market CF-301, CF-404 or any other product candidate, which would significantly harm our business.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	34
</P>
<A NAME="eolPage38"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If clinical trials of CF-301, CF-404 or any other product candidate that we develop fail to demonstrate
	safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to
	complete, the development and commercialization of CF-301, CF-404 or any other product candidate.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Before obtaining marketing
	approval from regulatory authorities for the sale of CF-301, CF-404 or any other product candidate, we must complete preclinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in
	humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing
	and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying
	interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive
	marketing approval or commercialize our product candidates, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	clinical trials of our product candidates may produce negative or inconclusive results, or significant adverse side effects, and we may decide, or regulators may require us, to conduct additional clinical trials or
	abandon product development programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these
	clinical trials at a higher rate than we anticipate;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulators or institutional review boards (&#147;IRBs&#148;) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we may voluntarily suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulators or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being
	exposed to unacceptable health risks;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost of clinical trials of our product candidates may be greater than we anticipate;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we are required to conduct additional clinical trials or other testing of CF-301, CF-404 or any other product candidate that we develop
	beyond those that we contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety
	concerns, we may:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	be delayed in obtaining marketing approval or sales revenues for our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	35
</P>
<A NAME="eolPage39"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not obtain marketing approval at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtain approval for indications or patient populations that are not as broad as intended or desired;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	be subject to additional post-marketing testing requirements; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	have the product removed from the market after obtaining marketing approval.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our product
	development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant
	clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or may allow our competitors to bring products to market before we do and may impair our ability to
	successfully commercialize our product candidates and may harm our business and results of operations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may be required to suspend or discontinue
	clinical trials due to adverse side effects or other safety risks that could preclude approval of CF-301, CF-404 or any other product candidates.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our clinical trials may be suspended at any time for a number of reasons. For example, it is possible that exposure to CF-301 could result in
	adverse clinical events such as localized inflammation in the region surrounding blood vessels, or having a hypersensitivity reaction, such as serum sickness or anaphylaxis. A clinical trial may be prevented from commencing or may be suspended or
	terminated by us, our collaborators, IRBs, the FDA or other regulatory authorities due to the risks of or occurrence of such adverse events, an unacceptable safety risk to participants, a failure to conduct the clinical trial in accordance with
	regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions,
	lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the data safety monitoring board or IRBs for a clinical trial. We may voluntarily suspend or terminate our clinical trials if at any time we believe that
	they present an unacceptable risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to
	generate product revenues, if at all, from any of these product candidates will be delayed or eliminated. Any of these occurrences may significantly harm our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Delays in clinical trials are common and have many causes, and any such delays could result in increased costs to us and jeopardize, delay or prevent
	our ability to obtain regulatory approval and commence product sales as currently contemplated.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may experience delays in
	clinical trials of our product candidates. Our planned clinical trials might not begin on time, might need to be redesigned, might not enroll a sufficient number of patients or might not be completed on schedule, if at all. Clinical trials can be
	delayed for a variety of reasons, including the following:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	imposition of a clinical hold by the FDA or other regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in recruiting suitable patients to participate in a trial;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in having patients complete participation in a trial or return for post-treatment follow-up;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	clinical sites dropping out of a trial to the detriment of enrollment;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	adverse side effects in patient populations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	time required to add new sites;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	36
</P>
<A NAME="eolPage40"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in obtaining sufficient supplies of clinical trial materials; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays resulting from negative or equivocal findings of the data safety monitoring board for a trial.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the
	patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages
	of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing our clinical trials could increase our costs, slow down our
	product development and approval process and jeopardize our ability to commence product sales and generate revenues.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are significantly dependent
	on our license agreements with Rockefeller that relate to CF-301.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under our various license agreements with Rockefeller, we are
	obligated to use our diligent efforts to develop and commercialize licensed products, including CF-301. Rockefeller may terminate the agreement in the event of our breach of the terms of the license agreements. In the event of such termination,
	Rockefeller has the right to retain its license and other rights under the agreement, subject to continuing royalties and other obligations. Our breach of the agreement, including non-payment of any milestone payment, and Rockefeller&#146;s
	subsequent termination of the agreement, could result in the loss of our rights to develop and commercialize CF-301, which would seriously harm our ability to generate revenues or achieve profitability.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We rely on CROs to conduct our preclinical studies and will rely on CROs to conduct our clinical trials. If these third parties do not successfully
	carry out their contractual duties or meet expected deadlines, we may be delayed in obtaining, or may ultimately not be able to obtain, regulatory approval for commercialization of CF-301, CF-404 or any other product candidates.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have relied and will continue to rely on CROs for the execution of our preclinical studies and to recruit patients and monitor and manage
	data for our clinical programs for CF-301, CF-404 or any other product candidate. We control only certain aspects of our CROs&#146; activities, but we are responsible for ensuring that each of our studies is conducted in accordance with the
	applicable protocol and legal, regulatory and scientific standards. Our reliance on the CROs does not relieve us of these regulatory responsibilities. We and our CROs are required to comply with the FDA&#146;s regulations and current good clinical
	practices (&#147;GCPs&#148;), which is an international guideline meant to protect the rights and health of clinical trial subjects. The FDA enforces its regulations and GCPs through periodic inspections of trial sponsors, principal investigators
	and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our
	product candidates. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. In addition, to evaluate the safety and effectiveness of CF-301, CF-404 or any other product candidate to a
	statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply
	with these regulations or recruit a sufficient number of patients, we may have to repeat clinical trials, which would delay the regulatory approval process.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, our CROs are not our employees and we cannot control whether or not they devote sufficient time and resources to our
	non-clinical, preclinical or clinical programs. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could
	impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the
	clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
	approval for or
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	37
</P>
<A NAME="eolPage41"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	successfully commercialize CF-301, CF-404 or any other product candidate that we seek to develop. As a result, our financial results and the commercial prospects for CF-301, CF-404 or any other
	product candidate that we seek to develop would be harmed, our costs could increase and our ability to generate revenues could be delayed or ended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have no experience as a company in bringing a drug to regulatory approval.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As a company, we have never obtained regulatory approval for, or commercialized, a drug or biologic. It is possible that the FDA may refuse to
	accept any or all of our planned BLAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval of CF-301,
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CF-404
</FONT>
	or any other product
	candidate. If the FDA does not accept or approve any or all of our planned BLAs, it may require that we conduct additional preclinical, clinical or manufacturing validation studies, which may be costly, and submit that data before it will reconsider
	our applications. Depending on the extent of these or any other FDA required studies, approval of any BLA or application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have
	available. Any delay in obtaining, or an inability to obtain, regulatory approvals would prevent us from meeting our timelines for commercializing CF-301, CF-404 or any other product candidate, generating revenues and achieving and sustaining
	profitability.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Even if the FDA approves CF-301, CF-404 or any other product candidate, adverse effects discovered after approval could adversely
	affect our markets.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we obtain regulatory approval for CF-301, CF-404 or any other product candidate that we develop, and we or
	others later discover that our products cause adverse effects, a number of potentially significant negative consequences could result, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory authorities may withdraw their approval of the product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory authorities may require the addition of labeling statements, such as warnings or contraindications or imposition of a risk management strategy;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we may be required to change the way the product is administered, conduct additional clinical studies or restrict the distribution of the product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we could be sued and held liable for harm caused to patients and our liability insurance may not adequately cover those claims; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our reputation may suffer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Any of these events could prevent us from maintaining market
	acceptance of the affected product candidate and could substantially increase the costs of, or prevent altogether, the commercialization of our product candidates.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	There are underlying risks associated with the manufacture of our product candidates, which could include cost overruns, new impurities, difficulties in
	scaling up or reproducing manufacturing processes and lack of timely availability of raw materials.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have not yet manufactured
	all supplies for our contemplated Phase 3 human clinical trials, scaled up the process for manufacture, validated the process, or contractually secured third parties for manufacture and commercial supply.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not currently have nor do we plan to build the infrastructure or capability internally to manufacture CF-301. We employ the services of
	Fujifilm Diosynth Biotechnologies UK LTD (&#147;Fujifilm UK&#148;) to supply the active pharmaceutical ingredient for CF-301. We do not yet have contracts to produce a commercial supply of the active pharmaceutical ingredient of CF-301; however, we
	intend to pursue agreements with Fujifilm UK to do so.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	38
</P>
<A NAME="eolPage42"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We employ the services of CanGene bioPharma (&#147;CanGene&#148;) to produce CF-301 in its final
	vialed drug product form. We do not have contracts for the commercial supply of CF-301 drug product. We intend to pursue agreements with third-party manufacturers regarding commercial supply at an appropriate future time. We intend to locate second
	fill finish third-party manufacturers to supply other world regions such as the European Union or Asia.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Late stage process development
	activities, including manufacturing process scale up and validation of the bulk drug substance, pose inherent risks that may be greater for biological products than for small molecules. The process will undergo a 35-fold scale up from the current
	clinical process and then be repeated under protocol successfully three times for validation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, regulatory requirements could
	pose barriers to the manufacture of our active pharmaceutical ingredient and finished drug product for our product candidates. Our third-party manufacturers are required to comply with cGMPs. As a result, the manufacturing facilities and processes
	used by Fujifilm UK and any of our future manufacturers must pass inspection by the FDA as part of our BLA review and before approval of the applicable product candidate. Similar regulations apply to manufacturers of our products for use or sale in
	foreign countries. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, we will not be able to secure the
	applicable approval for our product candidates. If these facilities are not deemed compliant with cGMPs for the commercial manufacture of our product candidates, we may need to find alternative manufacturing facilities, which would result in
	significant delays of up to several years in obtaining approval. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar
	regulatory requirements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If Fujifilm UK or any alternate supplier of active pharmaceutical ingredient or finished drug product for our
	product candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of its agreement with us or does not devote sufficient time, energy and care to providing our manufacturing needs,
	we could experience significant interruptions in the supply of our product candidates, which could impair our ability to supply our product candidates at the levels required for our clinical trials and commercialization and prevent or delay its
	successful development and commercialization.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Developments by competitors, many of which have greater financial and other resources than we do, may
	render our products or technologies obsolete or non-competitive.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The pharmaceutical and biotechnology industries are intensely
	competitive. We compete directly and indirectly with other pharmaceutical companies, biotechnology companies and academic and research organizations in developing therapies to treat diseases. Smaller or early-stage companies may also prove to be
	significant competitors, particularly through collaborative arrangements with large, established companies. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff
	and experienced marketing and manufacturing organizations and well-established sales forces. We compete with companies that have products on the market or in development for the same indications as our product candidates. We may also compete with
	organizations that are developing similar technology platforms. Competitors may develop more effective, more affordable or more convenient products or may achieve earlier patent protection or commercialization of their products. These competing
	products may render our product candidates obsolete or limit our ability to generate revenue from our product candidates. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being
	concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in
	developing, acquiring or licensing, on an exclusive basis, drug products that are more effective or less costly than CF-301, CF-404 and our other product candidates.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	39
</P>
<A NAME="eolPage43"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	The level of commercial success of CF-301, CF-404 and any other product candidates that we develop will
	depend upon attaining significant market acceptance of these products among physicians and payors.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if CF-301, CF-404 or any
	other product candidates that we develop is approved by the appropriate regulatory authorities for marketing and sale, physicians may not prescribe the approved product. Market acceptance of CF-301, CF-404 and any other product candidate that we
	develop by physicians, patients and payors will depend on a number of factors, many of which are beyond our control, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the indications for which the product is approved;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	acceptance by physicians and payors of each product as a safe and effective treatment;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the availability, efficacy and cost of competitive drugs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the effectiveness of our or any third-party partner&#146;s sales force and marketing efforts;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other health care payors, and/or by government health care programs, including Medicare and Medicaid;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	limitations or warnings contained in a product&#146;s FDA-approved labeling; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	prevalence and severity of adverse side effects.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if the medical community accepts that
	our product candidates are safe and efficacious for their approved indications, physicians may not immediately be receptive to the use or may be slow to adopt our product candidates as accepted treatments for their approved indications. While we
	believe our product candidates may demonstrate significant advantages in clinical studies, we cannot assure you that labeling approved by the FDA will permit us to promote these advantages. In addition, our efforts to educate the medical community
	and third-party payors on the benefits of any product candidates that we develop may require significant resources and may never be successful.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Coverage and reimbursement may not be available for CF-301, CF-404 or any other product candidates that we develop, which could make it difficult for us
	to sell our products profitably.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Market acceptance and sales of CF-301, CF-404 or any other product candidate that we develop
	will depend on coverage and reimbursement policies and may be affected by health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will
	pay for and establish reimbursement levels. We cannot be sure that reimbursement will be available for CF-301, CF-404 or any other product candidate that we develop. Also, we cannot be sure that the amount of reimbursement available, if any, will
	not reduce the demand for, or the price of, our products. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize CF-301, CF-404 or any other product candidate that we develop.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the
	health care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act (&#147;MMA&#148;),
	changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by those covered by Medicare under a new Part D and introduced a new reimbursement methodology based on average sales
	prices
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	40
</P>
<A NAME="eolPage44"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	for Medicare Part B physician-administered drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to use formularies whereby they can limit the number of drugs
	that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and
	other provisions of this legislation could decrease the coverage and price that we receive for any approved products and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often
	follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and therefore any reduction in Medicare reimbursement may result in a similar reduction in payments from private payors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively,
	the &#147;Affordable Care Act&#148;), became law in the United States. The goal of the Affordable Care Act is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. The
	Affordable Care Act, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established
	annual fees on manufacturers of certain branded prescription drugs, required manufacturers to participate in a discount program for certain outpatient drugs under Medicare Part D and promoted programs that increase the federal government&#146;s
	comparative effectiveness research, which will impact existing government healthcare programs and will result in the development of new programs. An expansion in the government&#146;s role in the United States healthcare industry may further lower
	rates of reimbursement for pharmaceutical products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other legislative changes have been proposed and adopted in the United States since
	the Affordable Care Act was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted
	deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of
	Medicare payments to providers of 2%&nbsp;per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2025 unless additional Congressional action is taken. On
	January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, further reduced Medicare payments to several providers.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	While we cannot predict the impact these new laws will have in general or on our business specifically, they may result in downward pressure
	on pharmaceutical reimbursement, which could negatively affect market acceptance of CF-301 or any future products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to
	experience pricing pressures in connection with the sale of CF-301, CF-404 and any other product candidate that we develop, due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional
	legislative proposals. If we fail to successfully secure and maintain coverage and reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our business will be
	harmed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Even if we obtain FDA approval of CF-301, CF-404 or any other product candidate, we may never obtain approval or commercialize our products
	outside of the United States, which would limit our ability to realize their full market potential.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In order to market CF-301,
	CF-404 or any other products outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory
	authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation
	and additional
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	41
</P>
<A NAME="eolPage45"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and require additional preclinical studies or clinical trials
	which would be costly and time consuming. Regulatory requirements can vary widely from country to country and satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition,
	our failure to obtain regulatory approval in the United States or any foreign country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in the United
	States or any foreign country and we do not have experience as a company in obtaining regulatory approval in international markets.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We currently
	have no marketing and sales organization and have no experience in marketing drug products. If we are unable to establish our own marketing and sales capabilities, or enter into agreements with third parties, to market and sell our products after
	they are approved, we may not be able to generate revenues.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not have the capabilities to market, sell and distribute any of
	our drug products. In order to commercialize any products, we must develop these capabilities on our own or make arrangements with third parties for the marketing, sales and distribution of our products. The establishment and development of our own
	sales force would be expensive and time consuming and could delay any product launch, and we cannot be certain that we would be able to successfully develop this capability. As a result, we may seek one or more third parties to handle some or all of
	the sales, marketing or distribution for CF-301, CF-404 or any other product candidate in the United States or elsewhere. However, we may not be able to enter into arrangements with third parties to sell CF-301, CF-404 or any other product candidate
	on favorable terms or at all. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize CF-301, CF-404 or any other product
	candidate that we develop, which would negatively impact our ability to generate product revenues. Further, whether we commercialize products on our own or rely on a third party to do so, our ability to generate revenue will be dependent on the
	effectiveness of the sales force. In addition, to the extent we rely on third parties to commercialize our approved products, we may likely receive less revenues or profits than if we commercialized these products ourselves.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may form or seek strategic alliances in the future, and we may not realize the benefits of such alliances.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may form or seek strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that
	we believe will complement or augment our development and commercialization efforts with respect to CF-301, CF-404 and any future product candidate that we may develop. Any of these relationships may require us to incur non-recurring and other
	charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the
	negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for CF-301, CF-404 and any future product candidate because it may be deemed
	to be at too early of a stage of development for collaborative effort and third parties may not view CF-301, CF-404 and any future product candidate as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into
	new strategic partnership agreements could delay the development and commercialization of CF-301, CF-404 and any other product candidate that we develop, which would harm our business prospects, financial condition and results of operations.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	42
</P>
<A NAME="eolPage46"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance
	Matters
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize,
	or will be delayed in commercializing, CF-301, CF-404 and any future product candidate, and our ability to generate revenue will be materially impaired.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-301, CF-404 and any other product candidate that we develop and the activities associated with their development and commercialization,
	including their design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, importation and exportation are subject to comprehensive regulation by the FDA and other regulatory agencies in the
	United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any product from
	regulatory authorities in any jurisdiction. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish
	the product candidate&#146;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority.
	CF-301, CF-404 and any other product candidate that we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects or other characteristics that may preclude our obtaining marketing
	approval or prevent or limit commercial use.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The process of obtaining marketing approvals, both in the United States and abroad, is
	expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during
	the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and
	comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other
	studies. If we experience delays in obtaining approvals or if we fail to obtain approval of our product candidates that we develop, our ability to generate revenues will be materially impaired.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future
	development and regulatory difficulties.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if we obtain regulatory approval in the United States, the FDA may still impose
	significant restrictions on the indicated uses or marketing of the approved product, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved BLA is obligated to monitor and
	report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product
	labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
	by the FDA and other regulatory authorities for compliance with cGMPs and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or
	frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market
	or suspension of manufacturing.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the
	manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising,
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	43
</P>
<A NAME="eolPage47"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information
	and reports, registration requirements and continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we or our partners fail to comply with applicable regulatory requirements following approval of any of our future product candidates, a
	regulatory agency may:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	issue a warning or untitled letter asserting that we are in violation of the law;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seek an injunction or impose civil or criminal penalties or monetary fines;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	suspend or withdraw regulatory approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	suspend any ongoing clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	refuse to approve a pending BLA or supplements to a BLA submitted by us;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seize product; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	refuse to allow us to enter into supply contracts, including government contracts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Any
	government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
	commercialize our future products and generate revenues.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If foreign approval for CF-301, CF-404 or any other product candidate is obtained, there
	are inherent risks in conducting business in international markets.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercialization of our product candidates in international
	markets is an element of our long-term strategy. If approved for commercialization in a foreign country, we intend to enter into agreements with third parties to market CF-301, CF-404 or any other product candidate whenever it may be approved and
	wherever we have the right to market it. Consequently, we expect that we will be subject to additional risks related to entering into international business relationships, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	potentially reduced protection for intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying
	them locally;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	unexpected changes in tariffs, trade barriers and regulatory requirements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	economic weakness, including inflation, or political instability in particular foreign economies and markets;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	compliance with laws for employees working and traveling abroad;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	foreign taxes, including withholding of payroll taxes;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	foreign currency fluctuations, which could result in increased operating expenses and reduced revenues;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	workforce uncertainty in countries where labor unrest is more common than in the United States;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	production shortages resulting from any events affecting active pharmaceutical ingredient and/or finished drug product supply or manufacturing capabilities abroad;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	failure to comply with the rules and regulations of the Office of Foreign Asset Control, the Foreign Corrupt Practices Act and other applicable anti-bribery rules and regulations in other jurisdictions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	44
</P>
<A NAME="eolPage48"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	These and other risks may materially adversely affect our ability to attain or sustain revenue
	from international markets and therefore materially adversely affect our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Product liability lawsuits against us could divert our
	resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We face an
	inherent risk of product liability exposure related to the testing of CF-301, CF-404 and any other product candidate that we develop in human clinical trials and we will face higher degrees of this risk if we commercially sell any products that we
	develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	distraction of our management or other internal resources from pursuing our business strategies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	decreased demand for any product candidates or products that we may develop;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	injury to our reputation and significant negative media attention;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	withdrawal of clinical trial participants;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	significant costs to defend the related litigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	substantial monetary awards to trial participants or patients;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	loss of revenue; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the inability to commercialize any products that we may develop.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We maintain product
	liability insurance coverage in relation to our clinical trials. Such coverage may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a
	reasonable cost or in an amount adequate to satisfy any liability that may arise.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we fail to comply with environmental, health and safety laws
	and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
	handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may
	also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and wastes, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury
	resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure
	to comply with such laws and regulations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we
	may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and
	regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	45
</P>
<A NAME="eolPage49"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our product candidates may face competition sooner than anticipated.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called the
	Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an
	application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA
	until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing
	product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented
	by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material
	adverse effect on the future commercial prospects for our biological products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We believe that any of our product candidates approved as
	a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product
	candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been
	the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not
	yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our relationships with customers and
	third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits
	and future earnings.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Healthcare providers, physicians and third-party payors play a primary role in the recommendation and
	prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may
	constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations
	include the following:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
	induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity
	does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of
	the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the
	federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
	the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
	Health Act, imposes criminal and civil liability for
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	46
</P>
<A NAME="eolPage50"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
	executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and
	transmission of individually identifiable health information;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
	healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the federal transparency requirements under the Affordable Care Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the
	Children&#146;s Health Insurance Program (with certain exceptions) to report to the Department of Health and Human Services information related to physician payments and other transfers of value and ownership and investment interests held by
	physicians and their immediate family members and payments or other transfers of value made to such physician owners; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
	third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
	government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
	substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and
	regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion
	from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in
	compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	The adverse outcome of litigation or arbitration proceedings commenced by or against us could materially harm our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The adverse outcome of any litigation or arbitration proceedings commenced by or against us could have a material adverse effect on our
	business and impede the achievement of our development and commercialization objectives.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the ordinary course of our operations, claims
	involving our actions, actions of third parties or agreements to which we are a party may be brought by and against us. The claims and charges can involve actual damages, as well as contractually agreed upon liquidated sums. These claims, if not
	resolved through negotiation, are often subject to lengthy and expensive litigation or arbitration proceedings.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	47
</P>
<A NAME="eolPage51"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to Employee Matters and Managing Growth
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our future success depends on our ability to attract and retain qualified personnel.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are dependent on our Chief Executive Officer, Julia P. Gregory, as well as the other principal members of our management and scientific
	teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. The loss of the services of any of these persons could impede the
	achievement of our development and commercialization objectives. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Recruiting and retaining qualified scientific, clinical, and sales and marketing personnel will be critical to our success. We may not be able
	to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also compete for the hiring of scientific and clinical personnel from universities
	and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by
	employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Changes in our management may negatively affect our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our success and the execution of our growth strategy depend largely on the continued service of our senior executive management team. We
	cannot be certain that changes in management or our board of directors will not lead to additional management departures or changes, affect our ability to hire or retain key personnel, or otherwise negatively affect our business. Additionally, we
	cannot be assured of the continued service of our senior management team. The unexpected loss of any members of our senior management team could be disruptive to our operations, jeopardize our ability to raise additional funding and have an adverse
	effect on our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We expect to expand our development, regulatory and sales, marketing and distribution capabilities, and as a result, we may
	encounter difficulties in managing our growth, which could disrupt our operations.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to experience growth in the number
	of our employees and the scope of our operations, particularly in the areas of drug discovery, drug development, regulatory affairs and commercialization. To manage our anticipated future growth, we must continue to implement and improve our
	managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the various levels of experience of our management team in managing a
	company with significant anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may
	divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to Our Intellectual Property
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we or our licensors are unable to obtain and maintain patent protection for our owned or licensed technology and products, or if the scope of the
	patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our success depends in large part on our and our licensors&#146; ability to obtain and maintain patent protection in the United
	States and other countries with respect to our proprietary technology and products or technology or
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	48
</P>
<A NAME="eolPage52"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	products that may have been licensed to us. Similar to our licensors, we seek to protect our proprietary position by filing patent applications in the United States and abroad related to our
	novel technologies and product candidates that are important to our business. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable
	cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of either our or their research and development output before it is too late to obtain patent protection. Moreover, if we license
	technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering this intellectual property.
	These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents without our consent. Therefore, in these circumstances, we could not be certain that these
	patents and applications would be prosecuted and enforced in a manner consistent with the best interests of our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The patent
	position of biotechnology and pharmaceutical companies generally is highly uncertain and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights
	and any patent rights we may license from a third party are highly uncertain. Our or our licensors&#146; pending and future patent applications may not result in issued patents that protect our technology or products, in whole or in part, or which
	effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our or our
	licensors&#146; patents or narrow the scope of such patent protection.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The laws of foreign countries may not protect our rights to the
	same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Assuming the other requirements for patentability are met,
	historically, in the United States, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. The United States currently uses a
	first-inventor-to-file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. Publications of discoveries in the scientific literature often lag
	behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all. Therefore, we cannot be certain that we were the first to make
	the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and
	Trademark Office, or become involved in opposition, derivation, reexamination, litigation, inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse
	determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or
	result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade
	companies from collaborating with us to license, develop or commercialize current or future product candidates.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if our or our
	licensors&#146; patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our
	competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may
	be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
	could limit our ability to prevent others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	49
</P>
<A NAME="eolPage53"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
	or shortly after such candidates are commercialized and such patents may not be able to claim the benefits of any patent term extension laws or regulations. As a result, our patent portfolio may not provide us with sufficient rights to exclude
	others from commercializing products similar or identical to ours.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may become involved in lawsuits to protect or enforce our patents or other
	intellectual property, which could be expensive, time consuming and unsuccessful, and which could result in our patents or other intellectual property rights becoming invalidated.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Competitors may infringe our or our licensors&#146; patents, trademarks, copyrights or other intellectual property. To stop infringement or
	unauthorized use, we or our licensors may be required to file infringement claims, which can be expensive and time consuming. Any claims we or our licensors assert against perceived infringers could provoke these parties to assert counterclaims
	against us alleging that some or all of our patents or other intellectual property rights are not valid or that we or our licensors infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a
	court may decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly, or may refuse to stop the other party from using the technology at issue on the grounds that such
	patents do not cover the technology in question and therefore cannot be infringed. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid, unenforceable, or not infringed, or that the
	party against whom we have asserted trademark infringement claims has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such marks. In any infringement litigation, any award of monetary damages may
	be unlikely or very difficult to obtain, and any such award we may receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk
	that we could incur substantial litigation costs or that some of our confidential information could be compromised by disclosure during this type of litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Third parties may initiate legal proceedings alleging that we or our licensors are infringing their intellectual property rights, the outcome of which
	would be uncertain and could have a material adverse effect on the success of our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our commercial success depends upon
	our ability and the ability of our licensors and collaborators to develop, manufacture, market, and sell our or our licensors&#146; product candidates and use our proprietary technologies without infringing the intellectual property and other
	proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, future adversarial proceedings or litigation regarding
	intellectual property rights with respect to our products and technology, including reexamination or interference proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing or
	future intellectual property rights.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we or our licensors are found to infringe a third party&#146;s intellectual property rights, we
	or our licensors could be enjoined from further using certain products and technology or may be required to obtain a license from such third party to continue developing and marketing such products and technology. However, we may not be able to
	obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including
	by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent or
	other intellectual property rights of a third party. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that
	we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	50
</P>
<A NAME="eolPage54"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may be subject to claims by third parties asserting that we or our employees have misappropriated their
	intellectual property, or claiming ownership of what we regard as our own intellectual property.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Many of our employees were
	previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we use customary non-disclosure agreements and try to ensure that our employees do not use the
	proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
	employee&#146;s former employer. Litigation may be necessary to defend against these claims.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, while we typically require our
	employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
	intellectual property that we regard as our own, or such agreements may be inadequately drafted at times thereby not ensuring assignment to us of all potential intellectual property rights. If we fail in prosecuting or defending any such claims, in
	addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to
	management.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal
	responsibilities.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims
	may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
	proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our
	operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct or defend such litigation or proceedings. Some of our
	competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
	proceedings could have a material adverse effect on our ability to compete in the marketplace.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to seeking patents for some of
	our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into
	non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. However, we
	cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets, nor can we guarantee that such agreements will always be adequately drafted so as to be enforceable. If we are unable to
	protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Enforcing a claim that a party
	illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, because of potential differences in laws in different jurisdictions, some courts inside and outside the
	United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it,
	from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	51
</P>
<A NAME="eolPage55"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have not yet registered our trademarks in all of our potential markets, and failure to secure those
	registrations could adversely affect our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our future trademark applications may not be allowed for registration, and our
	registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections from the U.S. Patent and Trademark Office or other applicable foreign intellectual property offices. Although we are given
	an opportunity to respond to those rejections, we may be unable to overcome such rejections, or have to expend additional resources to secure registrations, such as commencing cancellation proceedings against third-party trademark registrations to
	remove them as obstacles to our trademark applications. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications
	and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more
	difficulty in enforcing them against third parties than we otherwise would.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, we have not yet proposed a proprietary name for
	our product candidates in any jurisdiction. Any proprietary name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark.
	The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant
	additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Risks Related to Our Securities
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	The price of our common stock and Warrants may be volatile and you could lose all or part of your investment.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There has been significant volatility in the market price and trading volume of equity and derivative securities, which is unrelated to the
	financial performance of the companies issuing the securities. In addition, equity markets have experienced significant price and volume fluctuations that have affected the market prices for the securities of biotechnology and also newly public
	companies for a number of reasons, including reasons that may be unrelated to the business or operating performance of the companies. These broad market fluctuations may negatively affect the market price of our common stock.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prior to our initial public offering, there was no public market for our common stock and Class&nbsp;A Warrants to purchase one share of
	common stock at an exercise price of $4.80 per share (the &#147;Class A Warrants&#148;). The trading price of our securities is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are
	beyond are control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this Annual Report, these factors include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to implement our preclinical, clinical and other development or operational plans;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	adverse regulatory decisions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	strategic actions by us or our competitors, such as acquisitions or restructurings;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	new laws or regulations, or new interpretations of existing laws or regulations, applicable to our business;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	actual or anticipated fluctuations in our financial condition or annual or quarterly results of operations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our cash position;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	52
</P>
<A NAME="eolPage56"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	public reaction to our press releases, other public announcements and filings with the SEC;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in investor and financial analyst perceptions of the risks and condition of our business;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in, or our failure to meet, performance expectations of investors or financial analysts (including, without limitation, with respect to the status of development of our lead product candidates);
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in market valuations of biotechnology companies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in key personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	increased competition;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	sales of common stock by us or members of our management team;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	trading volume of our common stock and Class&nbsp;A Warrants;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	issuances of debt or equity securities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the granting or exercise of employee stock options or other equity awards;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in accounting standards, policies, guidance, interpretations or principles;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	ineffectiveness of our internal controls;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	actions by institutional or other large shareholders;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	significant lawsuits, including patent or stockholder litigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	general political, market and economic conditions; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	other events or factors, many of which are beyond our control.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, the stock market
	in general, and the NASDAQ Capital Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad
	market and industry factors may negatively affect the market price of our common stock and Class&nbsp;A Warrants, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against
	companies following periods of volatility in the market price of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s attention and resources, which would harm
	our business, operating results or financial condition.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are required to meet the NASDAQ Capital Market&#146;s continued listing requirements and
	other NASDAQ rules, or we may risk delisting. Delisting could negatively affect the price of our common stock and the Class&nbsp;A Warrants, which could make it more difficult for us to sell securities in a future financing or for you to sell our
	common stock or the Class&nbsp;A Warrants.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are required to meet the continued listing requirements of the NASDAQ Capital
	Market and other NASDAQ rules, including those regarding director independence and independent committee requirements, minimum stockholders&#146; equity, minimum share price and certain other corporate governance requirements. In particular, we are
	required to maintain a minimum bid price for our listed common stock of $1.00 per share. If we do not meet these continued listing requirements, our common stock and the Class&nbsp;A Warrants could be delisted. Delisting from the NASDAQ Capital
	Market would cause us to pursue eligibility for trading of these securities on other markets or exchanges, or on the &#147;pink sheets.&#148; In such case, our stockholders&#146; ability to trade, or obtain quotations of the market value of our
	common stock and the Class&nbsp;A Warrants would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of these securities. There can
	be no assurance that our securities, if delisted from the NASDAQ Capital Market in the future, would be listed on a national securities exchange, a
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	53
</P>
<A NAME="eolPage57"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	national quotation service, the over-the-counter markets or the pink sheets. Delisting from the NASDAQ Capital Market, or even the issuance of a notice of potential delisting, would also result
	in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market liquidity of our securities, decrease securities analysts&#146; coverage of us or diminish investor, supplier and employee confidence.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may issue additional common shares, warrants or other securities to finance our growth.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may finance the development of our product pipeline or generate additional working capital through additional equity financing. Therefore,
	subject to the rules of the NASDAQ, we may issue additional shares of our common stock, warrants and other equity securities of equal or senior rank, with or without shareholder approval, in a number of circumstances from time to time. The issuance
	by us of shares of our common stock, warrants or other equity securities of equal or senior rank will have the following effects:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the proportionate ownership interest in us held by our existing shareholders will decrease;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the relative voting strength of each previously outstanding share of common stock may be diminished; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the market price of our common stock or the Class&nbsp;A Warrants may decline.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition,
	if we issue our common shares and/or warrants in a future offering (or, in the case of our common stock, the exercise of outstanding warrants to purchase our common stock), it could be dilutive to our security holders.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Future sales of our common stock or warrants may cause the market price of our securities to decline.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sales of substantial amounts of shares of our common stock or warrants in the public market, or the perception that these sales may occur,
	could adversely affect the price of our securities and impair our ability to raise capital through the sale of additional equity securities. We have 27.5&nbsp;million shares of common stock outstanding. As of March 9, 2016, 22.8&nbsp;million shares
	of our outstanding common stock are freely tradable, without restriction, in the public market unless held by our &#147;affiliates,&#148; as defined under Rule 144 of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
	Additionally, we have Class&nbsp;A Warrants to purchase 6.9&nbsp;million shares of common stock outstanding as of March 9, 2016. All shares of common stock underlying the Class&nbsp;A Warrants will be freely tradable upon exercise of the
	Class&nbsp;A Warrants unless held by our affiliates. The remaining shares of common stock and the shares of common stock underlying our Class&nbsp;A Warrants are, or will be upon exercise of the Class&nbsp;A Warrants, &#147;restricted
	securities,&#148; as that term is defined in Rule 144 under the Securities Act, and will be freely tradable subject to the applicable holding period, volume, manner of sale and other limitations under Rule 144 or Rule 701 of the Securities Act.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have registered 3,358,270 shares of our common stock as of December&nbsp;31, 2015 that we may issue under our employee benefit plans. These
	shares can be freely sold in the public market upon issuance, unless pursuant to their terms these stock awards have transfer restrictions attached to them. Additionally, pursuant to the 2014 Omnibus Incentive Plan, or the 2014 Plan, our management
	is authorized to grant stock options and other equity linked award to our employees, directors and consultants. The number of shares available for future grant under our 2014 Plan will automatically increase on January&nbsp;1st each year, from
	January&nbsp;1, 2015 through January&nbsp;1, 2024, by an amount equal to four percent of all shares of our capital stock outstanding as of December&nbsp;31st of the preceding calendar year, subject to the ability of our board of directors to take
	action to reduce the size of such increase in any given year. Unless our board of directors elects not to increase the number of shares underlying our 2014 Plan each year, our stockholders may experience additional dilution, which could cause our
	stock price to decline.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	54
</P>
<A NAME="eolPage58"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our executive officers and directors hold a significant concentration of our common stock, which could
	limit the ability of our other stockholders to influence the direction of our Company.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As calculated by the SEC rules of
	beneficial ownership, our executive officers and directors of our Company own 14.7% of our outstanding common stock as of March 9, 2016. Accordingly, they collectively have the ability to significantly influence or determine the election of all of
	our directors or the outcome of most corporate actions requiring stockholder approval such as: (i)&nbsp;a merger or a sale of our Company, (ii)&nbsp;a sale of all or substantially all of our assets and (iii)&nbsp;amendments to our certificate of
	incorporation or bylaws. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our
	stockholders with interests different from those individuals. These individuals also have significant control over our business as officers and directors of our Company. There is a risk that they may exercise this ability in a manner that advances
	their best interests and not necessarily those of our other stockholders.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If shares of our common stock or the Class&nbsp;A Warrants become subject
	to the penny stock rules, it would become more difficult to trade them.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The SEC has adopted regulations which generally define a
	&#147;penny stock&#148; to be an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to specific exemptions, including an exemption for any securities listed on a national
	securities exchange. The rules impose additional sales practice requirements on broker-dealers for transactions involving &#147;penny stock&#148;, with some exceptions. If shares of our common stock or the Class&nbsp;A Warrants were delisted from
	the NASDAQ Capital Market and determined to be &#147;penny stock&#148;, broker-dealers may find it more difficult to trade such securities and investors may find it more difficult to acquire or dispose of such securities on the secondary market.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	The Class&nbsp;A Warrants are a risky investment. You may be unable to exercise your Class&nbsp;A Warrants for a profit.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The value of the Class&nbsp;A Warrants depends on the value of our common stock, which depends on factors related and unrelated to the success
	of our clinical development program and cannot be predicted at this time. The Class&nbsp;A Warrants expire on February&nbsp;1, 2017.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If
	the price of shares of our common stock does not increase to an amount sufficiently above the exercise price of the Class&nbsp;A Warrants during the exercise period of the Class&nbsp;A Warrant, you may be unable to recover any of your investment in
	the Class&nbsp;A Warrants. There can be no assurance that any of the factors that could impact the trading price of our common stock will result in the trading price increasing to an amount that will exceed the exercise price or the price required
	for you to achieve a positive return on your investment in the Class&nbsp;A Warrants.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Holders of the Class&nbsp;A Warrants have no rights as common
	stockholders until they acquire our common stock.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Until holders of the Class&nbsp;A Warrants acquire shares of our common stock
	upon exercise of the Class&nbsp;A Warrants, such holders have no rights with respect to our common stock issuable upon exercise of the Class&nbsp;A Warrants, including the right to receive dividend payments, vote or respond to tender offers. Upon
	exercise of a holder&#146;s Class&nbsp;A Warrants, such holder will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	55
</P>
<A NAME="eolPage59"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Although we are required to use our best efforts to maintain an effective registration statement covering
	the issuance of the shares of common stock underlying the Class&nbsp;A Warrants at the time that holders of our Class&nbsp;A Warrants exercise their Class&nbsp;A Warrants, we cannot guarantee that a registration statement will continue to be
	effective, in which case holders of our Class&nbsp;A Warrants may not be able to receive freely tradable shares of our common stock upon exercise of the Class&nbsp;A Warrants.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Holders of our Class&nbsp;A Warrants are able to exercise the Class&nbsp;A Warrants and receive freely tradable shares only if (i)&nbsp;a
	current registration statement under the Securities Act relating to the shares of our common stock underlying the Class&nbsp;A Warrants is then effective, or an exemption from such registration is available, and (ii)&nbsp;such shares of our common
	stock are qualified for sale or exempt from qualification under the applicable securities laws of the states in which the various holders of Class&nbsp;A Warrants reside. Although we have undertaken, and therefore have a contractual obligation, to
	use our best efforts to maintain a current registration statement covering the shares of common stock underlying the Class&nbsp;A Warrants, we may not be able to do so. If we are not able to do so, holders may not be able to exercise their
	Class&nbsp;A Warrants and receive freely tradable shares of our common stock but rather may only be able to receive restricted shares upon exercise. In addition, we have agreed to use our best efforts to register the shares of our common stock
	underlying the Class&nbsp;A Warrants under the blue sky laws of the states of residence of the existing holders of the Class&nbsp;A Warrants, to the extent an exemption is not available. The value of the Class&nbsp;A Warrants may be greatly reduced
	if a registration statement covering the shares of our common stock issuable upon exercise of the Class&nbsp;A Warrants is not kept current or if the securities are not qualified, or exempt from qualification, in the states in which the holders of
	Class&nbsp;A Warrants reside.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	There can be no assurance that we will ever provide liquidity to our investors through a sale of our
	company
</I>
</B>
<B>
	.
</B>
<B>
<I>
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	While acquisitions of pharmaceutical companies like ours are not uncommon, potential investors are
	cautioned that no assurances can be given that any form of merger, combination, or sale of our company will take place, or that any merger, combination, or sale, even if consummated, would provide liquidity or a profit for our investors. You should
	not invest in our company with the expectation that we will be able to sell the business in order to provide liquidity or a profit for our investors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We incur significant increased costs as a result of operating as a new public company and our management is required to devote substantial time to
	complying with public company regulations.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We completed an initial public offering on August&nbsp;1, 2014. As a new public
	company, we incur significant legal, accounting and other expenses, including costs associated with our public company reporting requirements under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). We must also follow
	the rules, regulations and requirements subsequently adopted by the SEC and the NASDAQ and any failure by us to comply with such rules and requirements could negatively affect investor confidence in us and cause the market price of our common stock
	or Class&nbsp;A Warrants to decline. Our executive officers and other personnel will also need to devote substantial time and financial resources to comply with these rules, regulations and requirements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to
	make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results
	of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. For example, we expect these rules and regulations to make it more difficult and more
	expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to
	respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	56
</P>
<A NAME="eolPage60"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we do not develop and implement all required accounting practices and policies, we may be unable to
	provide the financial information required of a U.S. publicly traded company in a timely and reliable manner.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prior to the IPO,
	we did not adopt all of the financial reporting and disclosure procedures and controls required of a U.S. publicly traded company because we were a privately held company. The implementation of all required accounting practices and policies and the
	hiring of additional financial staff have increased our operating costs and requires significant time and resources from our management and employees. If we fail to maintain effective internal controls and procedures and disclosure procedures and
	controls, we may be unable to provide financial information and required SEC reports that a U.S. publicly traded company is required to provide in a timely and reliable fashion. Any such delays or deficiencies could penalize us, including by
	limiting our ability to obtain financing, either in the public capital markets or from private sources and hurt our reputation and could thereby impede our ability to implement our strategy.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Reports published by analysts, including projections in those reports that exceed our actual results, could adversely affect the price and trading
	volume of our common stock or Warrants.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The projections of securities research analysts may vary widely and may not accurately
	predict the results we actually achieve. The price of our common stock or Class&nbsp;A Warrants may decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write
	reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, the price of our common stock or Class&nbsp;A Warrants could decline. If one or more of these analysts ceases coverage of us or fails to publish
	reports on us regularly, the price or trading volume of our common stock or Class&nbsp;A Warrants could decline.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If securities or industry analysts
	do not publish research or reports about our business, the prices of our securities and trading volume could decline.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The trading
	market for our securities depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If no securities or industry analysts commence coverage of
	our company, the trading prices for our securities may be negatively impacted.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have broad discretion in the use of the net proceeds from our
	initial public offering and private placement and may not use them effectively.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our management has broad discretion in the
	application of the net proceeds from our initial public offering and private placement and could spend the proceeds in ways that do not enhance the value of our common stock. Because of the number and variability of factors that will determine our
	use of the net proceeds from our completed offerings, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could delay the development of our product candidates
	or have a material adverse effect on our business. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses value. If we do not apply or invest the net proceeds from the offering in
	ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of our securities to decline.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
	less attractive to investors.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and may remain an
	emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not
	emerging growth companies. These exemptions include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	57
</P>
<A NAME="eolPage61"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
	additional information about the audit and the financial statements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	reduced disclosure obligations regarding executive compensation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have taken advantage of certain reduced reporting burdens. We cannot predict whether investors will find our securities less attractive if
	we rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our common stock or the Class&nbsp;A Warrants, and the prices for our securities may be more volatile.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have no present intention to pay cash dividends and, even if we change that policy, we may be restricted from paying cash dividends on our common
	stock.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not intend to pay cash dividends for the foreseeable future. We currently expect to retain all future earnings, if
	any, for use in the development, operation and expansion of our business. Any determination to pay cash dividends in the future will depend upon, among other things, our results of operations, plans for expansion, tax considerations, available net
	profits and reserves, limitations under law, financial condition, capital requirements and other factors that our board of directors considers to be relevant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more
	difficult and may prevent attempts by our stockholders to replace or remove our current management.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provisions in our corporate
	charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These
	provisions could also limit the price that investors might be willing to pay in the future for our securities, thereby depressing the market prices of our securities. In addition, because our board of directors is responsible for appointing the
	members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among
	other things, these provisions:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	allow the authorized number of our directors to be changed only by resolution of our board of directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	limit the manner in which stockholders can remove directors from the board of directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	limit who may call stockholder meetings;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#147;poison pill,&#148; that would work to dilute the
	stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
	Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
	voting stock, unless the merger or combination is approved in a prescribed manner.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	58
</P>
<A NAME="eolPage62"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_RISK_FACTORS>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_3">
</A>
	Item&nbsp;1B. Unresolved Staff Comments
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_4">
</A>
	Item&nbsp;2.
	Properties
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the second quarter of 2011, we opened our corporate headquarters and laboratory in Yonkers, New York. This 15,000 sq.
	ft. mixed use office, laboratory space consists of open laboratory and suites for molecular biology, microbiology, tissue culture, microscopy, a vivarium, and a robotics suite. This facility is leased through December&nbsp;31, 2027.
</P>
</EFX_PROPERTIES>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_5">
</A>
	Item&nbsp;3. Legal Proceedings
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
</EFX_LEGAL_PROCEEDINGS>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_6">
</A>
	Item&nbsp;4.
	Mine Safety Disclosures
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	59
</P>
<A NAME="eolPage63"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART II
</B>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_7">
</A>
	Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Market Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our common
	stock has been publicly traded on the NASDAQ Capital Market under the symbol &#147;CFRX&#148;. Trading of our common stock commenced on September&nbsp;12, 2014, the first date that shares of our common stock were publicly traded. Prior to that time,
	there was no public market for our common stock. The following table sets forth the high and low sales prices of our common stock as reported on the NASDAQ Capital Market for each quarter in the years ended December&nbsp;31, 2015 and
	December&nbsp;31, 2014.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
	Fiscal Year Ended December&nbsp;31, 2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	High
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Low
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Third Quarter (Beginning September 12, 2014)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.30
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourth Quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.44
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Fiscal Year Ended December 31, 2015
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	First Quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Second Quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.24
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.92
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Third Quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.80
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.90
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourth Quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Holders
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of March 9, 2016, there were approximately 1,613 holders of record of our common stock. This number does not include beneficial owners whose
	shares are held by nominees in street name.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Dividends
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to
	finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Recent Sales of Unregistered Securities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During the quarter ended December&nbsp;31, 2015, we issued 469,492 shares of common stock upon exercise of Class B Warrants. We received
	aggregate gross proceeds of $1,878,368 from the exercise of the Class B Warrants.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Use of Proceeds from Registered Securities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the Registration Statement on Form S-1 (File No.&nbsp;333-195378), as amended, that was declared effective by the SEC on
	July&nbsp;28, 2014, we registered our units, each unit consisting of one share of common stock, one Class&nbsp;A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B Warrant to purchase one-half share
	of common stock at an exercise price of $4.00 per full share (the &#147;Units&#148;), to be sold in our IPO (including 900,000 Units with respect to an over-allotment option granted by us to the underwriters in the offering). We sold a total of
	6,000,000 Units in the IPO at an initial public offering price per unit of $6.00 for gross proceeds of $36,000,000, and the underwriter of the IPO exercised its over-allotment option on August&nbsp;27, 2014 for another 880,333 Units for additional
	gross proceeds of $5,281,998. The net proceeds of the IPO, after underwriting discount, commissions and offering expenses, to the Company were approximately $35.0 million.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	60
</P>
<A NAME="eolPage64"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There has been no material changes in the planned use of proceeds from our IPO, as described in
	our final prospectus filed with the SEC on July&nbsp;
	29, 2014 pursuant to Rule 424(b)(1) under the Securities Act related to the Company&#146;s IPO.
</P>
</EFX_MARKET>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_8">
</A>
	Item&nbsp;6. Selected
	Financial Data
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following selected financial data should be read in conjunction with Item&nbsp;7, &#147;Management&#146;s
	Discussion and Analysis of Financial Condition and Results of Operations&#148;, the financial statements and the notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We derived the financial data for the years ended December&nbsp;31, 2015, 2014 and 2013 and as of December&nbsp;31, 2015 and 2014 from our
	audited financial statements, which are included elsewhere in this Annual Report on Form 10-K. We derived the financial data for the year ended December&nbsp;31, 2012 and as of December&nbsp;31, 2013 and 2012 from our audited financial statements
	that are not included elsewhere in this Annual Report on Form 10-K. The selected financial data in this section are not intended to replace our financial statements and related notes. Our historical results are not necessarily indicative of our
	future results.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="48%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:101.85PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Statement of Operations Data
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2012
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Loss from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,065,336
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(16,935,911
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(19,296,434
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(19,154,173
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss attributable to common stockholders
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34,617,536
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(19,283,454
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss per share of common stock, basic and diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3.86
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(19.16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	As of December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:66.20PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance Sheet Data
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2012
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash, cash equivalents and marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	32,921,653
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,393,059
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,145,270
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,886,264
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,861,137
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,053,622
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,683,835
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,205,664
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Long-term liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,416,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,249,046
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,481,765
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,502,946
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total stockholders&#146; equity (deficit)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,675,510
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,581,507
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(52,910,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(32,231,516
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_9">
</A>
	Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of
	Operations
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	You should read the following discussion and analysis of our financial condition and results of operations together with
	our financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on
	Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the &#147;Risk factors&#148; section of this Annual Report on Form
	10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
</I>
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Overview
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are a clinical-stage
	biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by
<FONT STYLE="WHITE-SPACE:NOWRAP">
	drug-resistant
</FONT>
	pathogens, particularly those treated in hospital settings. Drug-resistant infections account for two million illnesses in the United States and 700,000 deaths worldwide each year. We intend to address drug-resistant infections using product
	candidates from our lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Lysins are enzymes derived from naturally occurring bacteriophage, which are viruses that infect bacteria. When recombinantly
	produced and then applied to bacteria, lysins cleave a key component of the target bacteria&#146;s peptidoglycan cell wall, which results in rapid bacterial
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	61
</P>
<A NAME="eolPage65"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	cell death. Lysins kill bacteria faster than conventional antibiotics, which typically require bacterial cell division and metabolism in order to kill or stop the growth of bacteria. We believe
	that the properties of our lysins will make them suitable for targeting antibiotic-resistant organisms, such as Staphylococcus aureus (&#147;
<I>
	Staph aureus&#148;)
</I>
	which causes serious infections such as bacteremia, pneumonia and osteomyelitis.
	In addition, our lysins have demonstrated the ability to clear biofilms in animal models, and we believe they may be useful for the treatment of biofilm-related infections in prosthetic joints, indwelling devices and catheters. Beyond our lysin
	programs, we are exploring therapies using monoclonal antibodies (&#147;mAbs&#148;) designed to bind to viral targets. Our approach to antibody therapy employs a combination of multiple mAbs to either achieve greater efficacy or provide broader
	coverage across pathogenic strains.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have not generated any revenues and, to date, have funded our operations primarily through the
	issuance and sale of our Units, which consisted of one share of common stock, one Class&nbsp;A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B Warrant to purchase one-half share of common stock
	at an exercise price of $4.00 per full share (&#147;Units&#148;), common stock, convertible preferred stock and convertible debt to our investors. As of November&nbsp;2, 2015, the date of expiration of the Class B Warrants, holders of the Class B
	Warrants had exercised 4,812,328 Class B Warrants, resulting in the issuance of 2,406,164 shares of the Company&#146;s common stock and the receipt by the Company of approximately $9.6 million in gross proceeds. In June 2015, the Company completed a
	private placement of securities to institutional investors whereby the investors received an aggregate of 4,728,128 shares of the Company&#146;s common stock and warrants to purchase an additional 2,364,066 shares of common stock at an exercise
	price of $8.00 per share. The Company received net proceeds of $18.3 million, net of expenses. In August 2014, we completed our IPO, raising net proceeds of $35.0 million, net of an underwriting discount, commissions and offering expenses. In
	connection with the IPO, our Board of Directors and stockholders approved a 1-for-7 reverse stock split of our common stock. The reverse stock split became effective on July&nbsp;25, 2014. All share and per share amounts in the financial statements
	have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have never been profitable and our net losses from operations were $25.1 million, $30.1 million and $23.6 million for the years ended
	December&nbsp;31, 2015, 2014 and 2013, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses to increase in connection with our ongoing activities, particularly as we
	advance our product candidates through preclinical activities and clinical trials to seek regulatory approval and, if approved, commercialize such product candidates. Additionally, we expect to incur additional costs associated with operating as a
	public company. Accordingly, we will need additional financing to support our continuing operations. We expect to seek to fund our operations through public or private equity, debt financings, equity-linked financings, collaborations, strategic
	alliances, licensing arrangements, research grants or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our
	financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Financial Operations Overview
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Revenue
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have not generated any revenues to date. In the future, we may generate revenues from product sales. In addition, to the extent we enter
	into licensing or collaboration arrangements, we may have additional sources of revenue. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the amount and timing of payments that we may recognize upon the
	sale of our products, to the extent that any products are successfully commercialized, and the amount and timing of fees, reimbursements, milestone and other payments received under any future licensing or collaboration arrangements. If we fail to
	complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	62
</P>
<A NAME="eolPage66"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Research and development expenses
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and
	the development of our product candidates, which include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	employee-related expenses, including salaries, benefits, travel and non-cash share-based compensation expense;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	external research and development expenses incurred under arrangements with third parties such as contract research organizations, or CROs, contract manufacturers, consultants and academic institutions; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	facilities and laboratory and other supplies.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expense research and development costs to
	operations as incurred. We account for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received,
	rather than when the payment is made.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following summarizes our most advanced current research and development programs.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-301: lead lysin program
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-301
	is a parenteral, potent, bactericidal lysin targeting
<I>
	Staph aureus
</I>
	bacteria, making it a highly specific therapeutic candidate for the treatment of patients with
<I>
	Staph aureus
</I>
	bacteremia. We recently concluded a Phase 1 single ascending
	dose study in healthy volunteers. This trial was a randomized, double-blind, placebo-controlled, dose-escalation trial designed to evaluate the safety, tolerability and PK of four different intravenous doses of CF-301 alone. Subjects were randomized
	to receive a single IV dose of CF-301 or placebo, each administered as a two hour infusion. We have worldwide development and commercial rights to CF-301 and expect to fund the future development and commercialization costs related to this program.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	CF-404: lead mAb program
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-404 is a potent combination of three mAbs targeting the conserved regions of the influenza virus.
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CF-404
</FONT>
	cross-reacts with all human seasonal strains of influenza, making it a highly specific therapeutic candidate for the treatment of patients with life-threatening varieties of influenza. We initiated
	IND-enabling activities prior to the end of 2014 and expect to file our IND for CF-404 in the second half of 2016. We have worldwide development and commercial rights to CF-404 and expect to fund the future development and commercialization costs
	related to this program.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To date, a large portion of our research and development work has related to the establishment of both our lysin
	and antibody platform technologies, the advancement of our research projects to discovery of clinical candidates, manufacturing and preclinical testing of our clinical candidates and Phase 1 clinical testing of CF-301, the first lysin to enter
	clinical trials in the U.S. In the future, we intend to continue using our employee and infrastructure resources across multiple development programs well as research projects. In the years ended December&nbsp;31, 2015, 2014 and 2013, we recorded
	approximately $15.0 million, $8.9 million and $9.1 million, respectively, of research and development expenses. A breakdown of our research and development expenses by category is shown below. We do not currently utilize a formal time or laboratory
	project expense allocation system to allocate employee-related expenses, laboratory costs or depreciation to any particular project. Accordingly, we do not allocate these expenses to individual projects or product candidates. However, we do allocate
	some portions of our research and development expenses in the product development, external research and licensing and professional fees categories, by project, including CF-301 and CF-404, as shown below.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	63
</P>
<A NAME="eolPage67"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes our research and development expenses by category for the years
	ended December&nbsp;31, 2015, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="60%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Personnel related
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,178,451
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,747,487
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,182,153
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Product development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,457,384
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,311,452
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,044,774
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Laboratory costs
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,929,799
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,473,739
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,908,789
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	External research and licensing costs
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,324,425
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,956,861
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,175,221
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Professional fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	724,486
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	663,039
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	591,609
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Share-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	389,967
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	715,475
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	230,629
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total research and development expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,004,512
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,868,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,133,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes our research and development expenses by program for the years ended
	December&nbsp;31, 2015, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="60%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-301
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,847,190
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,666,016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,567,138
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	CF-404
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,315,797
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,507,285
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,273,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,231,790
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,153,255
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Personnel related and share-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,568,418
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,462,962
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,412,782
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total research and development expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,004,512
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,868,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,133,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We anticipate that our research and development expenses will increase substantially in connection with the
	commencement of clinical trials for our product candidates. However, the successful development of future product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the
	uncertainty of:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the scope, rate of progress and expense of our research and development activities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	clinical trial results;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the terms and timing of regulatory approvals;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to market, commercialize and achieve market acceptance for our product candidates in the future; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expense, filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A change in the outcome of any of these variables with respect to the development of CF-301, CF-404 or any other product candidate that we may
	develop could mean a significant change in the costs and timing associated with the development of CF-301, CF-404 or any such product candidate. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials
	beyond those which we currently anticipate will be required for the completion of clinical development of CF-301 or if we experience significant delays in enrollment in any clinical trials of CF-301, we could be required to expend significant
	additional financial resources and time on the completion of the clinical development of CF-301.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative expenses consist primarily of salaries and related costs for personnel, including non-cash share-based compensation
	expense, in our executive, finance, legal, human resource and business development functions. Other general and administrative expenses include facility costs, insurance expenses and professional fees for legal, consulting and accounting services.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	64
</P>
<A NAME="eolPage68"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We anticipate that our general and administrative expenses will increase in future periods to
	support increases in our research and development activities and as a result of increased headcount, expanded infrastructure, increased legal, compliance, accounting and investor and public relations expenses associated with being a public company
	and increased insurance premiums, among other factors.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Interest Income
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Interest income consists of interest earned on our cash and cash equivalents and available-for-sale securities.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Interest Expense
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Interest expense
	consists primarily of cash and non-cash interest costs, including the accretion of the carrying value of our Convertible Notes due 2015 to face value and the estimated value of equity linked securities issued in conjunction with the issuance of
	these notes, related to our outstanding debt. We capitalize costs incurred in connection with the issuance of debt. We amortize these costs over the life of our debt agreements as interest expense in our statement of operations. Upon the closing of
	our IPO, we accelerated the amortization of the remaining balances of debt issuance costs and debt discount to interest expense and recognized the cost of the beneficial conversion feature of our Convertible Notes due 2015 as an additional component
	of interest expense.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Critical Accounting Policies and Significant Judgments and Estimates
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
	we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the
	disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on our limited historical experience, known trends and events and various other factors
	that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
	these estimates under different assumptions or conditions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	While our significant accounting policies are described in more detail in the
	notes to our financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of
	operations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Fair Value of Warrant Liability
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 820,
<I>
	Fair Value Measurements and
	Disclosures
</I>
	(&#147;ASC 820&#148;), we classify and account for our warrant liability as a level 3 financial instrument. The valuation of a level 3 financial instrument requires inputs that reflect our own assumptions that are both significant to
	the fair value measurement and unobservable. We calculate the fair value estimate of our warrant liability on a recurring basis at each measurement date, based on relevant market information.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We use the Black-Scholes option pricing model to estimate the fair value of our warrant liability using various assumptions that require
	management to apply judgment and make estimates, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expected term of the warrant, which we estimate to be the remaining contractual life;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expected volatility of the underlying common stock, which we estimate based on the historical volatility of a representative peer group of publicly traded biopharmaceutical companies with similarities to us,
	including stage of drug development, area of therapeutic focus, number of employees and market capitalization;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	65
</P>
<A NAME="eolPage69"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the risk-free interest rate, which we based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expected dividend yield, which we estimate to be zero based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined
	with precision. If factors change and different assumptions are used, our warrant liability could be materially different in the future.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Accrued
	research and development expenses
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As part of the process of preparing our financial statements, we are required to estimate our
	accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not
	yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each
	balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates
	in our accrued research and development expenses are related to fees paid to CROs in connection with research and development activities for which we have not yet been invoiced.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs
	that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our
	vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended
	in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepayment expense accordingly. Although we do not expect our estimates to be materially different from
	amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any
	particular period. Differences between our estimates and amounts actually incurred to date, and any resulting adjustments, have not been material.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Stock-based compensation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We
	account for stock-based compensation in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718,
<I>
	Compensation-Stock Compensation
</I>
	, which we refer to as ASC 718. ASC 718 requires the measurement and
	recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Compensation expense based on the grant date fair value is generally amortized over the requisite
	service period of the award on a straight-line basis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We account for stock options granted to non-employees, which primarily consist of
	consultants and members of our scientific advisory board, using the fair value method. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms and stock-based compensation expense may be recognized using
	an accelerated recognition model.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We use the Black-Scholes option pricing model to estimate the fair value of stock option awards using
	various assumptions that require management to apply judgment and make estimates, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
	the expected term of the stock option award, which we calculate using the simplified method, as prescribed by the Securities and Exchange Commission
	Staff Accounting Bulletin No.&nbsp;107,
<I>
	Share-
</I>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	66
</P>
<A NAME="eolPage70"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<I>
	Based Payment,
</I>
	as we have insufficient historical information regarding our stock options to provide a basis for an estimate;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expected volatility of the underlying common stock, which we estimate based on the historical volatility of a representative peer group of publicly traded biopharmaceutical companies with similarities to us,
	including stage of drug development, area of therapeutic focus, number of employees and market capitalization;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the risk-free interest rate, which we based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the expected dividend yield, which we estimate to be zero based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the fair value of our common stock on the date of grant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If factors change and different
	assumptions are used, our stock-based compensation expense could be materially different in the future.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Recent Accounting Pronouncements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	See Note 2, Recent Accounting Pronouncements, of the Notes to Financial Statements, for a discussion of the impact of new accounting standards
	on our Financial Statements.
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Results of Operations
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Comparison of years ended December&nbsp;31, 2015 and 2014
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes our results of operations for the years ended December&nbsp;31, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Dollar&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	%&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating expenses:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="9" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,004,512
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,868,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,136,459
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	69
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,060,825
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,067,858
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,992,967
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other income (expense)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(55,627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(13,213,173
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,157,546
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Research and Development Expenses
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expense was $15.0 million for the year ended December&nbsp;31, 2015, compared with $8.9 million for the year ended
	December&nbsp;31, 2014, an increase of $6.1 million. This increase was primarily attributable to a $4.7 million increase in expenditures on our product candidates as we initiated and concluded our Phase 1 clinical study of CF-301 and continued to
	progress CF-404 through IND-enabling studies and manufacturing activities. The increase was also due to a $1.4 million increase in our research headcount and related salaries, benefits and laboratory costs in support of the discovery and study of
	additional product candidates.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	General and Administrative Expenses
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative expense was $10.1 million for the year ended December&nbsp;31, 2015, compared with $8.1 million for the year ended
	December&nbsp;31, 2014, an increase of $2.0 million. This increase was primarily attributable to an increase in our administrative and Board of Directors headcount, resulting in an $1.0 million increase in expenses, a $0.7 million increase in costs
	related to being a public company, including listing fees, filing fees, insurance and investor relations expenses, $0.6 million in severance costs that did not occur in 2014, and a $0.2 million increase in expenses related to business development
	activities. These increases were partially offset by a $0.5 million decrease in our legal expenses.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	67
</P>
<A NAME="eolPage71"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Other income (expense)
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other expense was $0.1 million for the year ended December&nbsp;31, 2015 compared with $13.2 million for the year ended December&nbsp;31, 2014,
	a decrease of $13.1 million. In 2015, we had non-cash expense of more than $0.1 million related to the change in fair value of our warrant liability, which was partially offset by interest income of less than $0.1 million from our marketable
	securities. In 2014, we had non-cash interest charges of $12.4 million related to our Convertible Notes and non-cash expense of $1.2 million related to the change in fair value of our warrant and embedded derivatives liabilities, which were
	partially offset by $0.4 million of income from the receipt of refundable state tax credits.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Comparison of years ended December 2014 and 2013
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes our results of operations for the years ended December&nbsp;31, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Dollar&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	%&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating expenses:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="9" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,868,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,133,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(265,122
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,067,858
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,163,259
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,095,401
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other income (expense)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(13,213,173
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,324,268
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,888,905
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	206
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Research and Development Expenses
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expense was $8.9 million for the year ended December&nbsp;31, 2014, compared with $9.1 million for the year ended
	December&nbsp;31, 2013, a decrease of $0.2 million. This decrease was primarily attributable to a $0.9 million decrease in our research headcount and related salaries, benefits and laboratory support costs and a $0.6 million decrease in product
	development costs associated with our lead product, CF-301, for which we obtained regulatory approval to initiate clinical trials in December 2014. This decrease was partially offset by a $0.8 million increase in external research and licensing
	expense as a result of the Trellis license and a $0.5 million increase in our non-cash stock-based compensation expense as a result of the vesting of retention grants upon the closing of our IPO.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	General and Administrative Expenses
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative expense was $8.1 million for the year ended December&nbsp;31, 2014, compared with $10.2 million for the year ended
	December&nbsp;31, 2013, a decrease of $2.1 million. This decrease was primarily attributable to the $3.6 million in severance related charges for the termination of the former CEO in 2013. This decrease was partially offset by an increase of $1.3
	million in legal expenses including the termination of the MorphoSys agreement and a $0.2 million increase in our insurance and investor relations costs related to being a public company.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Other income (expense)
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other expense was $13.2 million for the year ended December&nbsp;31, 2014 compared with $4.3 million for the year ended December&nbsp;31, 2013,
	an increase of $8.9 million. This increase was primarily attributable to the non-cash charge of $7.4 million related to the beneficial conversion feature recognized upon conversion of our Convertible Notes due 2015 upon the closing of our IPO and a
	$2.9 million increase in non-cash interest charges due to the accelerated amortization of the remaining debt discount and debt issuance costs balances upon the closing of our IPO. These increases were partially offset by a decrease of $1.4 million
	in non-cash expense from the change in fair value measurement of our warrant and embedded derivative liabilities.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	68
</P>
<A NAME="eolPage72"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_RESULTS_OF_OPERATIONS>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Sources of Liquidity
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have
	financed our operations to date primarily through proceeds from sales of Units, common stock, convertible preferred stock and convertible debt. To date, we have not generated any revenue from the sale of products. We have incurred losses and
	generated negative cash flows from operations since inception.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Since the date of our initial public offering, we have received gross
	proceeds of $41.3 million from the sale of Units in our IPO, $9.6 million from the exercise of the Class B Warrants issued as part of the Units sold in our IPO and $20.0 million from the sale of securities in a private placement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2015, we had approximately $32.9 million in cash, cash equivalents and marketable securities. We primarily invest our
	cash and cash equivalents in commercial money market accounts and our marketable securities in highly rated corporate debt securities.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	January 2016, we entered into a Sales Agreement with Cowen and Company, LLC (&#147;Cowen&#148;) to sell shares of our common stock, with aggregate gross sales proceeds of up to $30 million, through an &#147;at the market&#148; equity offering
	program under which Cowen will act as sales agent. As of the date of this report, we have not sold any shares under the program.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Cash flows
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table shows a summary of our cash flows for the years ended December&nbsp;31, 2015, 2014 and 2013:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="48%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by (used in):
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(22,182,601
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,864,762
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,056,424
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Investing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21,600,084
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,610,536
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,588,570
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Financing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,033,013
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,052,481
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,726,860
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Net cash used in operating activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in the components of
	working capital. Net cash used in operating activities in the year ended December&nbsp;31, 2015 increased by $7.3 million and $8.1 million as compared to the comparable periods in 2014 and 2013, respectively. This is attributable to the increase in
	our loss from operations in 2015 as we advanced our product candidates and expanded our research and administrative headcount.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Net cash (used in)
	provided by investing activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash used in investing activities in the years ended December&nbsp;31, 2015 and 2014 resulted
	from the investment of our cash balances into marketable securities. Net cash provided by investing activities in the year ended December&nbsp;31, 2013 resulted from the reduction of our restricted cash balances. As of December&nbsp;31, 2015 and
	2014, we had no restricted cash balances on our balance sheet.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Net cash provided by financing activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by financing activities in the year ended December&nbsp;31, 2015 resulted primarily from the completion of a private
	placement of our securities to institutional investors in June 2015, resulting in net proceeds of $18.3 million and the exercise of the Class B Warrants issued as part of the Units sold in our IPO,
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	69
</P>
<A NAME="eolPage73"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	resulting in net proceeds of $9.7 million. Net cash provided by financing activities in the year ended December&nbsp;31, 2014 resulted from the issuance of approximately 6.9&nbsp;million Units on
	the completion of our IPO, resulting in net proceeds of $35.0 million and the issuance of approximately $3.0 million of our Convertible Notes, which were converted into common stock on the closing of our IPO. In the year ended December&nbsp;31,
	2013, we received net proceeds of $10.6 million from the issuance of Convertible Notes, which were converted into common stock on the closing of our IPO, and repaid approximately $1.9 million of commercial debt.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Funding requirements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	All of our product
	candidates are in early clinical or preclinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	initiate the planned clinical trials of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	continue our ongoing preclinical studies, and initiate additional preclinical studies, of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	continue the research and development of our other product candidates and our platform technology;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seek to identify additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	acquire or in-license other products and technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	seek marketing approvals for our product candidates that successfully complete clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	establish, either on our own or with strategic partners, a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	maintain, leverage and expand our intellectual property portfolio; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We believe that our existing cash and cash equivalents and marketable securities, together with interest thereon, will be sufficient to fund
	our operations into the second quarter of 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties
	associated with the development and commercialization of our product candidates, and the extent to which we may enter into collaborations with third parties for development and commercialization of our product candidates, we are unable to estimate
	the amounts of increased capital outlays and operating expenses associated with completing the development of our current product candidates. Our future capital requirements will depend on many factors, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the progress and results of the clinical trials of our lead product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the scope, progress, results and costs of compound discovery, preclinical development, laboratory testing and clinical trials for our other product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the extent to which we acquire or in-license other products and technologies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs, timing and outcome of regulatory review of our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to establish any future collaboration arrangements on favorable terms, if at all.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	70
</P>
<A NAME="eolPage74"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Until such time, if ever, as we can generate substantial product revenues, we expect to finance
	our cash needs through a combination of equity and debt offerings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale
	of equity or other securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if
	available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through
	collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not
	be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to
	develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We incur significant increased
	costs as a public company that we have not previously incurred, including, but not limited to, increased personnel costs, increased directors fees, increased directors and officers insurance premiums, audit and legal fees, investor relations and
	external communications fees, expenses for compliance with the Sarbanes-Oxley Act and rules implemented by the SEC and NASDAQ and various other costs and expenses.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Effects of Inflation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We do not believe
	that inflation or changing prices had a significant impact on our results of operations for any periods presented herein.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Off-Balance Sheet
	Arrangements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We did not have during the periods presented, and we are currently not party to, any off-balance sheet arrangements.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_10">
</A>
	Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Not applicable
</P>
</EFX_MARKET_RISK>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_11">
</A>
	Item&nbsp;8. Financial Statements and Supplementary Data
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The financial statements required to be filed pursuant to this Item&nbsp;8 are appended to this report. An index of those financial statements
	is found in Item&nbsp;15 of Part IV of this Annual Report on Form 10-K.
</P>
</EFX_FINANCIAL_STATEMENTS>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_12">
</A>
	Item&nbsp;9. Changes in and Disagreements with
	Accountants on Accounting and Financial Disclosure
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
</EFX_ACCOUNTING_CHANGES>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_13">
</A>
	Item&nbsp;9A. Controls and Procedures
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Evaluation of Disclosure Controls and Procedures
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
	designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is
	required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As required by Rule
	13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer and our principal financial officer, conducted an evaluation as of the end of the period
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	71
</P>
<A NAME="eolPage75"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	covered by this Annual Report on Form 10-K of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based on that
	evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Management&#146;s Annual Report on Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule
	13a-15(f) under the Securities Exchange Act of 1934, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our management conducted an assessment of the effectiveness of our
	internal control over financial reporting based on the criteria set forth in &#147;Internal Control-Integrated Framework (2013)&#148; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment,
	management concluded that, as of December&nbsp;31, 2015, our internal control over financial reporting was effective.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This annual report
	does not include an attestation report of our registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for &#147;emerging growth companies&#148;.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Changes in Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act, our management, including our principal executive officer and our
	principal financial officer, conducted an evaluation of our internal control over financial reporting to determine whether any changes occurred during the quarter ended December&nbsp;31, 2015 that have materially affected, or are reasonably likely
	to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer and principal financial officer concluded that there were no changes during the quarter ended December&nbsp;31, 2015 that
	materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_14">
</A>
	Item&nbsp;9B. Other Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	72
</P>
<A NAME="eolPage76"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART III
</B>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_15">
</A>
	Item&nbsp;10. Directors, Executive Officers and Corporate Governance
</B>
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Director Biographical Information
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Biographical information concerning each of our directors is set forth below:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="35%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="2%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="59%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Age
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:27.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Position
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Steven C. Gilman, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	63
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director, Chairman of the Board
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Roger Pomerantz, M.D., F.A.C.P.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	59
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director, Vice Chairman of the Board
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Sol Barer, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	68
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director, Lead Independent Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Isaac Blech
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	66
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Julia P. Gregory, M.B.A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	63
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director and Chief Executive Officer
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	David N. Low, Jr.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	57
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Michael J. Otto, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	67
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	David A. Scheinberg, M.D., Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	59
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Cary W. Sucoff, J.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	64
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Lawrence Yuan Tian, Ph.D.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	61
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Director
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Steven C. Gilman, Ph.D.
</I>
	Dr.&nbsp;Gilman has served as Chairman of our board of directors since May
	2015. Until 2015, he served as the Executive Vice President, Research&nbsp;&amp; Development and Chief Scientific Officer at Cubist Pharmaceuticals, a biopharmaceutical company, until its acquisition by Merck&nbsp;&amp; Co. Prior to joining Cubist
	in 2008, he served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, he worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership
	roles including Vice President and General Manager of the Inflammation franchise, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer
	Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr.&nbsp;Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen
	Corporation, Temple Medical School, and Connecticut College. He currently serves on the board of directors of publicly traded companies Vericel Corporation and SCYNEXIS Inc., the Massachusetts Biotechnology Association and the Penn State University
	Biotechnology Advisory Board. Dr.&nbsp;Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from
	Miami University of Ohio. He has authored over 60 publications and is an inventor on 7 patents. We believe that Dr.&nbsp;Gilman&#146;s significant scientific, executive and board leadership experience in the pharmaceutical and biotechnology
	industries qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Roger J. Pomerantz, M.D., F.A.C.P.
</I>
	Dr.&nbsp;Pomerantz has
	served as a member of our board of directors since April 2014 and was appointed Vice Chairman in May 2014. Since 2014, Dr.&nbsp;Pomerantz has served as President and Chief Executive Officer of Seres Therapeutics, Inc., a biotechnology company. He
	has also served as Chairman of the board of directors of Seres since 2013. From 2011 to 2013, he was formerly Worldwide Head of Licensing&nbsp;&amp; Acquisitions, Senior Vice President at Merck&nbsp;&amp; Co., Inc. where he oversaw all licensing and
	acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr.&nbsp;Pomerantz was Global Head of Infectious Diseases for
	Johnson&nbsp;&amp; Johnson Pharmaceuticals. He joined Johnson&nbsp;&amp; Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr.&nbsp;Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns
	Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr.&nbsp;Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of
	Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed nine
	drugs
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	73
</P>
<A NAME="eolPage77"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	approved world-wide in important diseases, including HIV, HCV, and tuberculosis. We believe that Dr.&nbsp;Pomerantz&#146;s significant scientific, executive and board leadership experience in
	drug development and in the pharmaceutical industry qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Sol Barer, Ph.D
</I>
	.
	Dr.&nbsp;Barer has served as a member of our board of directors since April 2011. Dr.&nbsp;Barer served as our Chairman of the board of directors from February 2012 to May 2015. He was appointed Lead Independent Director in May 2015. Dr.&nbsp;Barer
	spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until Jan 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010.
	Dr.&nbsp;Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene. Dr.&nbsp;Barer serves as Chairman of the board of directors of the public companies Edge Therapeutics,
	InspireMD, and Medgenics, and the private company Centrexion and is on the board of directors of the public companies Aegerion Pharmaceuticals, Amicus Therapeutics and Teva Pharmaceutical Industries. He is an advisor to biopharmaceutical companies
	and not for profit organizations. He also serves as an investment advisor to the Israel Biotechnology Fund. In 2011 Dr.&nbsp;Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor&#146;s Advisory Committee which
	resulted in sweeping changes in the structure of New Jersey&#146;s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of
	Rutgers University and served two terms as Chair of the Board of Trustees of BioNJ, the New Jersey biotechnology organization. We believe that Dr.&nbsp;Barer&#146;s significant scientific, executive and board leadership experience in the
	pharmaceutical and biotechnology industries qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Isaac Blech
</I>
	.
	Mr.&nbsp;Blech has served as a member of our board of directors since August 2010. Mr.&nbsp;Blech is currently Vice Chairman of the board of directors of the public companies Cerecor, Inc., Edge Therapeutics, Inc., WaveGuide Corporation, root9B
	Technologies, Inc. and SpendSmart Payments Company and the private companies Centrexian Corporation, Regenovation, Inc. and X-4 Pharmaceuticals and Sapience Therapeutics. He is also on the board of directors of the public company Medgenics, Inc.
	Over the past 35 years, Mr.&nbsp;Blech has helped found some of the world&#146;s leading biotechnology companies, including Celgene Corporation, ICOS Corporation, Pathogenesis Corporation, Nova Pharmaceutical Corporation and Genetic Systems
	Corporation. These companies are responsible for major advances in oncology, infectious disease and cystic fibrosis. Mr.&nbsp;Blech earned a B.A. degree from Baruch College in 1975. We believe that Mr.&nbsp;Blech&#146;s broad experience as a
	founder, director and major investor in numerous biotechnology companies qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Julia P. Gregory
</I>
	. Ms.&nbsp;Gregory has been our Chief Executive Officer since November 2013 and a director since April 2014, previously
	serving as Executive Vice President and Chief Financial Officer since July 2012. Prior to joining ContraFect, Ms.&nbsp;Gregory was President and Chief Executive Officer of Five Prime Therapeutics, Inc. (&#147;Five Prime&#148;), a clinical-stage,
	biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology since 2009. Prior to Five Prime, Ms.&nbsp;Gregory was Executive Vice President, Corporate Development and Chief
	Financial Officer of Lexicon Pharmaceuticals, Inc. (&#147;Lexicon&#148;). While at Five Prime and Lexicon, she led transactions for several strategic partnerships including those with GlaxoSmithKline, Human Genome Sciences, Genentech, Inc., The
	Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. She was the Chief Financial Officer of Lexicon during its $220 million initial public offering and was involved in the creation of Lexicon&#146;s $500 million private equity
	investment plan with Invus, LLP. Prior to joining Lexicon, Ms.&nbsp;Gregory served as the head of investment banking for Punk, Ziegel&nbsp;&amp; Company, a specialty technology and healthcare investment banking firm, and was an investment banker
	with Dillon, Read&nbsp;&amp; Co., Inc. She has served as a director on the board of Clinipace, Inc. on behalf of and as Special Advisor to Morgan Stanley Expansion Capital and on the board of The Global TB Alliance for Drug Development, primarily
	funded by the Bill&nbsp;&amp; Melinda Gates Foundation. Ms.&nbsp;Gregory received her B.A. from George Washington University&#146;s Elliott School of International Affairs, where she was elected to Phi Beta Kappa, and her M.B.A. from the Wharton
	School of the University of Pennsylvania. We
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	74
</P>
<A NAME="eolPage78"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	believe that Ms.&nbsp;Gregory&#146;s significant financial, executive leadership and board experience qualify her to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	David N. Low, Jr.
</I>
	Mr.&nbsp;Low has served as a member of our board of directors since April 2014. Mr.&nbsp;Low has worked as an
	investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Since 2013, Mr.&nbsp;Low has served as a Senior Advisor at Lazard Freres&nbsp;&amp; Company, an
	investment bank. From 2002 to 2013, Mr.&nbsp;Low was a member of Lazard&#146;s Life Sciences Group as a Managing Director. Mr.&nbsp;Low has advised on major M&amp;A transactions in the life sciences, biotechnology and medical technology sectors, and
	has worked with private and public companies to raise capital, including emerging growth companies. Prior to joining Lazard, Mr.&nbsp;Low was a Managing Director at JP Morgan Chase&nbsp;&amp; Co. and a Senior Vice President at Lehman Brothers.
	Mr.&nbsp;Low serves on the board of directors of the We Teach Science Foundation (as Chairman), the Philharmonia Baroque Orchestra, and the French International School. Mr.&nbsp;Low holds an A.B. from Harvard College, where he graduated cum laude,
	an M.A. from the Johns Hopkins University School of Advanced International Studies and an M.B.A. from Yale University. We believe that Mr.&nbsp;Low&#146;s significant investment and financial advisory experience qualifies him to serve as a member of
	our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Michael J. Otto, Ph.D
</I>
	. Dr.&nbsp;Otto has served as a member of our board of directors since April 2014.
	Dr.&nbsp;Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. He led the research team responsible for the discovery of sofosbuvir for the treatment of HCV
	infections. In previous capacities he has served as Associate Director of Anti-Infectives Clinical Research at Rh&ocirc;ne-Poulenc Rorer, Vice President for Research and Development at Avid Therapeutics, Inc., Research Manager at DuPont
	Pharmaceuticals and Dupont Merck Pharmaceuticals and as Group Leader in the Virology Dept. at Sterling Drug in Rensselaer, NY. Prior to joining Sterling Drug, Dr.&nbsp;Otto was Research Assistant Professor at Yale University School of Medicine,
	Dept. of Pharmacology. Dr.&nbsp;Otto also served as the US editor for Antiviral Chemistry&nbsp;&amp; Chemotherapy from 1989 until 2012. Dr.&nbsp;Otto holds a B.S. degree from Loyola University of Chicago and a Ph.D. degree in medical microbiology
	from The Medical College of Wisconsin. He is the author or coauthor of over 100 research papers and book chapters and named inventor on several patents and patent applications. We believe that Dr.&nbsp;Otto&#146;s substantial scientific and
	executive leadership experience in the pharmaceutical industry qualifies him to serve as a member of our board of directors.
<I>
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	David A. Scheinberg, M.D., Ph.D
</I>
	. Dr.&nbsp;Scheinberg has served as a member of our board of directors since June 2010. Since 2003,
	Dr.&nbsp;Scheinberg has been the Chairman, of the Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute. He also founded and chairs the Experimental Therapeutics Center at Memorial Sloan-Kettering Cancer Center, co-chairs the
	Pharmacology Graduate Program at the Weill-Cornell University Medical College, and is a professor in the Gerstner-Sloan Kettering Graduate School at MSKCC as well as at Weill Cornell Medical College. From 1992 until 2003 he was Chief of Leukemia
	Service at Memorial Hospital. In 2013 he was Interim Director of Sloan-Kettering Institute. A physician-scientist, Dr.&nbsp;Scheinberg specializes in the care of patients with leukemia. He investigates new therapeutic approaches to cancer, both in
	the hospital and in the laboratory. The focus of his research is the discovery and development of novel, specific immunotherapeutic agents. Eight therapeutic agents developed by Dr.&nbsp;Scheinberg-which include the first humanized antibodies to
	treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines-have reached human clinical trials. He has published more than 200 peer-reviewed papers, chapters
	and books. In the private sector, Dr.&nbsp;Scheinberg was Founder and Chairman of the Board of Active Biotherapeutics, Inc., which was acquired by Progenics Pharmaceuticals. He is currently a Director of Progenics Pharmaceuticals, a public company,
	and a member of the scientific advisory boards of Oncopep and Ensysce pharmaceuticals. Dr.&nbsp;Scheinberg founded and is a Director of the Therapeutics Discovery Institute, a non-profit drug discovery corporation serving Rockefeller University,
	Weil Cornell Medical College and Memorial Sloan Kettering Cancer Center. He advises charitable foundations, cancer centers, and biotech companies and sits on several journal editorial boards. Dr.&nbsp;Scheinberg received his A.B., cum laude,
	distinction in all subjects, from the College of Arts and Sciences, Cornell University, in 1977. He earned his M.D. from Johns Hopkins University in 1983, and his Ph.D. from Johns Hopkins University School of
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	75
</P>
<A NAME="eolPage79"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Medicine, Department of Pharmacology and Experimental Therapeutics, in 1983. We believe that Dr.&nbsp;Scheinberg&#146;s significant scientific, executive and board leadership experience in drug
	and biologic therapy development and in the pharmaceutical industry qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Cary
	W. Sucoff.
</I>
	Mr.&nbsp;Sucoff has served on our board of directors since May 2010. Mr.&nbsp;Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated in the
	financing of more than 100 public and private companies, raising approximately $500 million of equity capital and playing a role in securing financing for biotech companies including Amgen, Centecor, Genzyme, Genentech, Icos, PathoGenesis, Vaxgen
	and Biotime. Since 2011, Mr.&nbsp;Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm. In addition to ContraFect, Mr.&nbsp;Sucoff currently serves on the board of directors of The SpendSmart Payments Company,
	root9B Technologies, and Legacy Education Alliance, Inc. In addition, Mr.&nbsp;Sucoff currently serves as a consultant to Sapience Therapeutics. Mr.&nbsp;Sucoff is the President of New England Law/Boston, has been a member of the Board of Trustees
	for over 25 years and is the current Chairman of the Endowment Committee. Mr.&nbsp;Sucoff received a B.A. from SUNY Binghamton in 1974 and a J.D. from New England School of Law in 1977, where he was managing editor of the Law Review and graduated
	magna cum laude. He has been a member of the Bar of the State of New York since 1978. We believe that Mr.&nbsp;Sucoff&#146;s broad financial and legal experience qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Lawrence Yuan Tian.
</I>
	Dr.&nbsp;Tian has served on our board of directors since May 2015. He has been the Chairman and Chief Executive
	Officer of CIFCO International Group since 2007. From 1992 to 2007, he was Chairman of the China International Futures Company, Ltd. Since 2010, Dr.&nbsp;Tian has been Chairman of the US-China Business Leaders Roundtable. In 2001, Dr.&nbsp;Tian
	founded and was elected Chairman of the China Entrepreneurs Forum. Dr.&nbsp;Tian has published numerous articles on economic policies, market reform and business development. Dr.&nbsp;Tian received his B.A., M.A. and Ph.D. in Economics from Wuhan
	University. We believe that Dr.&nbsp;Tian&#146;s significant international business experience and financial expertise qualifies him to serve as a member of our board of directors.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Executive Officers of the Registrant
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Biographical information concerning each of our executive officers is set forth below. Information concerning Julia P. Gregory, our Chief
	Executive Officer, may be found above in the section entitled &#147;Director Biographical Information.&#148;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
</I>
</B>
<I>
	Michael
	Wittekind, Ph.D.
</I>
<B>
<I>
</I>
</B>
	Dr.&nbsp;Wittekind, age 61, has served as our Senior Vice President and Chief Scientific Officer since August 2012. Prior to joining ContraFect, Dr.&nbsp;Wittekind served as the Executive Director of Research for
	Amgen Inc. (&#147;Amgen&#148;), a biopharmaceutical company, since 2003, where he directed the Protein Science Department at the Amgen-Seattle site. While at Amgen, he was involved in the discovery efforts for multiple protein therapeutics currently
	undergoing clinical trials, including antibodies, antibody-drug conjugates, and protein fusions. Previously, Dr.&nbsp;Wittekind was the Director of Process Development for Phylos Inc., where he played a key role in the development of alternate
	scaffold therapeutic discovery, design, and production. Dr.&nbsp;Wittekind has also served as the Associate Director of the Gene Expression and Protein Biochemistry Department of the Bristol-Myers Squibb Pharmaceutical Research Institute, directing
	groups in both the Lawrenceville and Hopewell, New Jersey sites leading structural biology research as well as protein and small molecule therapeutic efforts. Dr.&nbsp;Wittekind received his Ph.D. from the University of Wisconsin-Madison in
	Biochemistry and pursued his postdoctoral studies at the University of Washington. Dr.&nbsp;Wittekind&#146;s research interests have encompassed genetics, molecular biology, structural biology, and engineering of novel antibodies and proteins,
	resulting in over 40 publications and patents.
<B>
<I>
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Cara Cassino, M.D.
</I>
	Dr.&nbsp;Cassino, age 54, has served as our Chief
	Medical Officer since September 2015. Dr.&nbsp;Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory
	submissions in the United
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	76
</P>
<A NAME="eolPage80"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	States and globally. Prior to joining ContraFect, Dr.&nbsp;Cassino served as Senior Vice President at Forest Laboratories, Inc., a biopharmaceutical company (acquired by Actavis plc, now Allergan
	plc), where she oversaw Global Clinical Development, since 2014. While at Forest, she was responsible for pre- and post-marketing clinical activities for a portfolio of 35 compounds, and also clinical due diligence for M&amp;A activity including the
	$2.9 billion acquisition of Aptalis Pharma and the $1.1 billion acquisition of Furiex Pharmaceuticals. Previously, Dr.&nbsp;Cassino held a number of senior positions at Pfizer, including Global Medical Team Leader of Pfizer&#146;s antibacterial
	franchise which included Zyvox (linezolid) and Medicines Development Group VP for Pulmonary Vascular Disease and Rare Diseases. Dr.&nbsp;Cassino also served as Executive Medical Director for the late stage U.S. respiratory franchise at
	Boehringer-Ingelheim Pharmaceuticals, Inc, and was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at New York University School of Medicine. Dr.&nbsp;Cassino received her BA, summa cum laude, in Chemistry
	and Fine Arts from New York University (NYU) where she was elected Phi Beta Kappa, followed by an M.D. from NYU School of Medicine. She completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital and a fellowship in
	Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Centers. Dr.&nbsp;Cassino is Board Certified in both internal medicine and pulmonary medicine.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Daniel Couto
</I>
	. Mr.&nbsp;Couto, age 44, currently serves as our Senior Vice President, Manufacturing&nbsp;&amp; Facilities Operations. He
	has over 20 years of experience in Operations Management. Prior to joining ContraFect in 2011, he served as Vice President of Commercial Manufacturing Operations for Merck Sharp&nbsp;&amp; Dohme Biologics UK Ltd. for three years. Previously, he was
	Director of Manufacturing for Nuvelo Inc. for three years, where he was responsible for seven worldwide contract manufacturing sites. Mr.&nbsp;Couto also served in similar director and senior management positions at Genzyme Transgenics Corp.,
	Advanced Biosystems Corp., ImmuCell Corp. and Sepracor Corp. Mr.&nbsp;Couto holds patents for several novel separation technologies such as Bulk Protein Crystallization, High Performance Tangential Flow Filtration, and Simulated Moving Bed.
	Mr.&nbsp;Couto received his B.S. Degree in Chemical Engineering from Rensselaer Polytechnic Institute.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Josh Muntner
</I>
	.
	Mr.&nbsp;Muntner, age 47, has served as the Senior Vice President of Business Development since 2015. Mr.&nbsp;Muntner has more than 15 years of transaction experience assisting life sciences companies with financing and M&amp;A advisory
	transactions. Prior to joining ContraFect, he served as Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, a financial services firm from 2012 to 2015. Mr.&nbsp;Muntner was also a Managing Director at
	ThinkEquity, an investment bank from 2009 to 2012. Previously, Mr.&nbsp;Muntner spent nine years at Oppenheimer&nbsp;&amp; Co. and its U.S. predecessor, CIBC World Markets, in positions of increasing responsibility. Mr.&nbsp;Muntner also served as
	an investment banker at Prudential Securities. Mr.&nbsp;Muntner received his B.F.A. degree from Carnegie Mellon and his M.B.A. degree from The Anderson School at UCLA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Michael Messinger, CPA
</I>
	. Mr.&nbsp;Messinger, age 41, currently serves as our Vice President, Finance. He has more than 15 years of
	experience in finance, accounting and forecasting for clinical development. Prior to joining ContraFect in November 2012, he served as Director of Finance at Lexicon Pharmaceuticals, Inc. (&#147;Lexicon&#148;) for eight years and also held the
	position of Controller for three years. Prior to working at Lexicon, Mr.&nbsp;Messinger served as Controller of Coelacanth Corporation (which was acquired by Lexicon) for two years. While at Lexicon, Mr.&nbsp;Messinger was responsible for the
	financial management of Lexicon&#146;s partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon&#146;s development programs. Mr.&nbsp;Messinger received his B.B.A. degree in accounting from
	the University of Michigan. He started his career as an auditor at Ernst&nbsp;&amp; Young LLP.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Natalie Bogdanos, J.D.
</I>
	Ms.&nbsp;Bogdanos, age 47, currently serves as our General Counsel and Corporate Secretary. She has over 17 years of experience in the legal field. Prior to joining ContraFect in 2014, Ms.&nbsp;Bogdanos served as Associate General Counsel at
	Memorial Sloan-Kettering Cancer Center (&#147;MSKCC&#148;) where she held a joint appointment with the Office of the General Counsel and the Office of Technology Development (&#147;OTD&#148;). At MSKCC, she provided legal counsel and guidance to
	various departments throughout the institution while having sole responsibility for the legal oversight of the OTD. She led the contracts group,
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	77
</P>
<A NAME="eolPage81"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	managed the institution&#146;s patent portfolio, provided regulatory guidance and compliance, and advised on litigation strategy. Prior to MSKCC, she was General Counsel at Enzo Biochem, Inc.
	(&#147;Enzo&#148;), a publicly-traded biotechnology company, from 2003 to 2012. At Enzo, she was responsible for leading the legal department, handling contracts and complex business development agreements, ensuring SEC and regulatory compliance,
	overseeing litigation and managing Enzo&#146;s portfolio of 500+ patents and patent applications. Previously, Ms.&nbsp;Bogdanos was an associate at Amster, Rothstein&nbsp;&amp; Ebenstein from 1999 to 2003 where her practice focused on patent
	litigation and patent prosecution. Ms.&nbsp;Bogdanos has also served as a legal consultant to pharmaceutical companies and was a faculty member at the Practising Law Institute. Prior to attending law school, she was a research technician at the
	Public Health Research Institute where her work focused on Staphylococcus aureus. Ms.&nbsp;Bogdanos is an attorney licensed to practice before the United States Patent and Trademark Office. She is admitted to practice law in New York, the United
	States District Court, Southern and Eastern District of New York and the United States Court of Appeals for the Federal Circuit. Ms.&nbsp;Bogdanos received her Juris Doctor from New York Law School and her Bachelor of Arts in Biology, with honors,
	from Queens College of the City University of New York.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Nancy Dong
</I>
	. Ms.&nbsp;Dong, age 51, has served as Vice President and
	Controller of the Company since 2010. She has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing, a
	direct marketing firm, from 2009 to 2010 and at Alley Corp, a company that provides strategic advice to companies within its network, from 2007 to 2009. She also served as Vice President of Finance and Administration at DCM, a tele-services firm
	supporting the performing arts, from 2002 to 2007. Ms.&nbsp;Dong also held the positions of COO/CFO at Semaphore, a project management software development firm. Ms.&nbsp;Dong received her B.A. degree from Yale University and a MPPM degree from The
	Wharton School at the University of Pennsylvania. She started her career as a management consultant at Ernst&nbsp;&amp; Young LLP.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Section&nbsp;16(a) Beneficial Ownership Reporting Compliance
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s executive officers and directors, and persons who own more than 10% common
	stock, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (&#147;SEC&#148;) and The NASDAQ Stock Market, LLC (&#147;NASDAQ&#148;). Executive officers, directors and greater than 10% stockholders are
	required by SEC regulations to furnish us with all copies of Section&nbsp;16(a) forms they file. Specific due dates for these reports have been established and we are required to identify in this proxy statement those persons who failed to timely
	file these reports. Based solely on our review of these forms and written representations from the officers and directors received by us, we believe that during the fiscal year ended December&nbsp;31, 2015, all Section&nbsp;16(a) filing requirements
	were complied with in a timely fashion.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Code of Ethics
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our board of directors has adopted a Code of Ethics and Business Conduct applicable to all officers, directors and employees, which is
	available on our website at http://ir.contrafect.com/governance-docs. We intend to satisfy the disclosure requirement under Item&nbsp;5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Ethics and Business Conduct, as
	well as NASDAQ&#146;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address specified above.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Audit Committee
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The members of our Audit Committee are Mr.&nbsp;Low, Dr.&nbsp;Pomerantz, and Mr.&nbsp;Sucoff. Our board of directors has determined that
	Mr.&nbsp;Low qualifies as an Audit Committee financial expert within the meaning of SEC regulations based on his formal education and the nature and scope of his previous experience. Our Audit Committee assists our board of directors in its
	oversight of our accounting and financial reporting process and the audits of our financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	78
</P>
<A NAME="eolPage82"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_DIRECTORS_AND_OFFICERS>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_16">
</A>
	Item&nbsp;11. Executive Compensation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Executive and Director Compensation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have elected to provide compensation disclosure pursuant to the reduced disclosure requirements applicable to emerging growth companies, as
	defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our executive compensation program, consisting of a
	three-part compensation strategy that includes base salary, annual performance-based cash bonuses and long-term equity incentive compensation, is designed to (i)&nbsp;pay for performance to encourage both Company and individual achievement;
	(ii)&nbsp;encourage efficient use of Company resources; and (iii)&nbsp;provide market competitive compensation to attract and retain highly qualified individuals who are capable of making significant contributions to the long-term success of the
	Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company does not adopt express formulae for weighting different elements of compensation or for allocating between long-term
	and short-term compensation but strives to develop comprehensive packages that are competitive with those offered by other companies with which the Company competes to attract and retain talented executives. Under the Company&#146;s compensation
	practices, cash compensation consists of an annual base salary and performance-based bonuses and equity-based compensation primarily consists of grants of stock options.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Named Executive Officers
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our named
	executive officers for 2015 set forth in this proxy statement (the &#147;Named Executive Officers&#148;) are:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Julia P. Gregory, M.B.A., Chief Executive Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Michael Wittekind, Ph.D., Chief Scientific Officer
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Daniel Couto, Senior Vice President, Manufacturing and Facilities Operations
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Barry Kappel, Ph.D., M.B.A., Senior Vice President, Business Development
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2015 Summary Compensation Table
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are an emerging growth company and have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting
	companies,&#148; as such term is defined under the Securities Exchange Act of 1934, which require compensation disclosure for our principal executive officer and the two most highly-compensated executive officers other than our principal executive
	officer. The table below sets forth the annual compensation earned during fiscal years 2015 and 2014 by our Named Executive Officers.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="41%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name and
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:61.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Principal Position
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Salary ($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Bonus
<BR>
	($)&nbsp;(1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Stock
<BR>
	Awards
<BR>
	($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option&nbsp;Awards
<BR>
	($) (2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	All Other
<BR>
	Compensation&nbsp;($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total ($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ROWSPAN="2">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Julia P. Gregory, M.B.A.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chief Executive Officer
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	489,250
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	171,238
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	909,651
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39,973
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,610,112
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2014
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	475,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	237,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	331,504
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	981,415
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,564
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,056,983
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ROWSPAN="2">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael Wittekind, Ph.D.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chief Scientific Officer
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	330,215
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	79,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	344,792
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39,973
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	794,033
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2014
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	114,808
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	142,415
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	136,976
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,564
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	738,764
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ROWSPAN="4">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel Couto
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Sr. Vice President, Manufacturing and Facilities Operations
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	300,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	69,030
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	149,910
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	32,023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(4)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	550,963
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ROWSPAN="3">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Barry Kappel, Ph.D (5)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Sr. Vice President, Business Development
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	78,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	309,758
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	521,733
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(6)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	910,241
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2014
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	270,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	110,860
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	98,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	130,200
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,564
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	640,905
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	79
</P>
<A NAME="eolPage83"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Represents annual bonuses earned under our performance-based bonus program.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The amounts reported in the &#147;Option Awards&#148; column reflect the aggregate grant date fair value of stock options awarded during the year computed in accordance with the provisions of Financial Accounting
	Standards Board Accounting Standard Codification, or ASC, Topic 718, disregarding estimated forfeitures. See Note 11 to our financial statements included with this Annual Report on Form 10-K regarding assumptions underlying the valuation of these
	equity awards. For Dr.&nbsp;Kappel, the amount reported also includes $99,090 of share-based compensation expense representing the incremental fair value, determined in accordance with ASC, Topic 718, with respect to the modification of options to
	purchase an aggregate of 42,678 shares of our common stock. Refer to the description of Dr.&nbsp;Kappel&#146;s separation and consulting agreement under the heading &#147;Employment Agreements&#148; for additional information.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The amounts reported in the &#147;All Other Compensation&#148; column include the sum of the incremental cost to us of all perquisites and other personal benefits, which are comprised of $32,023 for medical and life
	insurance costs paid by us and $7,950 of employer 401(k) contributions made by us on behalf of each Named Executive Officer.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(4)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The amount reported in the &#147;All Other Compensation&#148; column includes the sum of the incremental cost to us of all perquisites and other personal benefits, which is comprised of $32,023 for medical and life
	insurance costs paid by us for the Named Executive Officer.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(5)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Dr.&nbsp;Kappel resigned from his position as Senior Vice President of Business Development on April&nbsp;15, 2015 and served as a consultant to us until December&nbsp;31, 2015.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(6)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Includes $513,783 in severance payments pursuant to the terms of a separation and consulting agreement that we entered into with Dr.&nbsp;Kappel in connection with his resignation as our Senior Vice President of
	Business Development. Refer to the description of Dr.&nbsp;Kappel&#146;s separation and consulting agreement under the heading &#147;Employment Agreements&#148; for additional information.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	80
</P>
<A NAME="eolPage84"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding Equity Awards at 2015 Fiscal Year-End
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth information regarding outstanding stock options held by our Named Executive Officers as of December&nbsp;31,
	2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="74%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option Awards
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:97.90PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name and Principal Position
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number&nbsp;of&nbsp;securities
<BR>
	underlying&nbsp;unexercised
<BR>
	options exercisable
</B>
<BR>
<B>
	(#)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number&nbsp;of&nbsp;securities
<BR>
	underlying&nbsp;unexercised
<BR>
	options unexercisable
</B>
<BR>
<B>
	(#)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option
<BR>
	exercise
<BR>
	price
<BR>
	($/share)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option
<BR>
	expiration&nbsp;date
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Julia P. Gregory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	67,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8/10/2022
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chief Executive Officer
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,927
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,644
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(1)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/26/2023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	199,999
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	142,858
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(2)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4/28/2024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75,850
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	227,550
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/6/2025
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael Wittekind, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/31/2022
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chief Scientific Officer
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8/10/2022
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,642
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,215
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(1)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/26/2023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,714
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,714
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(4)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4/28/2024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(5)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2.91
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10/28/2024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	86,250
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/6/2025
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel Couto
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,285
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/6/2021
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Senior Vice President, Manufacturing
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9/2/2021
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	and Facility Operations
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	476
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11/28/2021
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/6/2022
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,321
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(1)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/26/2023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,143
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(6)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/20/2024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,143
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(4)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4/28/2024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	37,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2/6/2025
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Barry Kappel, Ph.D., M.B.A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,285
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4/15/2020
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Senior Vice President,
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9/1/2020
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Business Development
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,857
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,428
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,894
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,714
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,714
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,392
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12/31/2017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2.89
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/30/2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,875
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/30/2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,550
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.89
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3/30/2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	25% of the shares underlying the option vested on January&nbsp;1, 2013 and the remaining shares vest over three years with 25% of the shares underlying the option vesting annually thereafter.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The shares underlying the option vest over three years beginning on April&nbsp;1, 2014, with 8.33% of the shares underlying the option vesting at the end of each calendar quarter thereafter.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The shares underlying the option vest over four years beginning on January&nbsp;1, 2015, with 6.25% of the shares underlying the option vesting at the end of each calendar quarter thereafter.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(4)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	25% of the shares underlying the option vested on April&nbsp;29, 2014 and the remaining shares vest over three years with 25% of the shares underlying the option vesting annually thereafter.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(5)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	25% of the shares underlying the option vested on October&nbsp;28, 2014 and the remaining shares vest over three years with 25% of the shares underlying the option vesting annually thereafter.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(6)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	25% of the shares underlying the option vested on February&nbsp;24, 2014 and the remaining shares vest over three years with 25% of the shares underlying the option vesting annually thereafter.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	81
</P>
<A NAME="eolPage85"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Employment Agreements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Julia P. Gregory
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On April&nbsp;29,
	2014, we entered into an employment agreement with Julia Gregory, our current Chief Executive Officer, for a period of one year beginning on April&nbsp;1, 2014, and amended the CEO Agreement on August&nbsp;10, 2015 (together, the &#147;CEO
	Agreement&#148;). The CEO Agreement automatically renews for an additional one-year term unless we or Ms.&nbsp;Gregory elect to terminate the CEO Agreement at the expiration of the then-current one-year term. During the term of the CEO Agreement,
	Ms.&nbsp;Gregory is paid an annual base salary of $489,250, subject to an increase by us, and is eligible to earn an annual performance bonus in an amount up to 50% of her base salary for each calendar year. In connection with the execution of the
	CEO Agreement, Ms.&nbsp;Gregory was granted a stock option covering 342,857 shares, which vests in equal quarterly installments over a period of three years. In the event that Ms.&nbsp;Gregory ceases to serve as Chief Executive Officer but remains
	employed by us in another capacity, she will forfeit any unvested portion of the options granted to her in connection with the execution of the CEO Agreement, after giving effect to accelerated vesting of a prorated portion of the option that would
	have become vested at the end of the then-current quarter.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the event that Ms.&nbsp;Gregory is terminated without cause or resigns for
	good reason during the term of the CEO Agreement other than in connection with a change in control, then, subject to the execution and non-revocation of a release of claims, she is eligible to receive severance consisting of: (i)&nbsp;an amount
	equal to two times Ms.&nbsp;Gregory&#146;s base salary, paid over 18 months following the date of termination; (ii)&nbsp;deemed vesting of 100% of options granted to Ms.&nbsp;Gregory during the period she was serving as our Chief Financial Officer;
	(iii)&nbsp;accelerated vesting of the portion of the options granted to Ms.&nbsp;Gregory in connection with the execution of the CEO Agreement that would have vested through March&nbsp;31 of the year following the year in which termination occurs;
	and (iv)&nbsp;applicable premiums pursuant to COBRA for 12 months from the date of termination for Ms.&nbsp;Gregory and her dependents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If a change in control occurs during Ms.&nbsp;Gregory&#146;s term of employment, the term of the CEO Agreement will expire no earlier than one
	year from the date of the change in control. If Ms.&nbsp;Gregory&#146;s employment is terminated without cause or she resigns for good reason within twelve months following a change of control (and, in certain circumstances, if she is terminated
	without cause prior to the consummation of a change in control but following the execution of an agreement or approval by our board of directors that would result in a change in control), she will receive the following benefits, subject to the
	execution and non-revocation of a release of claims: (1)&nbsp;an amount equal to 2.25 times Ms.&nbsp;Gregory&#146;s base salary, paid over 18 months; (2)&nbsp;accelerated vesting of 100% of unvested equity awards; and (3)&nbsp;payment of COBRA
	premiums for 18 months. Ms.&nbsp;Gregory&#146;s estate will receive these benefits should her death occur: (1)&nbsp;during the term of her employment; and (2)&nbsp;during the time period commencing three months prior to the consummation of a change
	in control and ending 12 months following the consummation thereof.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Ms.&nbsp;Gregory is subject to non-competition and non-solicitation
	provisions during the term and for one year following any termination of employment.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Michael Wittekind, Ph.D.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In March 2012, we entered into a three-year employment agreement with Dr.&nbsp;Wittekind, to serve, at will, as Chief Scientific Officer. After
	the three-year period, the agreement renews for successive one-year terms unless terminated by either party. For 2015, Dr.&nbsp;Wittekind received an annual base salary of $330,215 and was eligible to receive an annual bonus equivalent to 35% of his
	annual salary, payable in cash and subject to performance against mutually agreed-upon goals. Effective January&nbsp;1, 2016, Dr.&nbsp;Wittekind&#146;s annual base salary was increased to $338,000.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effective November&nbsp;12, 2015, we entered into an amendment to Dr.&nbsp;Wittekind&#146;s employment agreement. In the event that
	Dr.&nbsp;Wittekind is terminated without cause or resigns for good reason, he is eligible for (i) severance
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	82
</P>
<A NAME="eolPage86"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	payments equal to 12 months of base salary continuation; (ii)&nbsp;a payment equal to twelve (12)&nbsp;months of bonus; and (iii)&nbsp;payments of COBRA premiums for 12 months. If there is a
	change of control and, within 12 months of such change in control, Dr.&nbsp;Wittekind is terminated without cause or resigns for good reason, he will receive the severance payments outlined above and, in addition, any then-outstanding stock options
	and equity awards will become immediately fully vested and exercisable. Any severance payment is subject to Dr.&nbsp;Wittekind&#146;s executing and not revoking a release of claims. Dr.&nbsp;Wittekind is subject to non-competition and
	non-solicitation provisions during the term of his agreement and for one year following termination.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Daniel Couto
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In March 2011, we entered into a three-year employment agreement with Mr.&nbsp;Couto, to serve, at will, as Vice President of Product
	Development. After the three-year period, the agreement renews for successive one year terms unless terminated by either party. In February 2014, Mr.&nbsp;Couto&#146;s title changed to Senior Vice President, Manufacturing and Facilities Operations.
	For 2015, Mr.&nbsp;Couto received an annual base salary of $300,000 and was eligible to receive an annual bonus equivalent to 30% of his annual salary payable in cash. Effective January&nbsp;1, 2016, Mr.&nbsp;Couto&#146;s base salary was increased
	to $309,300.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On November&nbsp;2, 2015, we entered into an amendment to Mr.&nbsp;Couto&#146;s employment agreement. In the event that
	Mr.&nbsp;Couto is terminated without cause or resigns for good reason, he is eligible for (i)&nbsp;severance payments equal to 12 months of base salary continuation; (ii)&nbsp;a payment equal to twelve (12)&nbsp;months of bonus; and
	(iii)&nbsp;payments of COBRA premiums for 12 months. If there is a change of control and, within 12 months of such change in control, Mr.&nbsp;Couto is terminated without cause or resigns for good reason, he will receive the severance payments
	outlined above and any then-outstanding stock options and equity awards will become immediately fully vested and exercisable. Any severance payment is subject to Mr.&nbsp;Couto&#146;s executing and not revoking a release of claims. Mr.&nbsp;Couto is
	subject to non-competition and non-solicitation provisions during the term of his agreement and for one year following termination.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Barry Kappel,
	Ph.D., M.B.A.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In October 2009, we entered into a three-year employment agreement with Dr.&nbsp;Kappel, to serve, at will, as Head,
	Business Development. After the three-year period, the agreement renews for successive one year terms unless terminated by either party. In February 2014, Dr.&nbsp;Kappel&#146;s title changed to Senior Vice President, Business Development. For 2015,
	Dr.&nbsp;Kappel received an annual base salary of $270,000 and was eligible to receive an annual bonus equivalent to 30% of his annual salary payable in cash. Dr.&nbsp;Kappel resigned from his position on April&nbsp;15, 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In connection with Dr.&nbsp;Kappel&#146;s resignation, we entered into a separation and consulting agreement with him whereby he agreed to
	provide consulting services to us until December&nbsp;31, 2015 and we agreed to provide Dr.&nbsp;Kappel (i)&nbsp;a cash payment of $465,750, of which $135,000 was paid in a lump sum, with the remainder paid in twenty-four monthly installments
	beginning in May 2015, (ii)&nbsp;a fully vested stock option covering 35,550 shares that remains exercisable until March&nbsp;30, 2016, (iii)&nbsp;payments of COBRA premiums for 18 months, and (iv)&nbsp;payment accrued but unused vacation days. In
	exchange for Dr.&nbsp;Kappel&#146;s consulting services, we also agreed to provide accelerated vesting of all of Dr.&nbsp;Kappel&#146;s outstanding, unvested stock options.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2015 Cash Bonuses
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Each Named Executive
	Officer is eligible to receive an annual performance-based cash bonus based on achievement of individual performance goals and Company goals, determined by our Compensation Committee at the beginning of each year. Each Named Executive Officer has a
	target annual bonus award amount, expressed as a percentage of the Named Executive Officer&#146;s base salary. For 2015, each Named Executive Officer other than Dr.&nbsp;Kappel was eligible to earn a cash bonus of up to $244,625 for
	Ms.&nbsp;Gregory, $118,300 for Dr.&nbsp;Wittekind, and$92,790 for Mr.&nbsp;Couto. Dr. Kappel did not receive a 2015 bonus.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	83
</P>
<A NAME="eolPage87"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As soon as practical after the year is completed, our Compensation Committee reviews actual
	performance against the stated Company goals and individual goals and determines subjectively what it believes to be the appropriate level of cash bonus, if any, for the Named Executive Officers. For 2015, the Company goals and objectives primarily
	related to research, clinical and financing activities. Individual goals were based on each person&#146;s specific expertise and experience.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In February 2016, our Compensation Committee reviewed the performance of the Company and of each individual executive against the 2015 Company
	and individual goals and objectives and elected to pay bonuses to the Named Executive Officers. The amounts awarded to each Named Executive Officer for 2015 performance are set forth in the Summary Compensation Table in the column entitled
	&#147;Bonus.&#148;
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Equity and Other Compensation Plans
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We generally offer stock options to our employees, including our Named Executive Officers, as the long- term incentive component of our
	compensation program. Our stock options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant and may be intended to qualify as &#147;incentive stock
	options&#148; under the Internal Revenue Code. As of March&nbsp;9, 2016, a total of 4,761,372 shares of our common stock were reserved for issuance under our equity incentive plans, with 4,290,542 subject to outstanding awards and 470,831 shares
	available for the issuance of future awards.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our stock options typically vest either (a)&nbsp;as to 25% of the shares subject to the
	option on the first anniversary of the date of grant and in equal quarterly installments over the ensuing 36 months or (b)&nbsp;as to all of the shares subject to the option, ratably on a quarterly basis over a four-year period following the date of
	grant, in either case subject to the holder&#146;s continued employment with us as of each applicable vesting date. From time to time, our board of directors may also construct alternate vesting schedules as it determines are appropriate to motivate
	particular employees.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We awarded stock options to our Named Executive Officers during 2015 in the following amounts:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="70%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="20%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:86.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Named Executive Officer
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015&nbsp;Options&nbsp;Granted
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Julia P. Gregory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	303,400
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael Wittekind, Ph.D
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	115,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel Couto
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Barry Kappel, Ph.D., M.B.A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	85,550
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	These options were granted with exercise prices equal to the fair market of our common stock on the date of
	grant, as determined by our board of directors. The shares granted to Ms.&nbsp;Gregory and Messrs. Wittekind and Couto vest over four years, with 6.25% of the shares underlying the option vesting at the end of each calendar quarter. The shares
	granted to Dr. Kappel vested in accordance with the terms of his separation and consulting agreement.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	401(k) Retirement Plan
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of the Internal
	Revenue Code. In general, all of our employees are eligible to participate beginning on the first day of their employment. The 401(k) plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current
	compensation by up to the statutorily prescribed limit, generally equal to $18,000 for 2015, and have the amount of the reduction contributed to the 401(k) plan. In 2015, the Company implemented a cash matching program whereby it contributes, on a
	dollar-for-dollar basis, an amount equal to 50% of employee contributions up to 3% of an employee&#146;s salary.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	84
</P>
<A NAME="eolPage88"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2015 Director Compensation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our non-employee directors are compensated on annual basis for their services on the board of directors as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each non-employee director receives an annual cash retainer of $40,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each non-employee director receives an annual stock option grant to purchase 15,000 shares of our common stock, generally granted on or about the Annual Meeting Date;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the Chairman of the board of directors, each Chairman of a committee of the board of directors or a member of a committee of the board of directors, receives additional cash compensation as follows:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Chairman of the board of directors receives an additional annual retainer of $160,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Lead Director of the board of directors receives an additional annual retainer of $20,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Vice Chairman of the board of directors receives an additional annual retainer of $10,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Chairman of the Audit Committee receives an additional annual retainer of $15,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Chairman of the Compensation Committee receives and additional annual retainer of $10,000;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Chairman of each of the Science and Technology Committee and the Nominating and Corporate Governance Committee receives an additional annual retainer of $7,500; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	member of the Compensation Committee, Science and Technology Committee or the Nominating and Corporate Governance Committee&#151;with respect to each such membership, an additional annual retainer of $5,000; member of
	the Audit Committee receives an additional annual retainer of $7,500.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each non-employee director receives an initial stock option grant to purchase 30,000 shares of our common stock upon being appointed to the board, granted as soon as reasonably practicable following the director&#146;s
	appointment.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We generally grant stock options to our non-employee directors as soon as reasonably practical after the
	Annual Meeting as compensation for their service on our board of directors in the coming year. These stock options have an exercise price equal to the fair market value of our common stock on the date of grant and have a term of ten years from the
	date of grant, subject to the director&#146;s continued service on our board of directors. The stock options vest as to 25% of the original number of shares underlying such options at the end of each calendar quarter following the date of grant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The initial stock options granted to non-employee directors upon joining the board have an exercise price equal to fair market value on
	the date of grant and have a term of ten years from the date of grant, subject to the director&#146;s continued service. The initial option grant vests 25% on the date of grant and 25% on each of the first three anniversaries of the date of grant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Each member of our board of directors is also entitled to be reimbursed for reasonable travel and other expenses incurred in connection
	with attending meetings of the board of directors and any committee on which he serves.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In May 2015, Dr.&nbsp;Steven Gilman was elected
	to the board of directors. In addition to the cash and equity compensation paid under our non-employee director compensation program described above, Dr.&nbsp;Gilman received an option to purchase 170,000 shares of our common stock that vests
	ratably over a three-year period.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	85
</P>
<A NAME="eolPage89"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth in summary form information concerning the compensation that we
	paid or awarded during the year ended December&nbsp;31, 2015 to each of our non-employee directors:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="46%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fees&nbsp;Earned
<BR>
	or Paid in
<BR>
	Cash ($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option
<BR>
	Awards
<BR>
	($)&nbsp;(2)(4)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Other
<BR>
	Compensation&nbsp;($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total ($)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Steven Gilman, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	150,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	598,664
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	748,664
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sol Barer, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	124,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Roger Pomerantz, M.D., F.A.C.P.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	114,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Isaac Blech.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	54,375
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	103,732
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David N. Low, Jr.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	55,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	104,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael J. Otto, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	45,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	94,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David Scheinberg, M.D., Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	55,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	104,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cary Sucoff.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	45,625
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	49,357
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	94,982
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lawrence Yuan Tian, Ph.D
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,740
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(3)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	230,740
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shengda Zan (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	(1)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Resigned from the position of director on May&nbsp;4, 2015. All unvested portions of outstanding stock option grants were immediately forfeited.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The amounts reported in the &#147;Option Awards&#148; column reflect the aggregate grant date fair value of stock options compensation awarded during the year computed in accordance with the provisions of ASC, Topic
	718. See Note 11 to our financial statements included with this Annual Report on Form 10-K regarding assumptions underlying the valuation of equity awards.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Represents compensation received under a consulting agreement we entered into with CIFCO International Group in April of 2013.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(4)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The following table shows the number of outstanding option awards held by each non-employee director as of December&nbsp;31, 2015. None of our non-employee directors held unvested stock awards as of December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="74%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="16%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Option&nbsp;Awards&nbsp;(#)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Steven Gilman, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	200,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sol Barer, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	162,854
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Roger Pomerantz, M.D., F.A.C.P.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	68,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Isaac Blech
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	162,853
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David N. Low, Jr.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael J. Otto, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David Scheinberg, M.D., Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	102,853
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cary Sucoff
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	119,995
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lawrence Yuan Tian, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shengda Zan
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	51,246
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Compensation Risk
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Compensation Committee, in consultation with management, has reviewed the design and operation of the Company&#146;s compensation
	arrangements and evaluated the relationship between the Company&#146;s risk management policies and practices and these arrangements. As a result of this review, the Compensation Committee has determined that the Company&#146;s compensation policies
	and practices are not reasonably likely to have a material adverse effect on the Company.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Compensation Committee Interlocks and
	Insider Participation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The compensation committee currently consists of David A. Scheinberg, M.D., Ph.D., who serves as chairman,
	Sol Barer, Ph.D. and Isaac Blech.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	86
</P>
<A NAME="eolPage90"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During 2015, none of our executive officers served as a member of the board of directors or
	compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or compensation committee. None of the members of our
	compensation committee has ever been an employee of the Company.
</P>
</EFX_COMPENSATION>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_17">
</A>
	Item&nbsp;12. Security Ownership of Certain Beneficial
	Owners and Management and Related Stockholder Matters
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Security Ownership Of Certain Beneficial Owners And Management
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth information as of March&nbsp;9, 2016 as to the shares of our common stock beneficially owned by:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each of our directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each of our Named Executive Officers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	all of our directors and executive officers as a group; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our outstanding shares of common stock.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	87
</P>
<A NAME="eolPage91"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Ownership information is based upon information furnished by the respective individuals or
	entities, as the case may be. Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. The percentage of common stock beneficially owned is
	based on 27,484,005 shares outstanding as of March&nbsp;9, 2016. Shares of our common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of March&nbsp;9, 2016 are considered outstanding and beneficially
	owned by the person holding the options or warrants for the purposes of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as disclosed in the footnotes to
	this table and subject to applicable community property laws, we believe that each person or entity identified in the table possesses sole voting and investment power over all shares of common stock shown as beneficially owned by such person or
	entity. Except as otherwise set forth below, the address of the beneficial owner is c/o ContraFect Corporation, 28 Wells Avenue, 3rd Floor, Yonkers, New York 10701.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="81%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number of
<BR>
	Shares of
<BR>
	Common
<BR>
	Stock
<BR>
	Beneficially
<BR>
	Owned
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Percentage
<BR>
	of Shares
<BR>
	Beneficially
<BR>
	Owned
</B>
<BR>
<B>
	(%)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	5% Stockholders:
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Broadfin Capital, LLC. (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,127,659
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jack W. Schuler (2)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,127,659
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Ernest W. Moody Revocable Trust (3)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,000,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Oracle Associates, LLC (4)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,773,048
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shengda Zan (5)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,571,240
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.7
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adage Capital Partners, L.P. (6)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,500,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Directors and Named Executive Officers:
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Steven Gilman, Ph.D. (7)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sol Barer, Ph.D. (8)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,381,924
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.9
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Roger J. Pomerantz, M.D. F.A.C.P. (9)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61,428
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Isaac Blech (10)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,443,657
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David N. Low, Jr. (11)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	91,835
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael J. Otto, Ph.D. (12)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41,428
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	David Scheinberg, M.D., Ph.D. (13)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	124,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cary Sucoff (14)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	189,992
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lawrence Yuan Tian, Ph.D. (15)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Julia P. Gregory (16)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	517,416
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.9
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael Wittekind, Ph.D. (17)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	136,899
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel Couto (18)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	85,026
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Barry Kappel, Ph.D. (19)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	158,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	*
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	All current directors and executive officers as a group (17 persons) (20)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,368,547
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14.7
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	*
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Represents beneficial ownership of less than one percent of our outstanding common stock.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based solely on a Schedule 13G filed with the SEC on February&nbsp;16, 2016 by Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler (the &#147;Broadfin Reporting Persons&#148;). The address for
	Broadfin Capital, LLC and Kevin Holter is 300 Park Avenue, 25
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	th
</SUP>
	Floor, New York, New York 10022. The address for Broadfin Healthcare Master Fund, Ltd. is 20 Genesis Close, Ansbacher House, P.O.
	Box 1344, Grand Cayman KY1-1108, Cayman Islands. Consists of (a)&nbsp;1,418,439 shares of common stock and (b)&nbsp;709,220 shares of common stock underlying warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60
	days after such date. Each of the Broadfin Reporting Persons has shared voting and dispositive power over all such shares.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The address for Jack W. Schuler is c/o Crabtree Partners, 100 W. Field Drive, Suite 360, Lake Forest, IL 60045. Consists of (a)&nbsp;1,418,439 shares of common stock and (b)&nbsp;709,220 shares of common stock
	underlying warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	88
</P>
<A NAME="eolPage92"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The address for the Ernest W. Moody Revocable Trust (the &#147;Trust&#148;) is 2116 Redbird Drive, Las Vegas, NV 89134. Consists of shares of common stock and shares of common stock underlying warrants that are
	exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date. The Trust has sole voting and dispositive power over all such shares.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(4)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based solely on a Schedule 13G filed with the SEC on June&nbsp;26, 2015 by Oracle Associates, LLC, Oracle Partners, L.P., Oracle Institutional Partners, L.P. and Larry Feinberg (the &#147;Oracle Reporting
	Persons&#148;). The address for each of the Oracle Reporting Persons is 200 Greenwich Avenue, 3
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	rd
</SUP>
	Floor, Greenwich, Connecticut 06830. Consists of (a)&nbsp;1,182,032 shares of common stock and
	(b)&nbsp;591,016 shares of common stock underlying warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date. Oracle Associates, LLC and Larry Feinberg have shared voting and dispositive power
	over all such shares. Oracle Partners, L.P. has shared voting and dispositive power over 1,418,439 shares. Oracle Institutional Partners, L.P. has shared voting and dispositive power over 354,609 shares.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(5)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Shengda Zan, a former member of our board of directors, is the sole director of Alpha Spring Limited. The address for Alpha Spring Limited is P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British
	Virgin Islands. Consists of (a)&nbsp;1,337,036 shares of common stock and (b)&nbsp;234,204 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such
	date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(6)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based solely on a Schedule 13G filed with the SEC on January&nbsp;28, 2016 by Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C., Adage Capital Advisors, L.L.C., Robert Atchinson and Phillip Gross (the
	&#147;Adage Reporting Persons&#148;). The address for each of the Adage Reporting Persons is 200 Clarendon Street, 52
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	nd
</SUP>
	Floor, Boston, Massachusetts 02116. Consists of shares of common stock as of
	March&nbsp;9, 2016. Each of the Adage Reporting Persons has shared voting and dispositive power over all such shares.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(7)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 50,000 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(8)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;775,932 shares of common stock and (b)&nbsp;605,992 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days
	after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(9)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 61,428 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(10)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;1,280,804 shares of common stock and (b)&nbsp;162,853 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such
	date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(11)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;30,550 shares of common stock and (b)&nbsp;61,285 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after
	such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(12)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 41,428 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(13)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;15,770 shares of common stock and (b)&nbsp;108,567 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days
	after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(14)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 189,992 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(15)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 23,571 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(16)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;50,282 shares of common stock and (b)&nbsp;467,134 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days
	after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(17)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;17,893 shares of common stock and (b)&nbsp;119,006 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(18)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of 85,026 shares of common stock underlying options that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days after such date.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(19)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;14,032 shares of common stock and (b)&nbsp;144,689 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days
	after such date.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	89
</P>
<A NAME="eolPage93"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(20)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of (a)&nbsp;2,203,008 shares of common stock and (b)&nbsp;2,165,539 shares of common stock underlying options and warrants that are exercisable as of March&nbsp;9, 2016 or will become exercisable within 60 days
	after such date.
</TD>
</TR>
</TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Equity Compensation Plan Information
</I>
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="59%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:49.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Plan Category
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number&nbsp;of&nbsp;securities
<BR>
	to be issued upon
<BR>
	exercise of
<BR>
	outstanding options,
<BR>
	warrants and rights
<BR>
	(3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted-
<BR>
	average
<BR>
	exercise
<BR>
	price of
<BR>
	outstanding
<BR>
	options,
<BR>
	warrants
<BR>
	and rights
<BR>
	(3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number&nbsp;of&nbsp;securities
<BR>
	remaining available
<BR>
	for future issuance
<BR>
	under equity
<BR>
	compensation
	plans
<BR>
	(excluding&nbsp;securities
</B>
<BR>
<B>
	reflected in first
<BR>
	column)
</B>
<BR>
<B>
	(3)(4)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Equity compensation plans approved by security holders (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,613,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.47
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,179
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Equity compensation plans not approved by security holders (2)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,032,833
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.10
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of the 2014 Omnibus Incentive Plan (the &#147;2014 Plan&#148;).
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Consists of the Amended and Restated 2008 Equity Incentive Plan.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	As of December&nbsp;31, 2015.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(4)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The 2014 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2015 and continuing until the expiration of the 2014 Plan, equal
	to the lesser of (i)&nbsp;4% of the outstanding shares of common stock on December&nbsp;31 immediately preceding such date or (ii)&nbsp;a lesser amount determined by the Company&#146;s board of directors.
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_18">
</A>
	Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Certain Relationships and Related Transactions
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Indemnification Agreements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have
	entered into indemnification agreements with each of our directors and executive officers in which we agree to indemnify, defend and hold harmless, and also advance expenses as incurred, to the fullest extent permitted under applicable law, from
	damage arising from the fact that such person is or was an officer or director of the Company or any of its subsidiaries. We maintain insurance policies for director and officer liability providing for maximum coverage in the amount of $20 million.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Policies and Procedures for Related Person Transactions
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our board of directors has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which we
	are a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or 5% stockholders, or their immediate family members, each of whom we refer to as a &#147;related person&#148;, has a direct or
	indirect material interest.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Company management is responsible for determining whether a transaction meets the requirements of a related
	person transaction requiring review under the related person transaction policy. If review is deemed to be required under the policy, it is the responsibility of the Audit Committee to review related person transactions and approve, ratify, revise
	or reject related person transactions. The Audit Committee will consider all relevant facts and circumstances and will only ratify those transactions that are in our best interests. If a related party transaction involves a related person who is a
	director or immediate family member of a director, such director may not participate in the deliberations or vote respecting such transaction; provided, however, that such director may be counted in determining the presence of a quorum at a meeting
	of the Audit Committee which considers such transaction. If management determines it is impractical or undesirable to wait until an Audit Committee meeting to consummate a transaction with a related person, the chairperson of the Audit Committee may
	approve
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	90
</P>
<A NAME="eolPage94"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	the transaction with the related person. Any such approval must be reported to the Audit Committee at the next regularly scheduled meeting.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following transactions involving related persons are pre-approved under the related party transaction policy:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any employment by us of an executive officer, if: (i)&nbsp;the related compensation is required to be reported in our proxy statement under Item&nbsp;402 of the SEC&#146;s compensation disclosure requirements (generally
	applicable to &#147;named executive officers&#148;); or (ii)&nbsp;the executive officer is not an immediate family member of another executive officer or director, the related compensation would be reported in our proxy statement under Item&nbsp;402
	of the SEC&#146;s compensation disclosure requirements if the executive officer was a &#147;named executive officer,&#148; and the Compensation Committee approved (or recommended that the Board approve) such compensation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any compensation or benefits paid to a director for service as a director, as long as the Board has approved such compensation or benefits;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any transaction with another company at which a related person&#146;s only relationship is as an employee (other than an executive officer), director or beneficial owner of less than 10% of that company&#146;s shares,
	if the aggregate amount involved does not exceed the greater of $1,000,000 or 2 percent of that company&#146;s total annual revenues;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any charitable contribution, grant or endowment by us to a charitable organization, foundation or university in which a related person&#146;s only relationship is as an employee (other than an executive officer), or a
	director or trustee, if the aggregate amount involved does not exceed the greater of $250,000 or 2 percent of the charitable organization&#146;s total annual receipts;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any transaction where the related person&#146;s interest arises solely from the ownership of a class of our equity securities and all holders of that class of equity securities received the same benefit on a pro rata
	basis (e.g., dividends);
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any transaction with a related person involving the rendering of services as a common or contract carrier, or public utility, at rates or charges fixed in conformity with law or governmental authority; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any transaction with a related person involving services as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture, or similar services.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Director Independence
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Except as may
	otherwise be permitted by the applicable listing standards of NASDAQ, a majority of the members of the board of directors shall be independent directors. The board of directors has determined that Dr.&nbsp;Gilman, Dr.&nbsp;Barer, Mr.&nbsp;Blech,
	Mr.&nbsp;Low, Dr.&nbsp;Otto, Dr.&nbsp;Pomerantz, Dr.&nbsp;Scheinberg and Mr.&nbsp;Sucoff qualify as independent directors under the applicable listing standards of NASDAQ. The board of directors has also determined that each director who currently
	serves on the Audit Committee is independent under the applicable listing standards of NASDAQ and Rule 10A-3 under the Exchange Act, that each director who currently serves on the Compensation Committee meets NASDAQ&#146;s heightened standard of
	independence applicable to compensation committee members, and that each director who currently serves on the Nominating and Corporate Governance Committee is independent under the applicable listing standards of NASDAQ. The board of directors has
	determined that Ms.&nbsp;Gregory and Dr.&nbsp;Tian are not independent as defined by the applicable listing standards of NASDAQ.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	91
</P>
<A NAME="eolPage95"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_OFFICER_TRANSACTIONS>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_19">
</A>
	Item&nbsp;14. Principal Accounting Fees and Services Principal Accountant Fees and
	Services
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table presents aggregate fees billed to us for services rendered by Ernst&nbsp;&amp; Young LLP during the years
	ended December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="64%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fiscal&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Audit Fees (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	305,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	511,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Audit-Related Fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tax Fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	All Other Fees (2)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	305,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	533,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Audit fees consisted of fees paid for our annual audits, review of our quarterly reports on Form 10-Q and our SEC filings related to our initial public offering and S-8 registration.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	All other fees related to services with respect our employee incentive plans.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Preapproval Policies and
	Procedures
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	It is our policy that the Audit Committee shall preapprove all audit services to be provided to the Company, whether
	provided by the principal auditor or other firms, and all other services (review, attest and non-audit) to be provided to the Company by the independent auditor;
<I>
	provided, however
</I>
	, that de minimis non-audit services may instead be approved in
	accordance with applicable SEC rules. The Audit Committee may form and delegate authority to one or more subcommittees, as it deems appropriate from time to time under the circumstances (including a subcommittee consisting of a single member), any
	preapproval decisions relating to audit, review, attest or non-audit services, provided that such decisions shall be presented to the full Audit Committee at its next scheduled meeting. During 2015, the Audit Committee pre-approved all audit and
	non-audit services in accordance with this policy.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	92
</P>
<A NAME="eolPage96"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART IV
</B>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D109824D10K_HTM_ROM109824_20">
</A>
	Item&nbsp;15. Exhibits and Financial Statement Schedules
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
	(1)
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	Financial Statements
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following documents are included on pages F-1 through F-27
	attached hereto and are filed as part of this Annual Report on Form 10-K.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="95%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_1">
	Report of Independent Registered Public Accounting Firm
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_2">
	Balance Sheets
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_3">
	Statements of Operations
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_4">
	Statements of Comprehensive Loss
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_5">
	Statement of Convertible Preferred Stock and Stockholders&#146; Equity
</A>
	(Deficit)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_6">
	Statements of Cash Flows
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_7">
	Notes to Financial Statements
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-9
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
	(2)
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	Financial Statement Schedules
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Schedules have been omitted since they are either not
	required or not applicable or the information is otherwise included herein.
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
	(3)
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	Exhibits
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The exhibits filed as part of this Annual Report on Form 10-K are listed in
	the Exhibit Index immediately preceding such Exhibits, which Exhibit Index is incorporated herein by reference.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	93
</P>
<A NAME="eolPage97"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_INDEX">
</A>
	Index to Financial Statements
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="95%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_1">
	Report of Independent Registered Public Accounting Firm
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_2">
	Balance Sheets
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_3">
	Statements of Operations
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_4">
	Statements of Comprehensive Loss
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_5">
	Statements of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit)
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_6">
	Statements of Cash Flows
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D109824D10K_HTM_TX109824_7">
	Notes to Financial Statements
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	F-9
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-1
</P>
<A NAME="eolPage98"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_1">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Board of Directors and Stockholders
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	ContraFect Corporation
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have audited the accompanying balance sheets of ContraFect Corporation as of December&nbsp;31, 2015 and 2014, and the related
	statements of operations, comprehensive loss, convertible preferred stock and stockholders&#146; equity (deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2015. These financial statements are the
	responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
	require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial
	reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
	the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the
	accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ContraFect
	Corporation at December&nbsp;31, 2015 and 2014, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2015, in conformity with U.S. generally accepted accounting principles.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
	/s/ Ernst&nbsp;&amp; Young LLP&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Metro
	Park, New Jersey
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	March 15, 2016
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-2
</P>
<A NAME="eolPage99"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_2">
</A>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Balance Sheets
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="72%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Assets
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Current assets:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,972,781
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,722,453
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,948,872
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,670,606
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prepaid expenses and other current assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,176,895
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	368,787
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total current assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34,098,548
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,761,846
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Property and equipment, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,618,968
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,148,155
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	143,621
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	143,621
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,861,137
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,053,622
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Liabilities and stockholders&#146; equity
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Current liabilities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accounts payable
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,517,417
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	481,626
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,251,767
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,741,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total current liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,769,184
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,223,069
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred rent
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	972,119
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	936,042
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrant liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	444,324
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,004
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,185,627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,472,115
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commitments and contingencies (Note 8)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stockholders&#146; equity:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preferred stock, $0.0001 par value, 25,000,000 shares authorized and none outstanding at December&nbsp;31, 2015 and 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Common stock, $0.0001 par value, 100,000,000 shares authorized, 27,482,692 shares outstanding at December&nbsp;31, 2015; 100,000,000
	shares authorized, 20,217,263 shares outstanding at December&nbsp;31, 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,748
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,021
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additional paid-in capital
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	148,282,546
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	118,038,560
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated other comprehensive loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,373
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated deficit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(117,579,411
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(92,458,447
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total stockholders&#146; equity
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,675,510
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,581,507
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total liabilities and stockholders&#146; equity
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,861,137
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,053,622
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="MARGIN-TOP:200PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	See accompanying notes.
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-3
</P>
<A NAME="eolPage100"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_3">
</A>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Statements of Operations
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating expenses:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development, including stock-based compensation of $389,967, $715,475 and $230,629, respectively
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,004,512
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,868,053
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,133,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General and administrative, including stock-based compensation of $1,599,895, $1,224,704 and $2,101,089, respectively
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,060,825
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,067,858
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,163,259
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total operating expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,065,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,935,911
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,296,434
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Loss from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,065,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(16,935,911
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(19,296,434
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other income (expense):
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Interest income (expense), net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75,693
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,412,620
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,712,178
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Refundable state tax credits
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	424,649
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in fair value of warrant and embedded derivative liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(131,320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,225,202
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,612,090
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total other income (expense)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(55,627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(13,213,173
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,324,268
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,149,084
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preferred stock dividend in-kind
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,468,452
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss attributable to common stockholders
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34,617,536
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Per share information:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss per share of common stock, basic and diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3.86
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic and diluted weighted average shares outstanding
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,328,922
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,973,599
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,011,789
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN-TOP:250PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	See accompanying notes.
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-4
</P>
<A NAME="eolPage101"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_4">
</A>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Statements of Comprehensive Loss
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,149,084
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive loss:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Unrealized loss on available-for-sale securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(29,746
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Comprehensive loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,150,710
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,149,711
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:500PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	See accompanying notes.
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-5
</P>
<A NAME="eolPage102"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_5">
</A>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Statement of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit)
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT" ALIGN="CENTER">
<TR>
<TD WIDTH="16%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series A
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series B
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series C
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series C-1
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Common Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Additional
<BR>
	Paid-In
<BR>
	Capital
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Loan
<BR>
	Receivable&nbsp;-
<BR>
	Officer
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
<BR>
	Loss
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Accumulated
<BR>
	Deficit
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Stockholders&#146;
<BR>
	Equity
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	(Deficit)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Balance, December&nbsp;31, 2012
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,200,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,964,283
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	4,651,163
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	10,175,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	9,090,909
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	27,752,294
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,006,417
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	101
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,588,592
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(600,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(34,220,209
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(32,231,516
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for license
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	5,580
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	10,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	10,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of warrants for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	22,149
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	22,149
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Loan forgiven-officer
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	600,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	600,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,309,569
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,309,569
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(23,620,702
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(23,620,702
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Balance, December&nbsp;31, 2013
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,200,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,964,283
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	4,651,163
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	10,175,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	9,090,909
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	27,752,294
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,011,997
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	101
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	4,930,310
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(57,840,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(52,910,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of preferred stock for license
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	151,515
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	500,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of warrants for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	26,354
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	26,354
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of securities in IPO, including over-allotment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	6,880,333
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	688
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	41,281,310
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	41,281,998
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for conversion of preferred stock on closing of IPO
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(2,200,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(1,964,283
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(4,651,163
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(10,175,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(9,090,909
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(27,752,294
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(151,515
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(500,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	6,861,968
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	686
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	44,860,093
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(4,468,452
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	40,392,327
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Financing cost of sale of securities in IPO
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(6,644,713
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(6,644,713
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for conversion of notes payable and for interest liabilities, recognition of
	beneficial conversion feature and the reclassification of note-related liabilities on closing of IPO
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	5,197,476
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	520
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	30,632,169
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	30,632,689
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Cancellation of placement agent warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	941,541
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	941,541
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Net shares of common stock issued in relation to vesting of retention grants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	133,109
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	532,438
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	532,451
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for license
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	132,380
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	499,987
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	500,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	979,071
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	979,071
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Unrealized loss on marketable securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(627
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(627
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(30,149,084
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(30,149,084
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Balance, December&nbsp;31, 2014
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	20,217,263
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,021
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	118,038,560
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(627
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(92,458,447
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	25,581,507
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-6
</P>
<A NAME="eolPage103"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT" ALIGN="CENTER">
<TR>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series A
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series B
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series C
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Series C-1
<BR>
	Convertible
<BR>
	Preferred Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Common Stock
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Additional
<BR>
	Paid-In
<BR>
	Capital
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Loan
<BR>
	Receivable&nbsp;-
<BR>
	Officer
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
<BR>
	Loss
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Accumulated
<BR>
	Deficit
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Stockholders&#146;
<BR>
	Equity
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	(Deficit)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<FONT STYLE="FONT-SIZE:6.5PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Net shares issued in relation to vesting of performance grant
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	11,778
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	54,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	54,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for services
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	28,445
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	167,535
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	167,538
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of securities in private placement
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	4,728,128
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	474
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	19,999,526
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	20,000,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Financing cost of sale of securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(1,665,554
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(1,665,554
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for exercise of options
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	23,235
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Issuance of common stock for exercise of warrants
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,473,793
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	247
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	9,698,317
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	9,698,564
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,989,862
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	1,989,862
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Unrealized loss on marketable securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(29,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(29,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(25,120,964
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(25,120,964
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:7PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:6.5PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-SIZE:6.5PT">
	Balance, December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	27,482,642
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	2,748
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	148,282,546
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	&#151;&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(30,373
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	(117,579,411
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-SIZE:6.5PT">
	30,675,510
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-SIZE:6.5PT">
	&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="MARGIN-TOP:200PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	See accompanying notes
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-7
</P>
<A NAME="eolPage104"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_6">
</A>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Statements of Cash Flows
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from operating activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,149,084
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adjustments to reconcile net loss to net cash used in operating activities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Depreciation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	537,344
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	551,323
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	559,237
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,989,862
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,511,509
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,309,569
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of preferred stock and other costs in exchange for licensed technology
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,000,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock in exchange for services
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	167,538
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock warrants in exchange for services
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	26,354
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,149
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Recognition of beneficial conversion feature
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,428,547
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Amortization of debt issuance costs
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,240,391
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	416,075
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Amortization of debt discount
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,550,527
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	738,935
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in fair value of warrant and embedded derivative liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	131,320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,225,202
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,612,090
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Increase in deferred rent
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,077
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	69,675
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	224,367
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other non-cash charges and expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	600,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net amortization of premium paid on marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	283,915
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Changes in operating assets and liabilities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Decrease (increase) in prepaid expenses and other current assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(808,108
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(170,377
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	69,387
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(Decrease) increase in accounts payable and accrued liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	600,415
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,148,829
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,002,469
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash used in operating activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(22,182,601
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,864,762
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,056,424
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from investing activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Decrease in restricted cash
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,575,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Purchases of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(33,524,927
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,671,233
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from maturities of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,933,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Purchases of property and equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,157
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from disposal of property and equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,697
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,570
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash (used in) provided by investing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21,600,084
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,610,536
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,588,570
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from financing activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from issuance of convertible notes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,036,350
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,963,650
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Payment of financing costs of convertible notes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(24,850
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,336,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from issuance of equity securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41,281,998
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Payment of financing costs of securities sold
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,665,554
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(6,241,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Repayment of lease and notes payable
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,900,510
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from exercise of warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,698,567
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by financing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,033,013
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,052,481
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,726,860
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net increase (decrease) in cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(15,749,672
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,577,183
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3,740,994
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents at beginning of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,722,453
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,145,270
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,886,264
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents at end of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,972,781
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,722,453
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,145,270
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Supplemental disclosures of cash flow information and non-cash investing and financing activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash paid for interest
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	107,632
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common and preferred stock for license received
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,000,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock for services
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	167,538
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cancellation of placement agent warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	941,541
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	See accompanying notes.
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-8
</P>
<A NAME="eolPage105"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D109824D10K_HTM_TX109824_7">
</A>
	ContraFect Corporation
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Notes to Financial Statements
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	December&nbsp;31, 2015
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	1. Organization and Description of Business
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Organization and Business
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	ContraFect Corporation (the &#147;Company&#148;) is a clinical-stage biotechnology company focused on protein and antibody therapeutic products
	for life-threatening infectious diseases, particularly those treated in hospital-based settings. The Company intends to address multi-drug resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms
	to target conserved regions of either bacteria or viruses. The Company&#146;s most advanced product candidates are CF-301, a lysin for the treatment of
<I>
	Staph aureus
</I>
	bacteremia, and CF-404, a combination of mAbs for the treatment of
	life-threatening seasonal and pandemic varieties of influenza.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has incurred losses from operations since inception as a
	research and development organization and has relied on its ability to fund its operations through public and private debt and equity financings. Management believes its cash, cash equivalents and marketable securities balances will be sufficient to
	fund operations into the second quarter of 2017 and expects operating losses and negative cash flows to continue at more significant levels in the future as it initiates additional clinical trials. Transition to profitability is dependent upon the
	successful development, approval, and commercialization of its product candidates and achieving a level of revenues adequate to support the Company&#146;s cost structure. The Company may never achieve profitability, and unless and until it does, the
	Company will continue to need to raise additional capital. Management intends to fund future operations through additional public or private equity financings, and may seek additional capital through arrangements with strategic partners or from
	other sources. There can be no assurances that such financing will be available to the Company on satisfactory terms, or at all.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	August 2014, the Company completed its initial public offering of 6,000,000 units, consisting of one share of common stock, one Class&nbsp;A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B
	Warrant to purchase one-half share of common stock at an exercise price of $4.00 per full share (the &#147;Units&#148;) and closed on the underwriter&#146;s over-allotment option for an additional 880,333 Units (the &#147;IPO&#148;), raising total
	net proceeds of $35.0 million, net of underwriting discount, commissions and offering expenses.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2015, the Company completed a
	private placement of securities to institutional investors whereby the investors received an aggregate of 4,728,128 shares of the Company&#146;s common stock and warrants to purchase an additional 2,364,066 shares of common stock at an exercise
	price of $8.00 per share. The Company received net proceeds of $18.3 million, net of expenses.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On November&nbsp;2, 2015, the
	Company&#146;s Class B Warrants to purchase common stock expired in accordance with their terms. As of November&nbsp;2, 2015, holders of the Class B Warrants had exercised 4,812,328 Class B Warrants, resulting in the issuance of 2,406,164 shares of
	the Company&#146;s common stock and the receipt by the Company of approximately $9.6 million in gross proceeds. The 2,068,005 Class B Warrants that were not exercised prior to expiration were terminated and are no longer exercisable.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The significant increase in common stock outstanding in August 2014 and June 2015 is expected to impact the year-over-year comparability of
	the Company&#146;s net loss per share calculations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2. Summary of Significant Accounting Policies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Basis of Presentation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The accompanying financial information has been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S.
	GAAP&#148;).
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-9
</P>
<A NAME="eolPage106"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Significant Risks and Uncertainties
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors
	include, but are not limited to: the results of clinical testing and trial activities of the Company&#146;s products, the Company&#146;s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or
	being developed by other companies, the price of, and demand for, the Company&#146;s products, the Company&#146;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products and the Company&#146;s
	ability to raise capital. See &#147;Risk Factors&#148; contained elsewhere in this Annual Report on Form 10-K for additional risks and uncertainties.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Reclassifications
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company concluded
	it was appropriate to classify its deferred rent as a non-current liability. Prior period financial statement amounts have been reclassified to conform to current period presentation. These reclassifications had no effect on reported results of
	operations or cash flow from operations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Use of Estimates
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
	reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates and assumptions on
	historical experience when available and on various factors that it believes to be reasonable under the circumstances. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to accruals, fair value
	measurements, stock-based compensation, warrant valuation and income taxes. The Company&#146;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#146;s
	original estimates in any periods presented.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash and Cash Equivalents
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company considers all highly liquid investments with maturities at the date of purchase of three months or less to be cash equivalents.
	Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposit, commercial paper and U.S. government and U.S.
	government agency obligations. Cash equivalents are reported at fair value.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Marketable Securities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities at December&nbsp;31, 2015 and December&nbsp;31, 2014 consisted of investments in short-term corporate debt securities.
	Management determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its marketable securities as
	available-for-sale pursuant to ASC 320,
<I>
	Investments&#151;Debt and Equity Securities
</I>
	. Marketable securities are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss)
	in stockholders&#146; equity (deficit) and a component of total comprehensive loss in the statements of comprehensive loss, until realized. The fair value of these securities is based on quoted prices for identical or similar assets. Realized gains
	and losses are included in investment income on a specific-identification basis. There were no realized gains or losses on marketable securities for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than
	the amortized cost and evidence indicates that a marketable security&#146;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-10
</P>
<A NAME="eolPage107"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	investments are recognized in the statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the
	Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#146;s investment policy, the severity and
	the duration of the impairment and changes in value subsequent to the end of the period.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities at December&nbsp;31, 2015
	consist of the following:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:75.20PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Marketable Securities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Amortized&nbsp;Cost
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Unrealized
</B>
<BR>
<B>
	Gains
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Unrealized
</B>
<BR>
<B>
	Losses
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Current:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,979,245
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	199
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,572
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,948,872
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities at December&nbsp;31, 2014 consisted of the following:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="48%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:75.20PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Marketable Securities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Amortized&nbsp;Cost
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Unrealized
</B>
<BR>
<B>
	Gains
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Unrealized
</B>
<BR>
<B>
	Losses
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Current:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,671,233
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	159
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(786
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,670,606
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	At December&nbsp;31, 2015 and December&nbsp;31, 2014, the Company held only current investments. Investments
	classified as current have maturities of less than one year. Investments that would be classified as non-current are those that have maturities of greater than one year and management does not intend to liquidate within the next twelve months.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	At December&nbsp;31, 2015 and December&nbsp;31, 2014, the Company held 28 and three debt securities, respectively, that individually and in
	total were in an immaterial unrealized loss position for less than one year. The aggregate fair value of debt securities in an unrealized loss position at December&nbsp;31, 2015 and December&nbsp;31, 2014 was $21,137,424 and $1,222,291,
	respectively. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than
	not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be
	other-than-temporarily impaired as of December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Concentrations of Credit Risk
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable
	securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company
	has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts,
	option contracts or other hedging arrangements.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Fair Value of Financial Instruments
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s financial instruments consist of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities,
	notes payable, convertible notes, warrant liabilities and embedded derivatives liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in
	nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The fair value of the Company&#146;s convertible notes, warrant liabilities and embedded derivatives liabilities are based upon
	unobservable inputs, as described further below.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-11
</P>
<A NAME="eolPage108"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company is required to disclose information on all assets and liabilities reported at fair
	value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820,
<I>
	Fair Value Measurements and Disclosures
</I>
	(ASC 820), establishes a hierarchy of inputs used in measuring fair value that maximizes
	the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on
	market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based
	on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three
	levels of the fair value hierarchy are described below:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Level 1&#151;Valuations based on unadjusted quoted prices in active markets for
	identical assets or liabilities that the Company has the ability to access at the measurement date.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Level 2&#151;Valuations based on
	quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Level 3&#151;Valuations that require inputs that reflect the Company&#146;s own assumptions that are both significant to the fair value
	measurement and unobservable.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the
	market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#146;s level within the
	fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company had no
	liabilities classified as Level 1 or Level 2. The carrying amounts reported in the accompanying financial statements for accounts payable and accrued expenses approximate their respective fair values due to their short-term maturities. The fair
	value of the warrant and embedded derivative liabilities are discussed in Note 3, &#147;Fair Value Measurements.&#148;
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Property, Office Equipment, and
	Leasehold Improvements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and
	equipment is provided by the straight-line method over their estimated useful lives, ranging from three to five years.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Leasehold
	improvements are amortized on a straight line basis over the useful life of the improvement or the initial lease term, whichever is shorter. Costs for normal repair and maintenance are charged to expense as incurred.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Deferred Rent
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has an
	operating lease for office and laboratory space. Rent expense is recorded on a straight-line basis over the initial lease term. The difference between the actual cash paid and the straight-line rent expense is recorded as deferred rent.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Research and Development Costs
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research
	and development costs are charged to expense as incurred and are typically made up of salaries and benefits, clinical trial activities, drug development and manufacturing costs, and third-party service fees, including for clinical research
	organizations and investigative sites. Costs for certain development activities, such
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-12
</P>
<A NAME="eolPage109"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided
	by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued
	expenses.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Share-based Compensation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company accounts for stock-based compensation in accordance with ASC 718,
<I>
	Compensation&#151;Stock Compensation,
</I>
	which requires the
	measurement and recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Compensation expense based on the grant date fair value is generally amortized
	over the requisite service period of the award on a straight-line basis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The fair value of options is calculated using the Black-Scholes
	option pricing model to determine the fair value of stock options on the date of grant based on key assumptions such as stock price, expected volatility and expected term. The Company&#146;s estimates of these assumptions are primarily based on
	third-party valuations, historical data, peer company data and judgment regarding future trends and factors.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Income Taxes
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company uses the asset and liability method to calculate deferred tax assets and liabilities. Deferred taxes are recognized based on the
	differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be
	recovered or settled. The Company records a valuation allowance against a deferred tax asset when it is more-likely-than-not that the deferred tax asset will not be realized.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company is subject to federal, state and local taxes and follows a recognition threshold and measurement attribute for the financial
	statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company recognizes tax benefits or expenses of uncertain tax positions in the year such determination is made when the position is &#147;more
	likely than not&#148; to be sustained assuming examination by tax authorities. Management has reviewed the Company&#146;s tax positions for all open tax years (tax years ended December&nbsp;31, 2008 through December&nbsp;31, 2015) and concluded that
	no provision for unrecognized tax benefits or expense is required in these financial statements. There are no income tax audits in progress as of December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Impairment of Long-lived Assets
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	accordance with ASC 360,
<I>
	Property, Plant, and Equipment
</I>
	, the Company&#146;s policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
	An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Through December&nbsp;31, 2015, no impairment of
	long-lived assets has occurred.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Segment and Geographic Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for
	evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company&#146;s chief operating decision maker is the chief executive officer. The Company and
	the chief decision maker view the Company&#146;s operations and manage its business as one operating segment. The Company operates in only one geographic segment.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-13
</P>
<A NAME="eolPage110"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Net Loss per Share Applicable to Common Stockholders
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic net loss per share applicable to common stockholders is calculated by dividing net loss applicable to common stockholders by the weighted
	average shares outstanding during the period, without consideration for common stock equivalents. Net loss applicable to common stockholders is calculated by adjusting the net loss of the Company for cumulative preferred stock dividends. Diluted net
	loss per share applicable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes
	of the dilutive net loss per share applicable to common stockholders calculation, stock options and warrant are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share applicable to common
	stockholders, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Comprehensive Income (Loss)
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions, and other events and
	circumstances from non-owner sources, and currently consists of net loss and changes in unrealized gains and losses on available-for-sale securities.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Recent Accounting Pronouncements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	August 2014, the FASB issued a new Accounting Standards Update,
<I>
	Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (ASU
	2014-15)
</I>
	. ASU 2014-15 provides guidance on management&#146;s responsibility to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern within one year of the date the financial statements are
	issued, and, if such conditions exist, to provide related footnote disclosures. The guidance is effective for annual periods ending after December&nbsp;15, 2016 and interim periods within annual periods beginning after December&nbsp;15, 2016. Early
	adoption is permitted. The Company expects to adopt this guidance when effective and is currently evaluating the effect that the updated standard will have on its financial statements and related disclosures.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In November 2015, the FASB issued a new Accounting Standards Update,
<I>
	Balance Sheet Classification of Deferred Taxes (ASU 2015-17).
</I>
	ASU
	2015-17 requires all deferred tax assets and liabilities, and any related valuation allowance, to be classified as non-current on the balance sheet. The classification change for all deferred taxes as non-current simplifies entities&#146; processes
	as it eliminates the need to separately identify the net current and net non-current deferred tax asset or liability in each jurisdiction and allocate valuation allowances. The Company elected to retrospectively adopt this accounting standard in the
	beginning of the Company&#146;s fourth quarter of fiscal 2015. The adoption of this standard did not have any impact on the Company&#146;s financial statements due to full valuation allowance recorded on the Company&#146;s deferred taxes.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2016, the FASB issued a new Accounting Standards Update,
<I>
	Recognition and Measurement of Financial Assets and Financial
	Liabilities (ASU 2016-01).
</I>
	ASU 2016-01 amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity&#146;s accounting
	related to (1)&nbsp;the classification and measurement of investments in equity securities and (2)&nbsp;the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure
	requirements associated with the fair value of financial instruments. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December&nbsp;15, 2017, with early adoption permitted for certain
	changes. The Company is currently evaluating the potential effects the new standard will have of the Company&#146;s financial statements and related disclosures.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In February 2016, the FASB issued a new Accounting Standards Update
<I>
	, Leases (ASU 2016-02),
</I>
	ASU 2016-02 is aimed at making leasing
	activities more transparent and comparable and requires most leases be
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-14
</P>
<A NAME="eolPage111"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	recognized by lessees on the balance sheets as a right-of-use asset and corresponding lease liability, regardless of whether they are classified as finance or operating leases. The new standard
	is effective for annual reporting periods beginning after December&nbsp;15, 2018, including interim periods within that reporting period, with early adoption permitted. The Company is currently evaluating the impact of the new pronouncement on the
	Company&#146;s financial statements and related disclosures.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	3. Fair Value Measurements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following fair value hierarchy table presents information about the Company&#146;s financial assets and liabilities
	measured at fair value on a recurring basis as of December&nbsp;31, 2015 and December&nbsp;31, 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="48%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair&nbsp;Value&nbsp;Measurement&nbsp;As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Quoted Prices
<BR>
	in Active
<BR>
	Markets for
<BR>
	Identical&nbsp;Assets
<BR>
	(Level 1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
<BR>
	Other&nbsp;Observable
<BR>
	Inputs
<BR>
	(Level 2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
<BR>
	Unobservable
<BR>
	Inputs
<BR>
	(Level 3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,607,134
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,948,872
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrant liability
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	444,324
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	32,556,006
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	444,324
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="12">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair&nbsp;Value&nbsp;Measurement&nbsp;As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Quoted Prices
<BR>
	in Active
<BR>
	Markets for
<BR>
	Identical&nbsp;Assets
<BR>
	(Level 1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
<BR>
	Other&nbsp;Observable
<BR>
	Inputs
<BR>
	(Level 2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
<BR>
	Unobservable
<BR>
	Inputs
<BR>
	(Level 3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,628,918
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,670,606
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrant liability
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,004
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,299,524
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,004
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company issued a warrant to the representative of the underwriters of its IPO (the
	&#147;Representative&#146;s Warrant&#148;) to purchase 206,410 shares of common stock at an exercise price of $7.50 per share (see Note 9, &#147;Capital Structure&#148;). The Company evaluated the Representative&#146;s Warrants against current
	accounting guidance and determined that these warrants should be classified as a liability and considers it as a Level 3 financial instrument. The warrant will be re-measured at each subsequent reporting period and changes in fair value will be
	recognized in the statement of operations. The following assumptions were used in a Black-Scholes option-pricing model to determine the fair value of the warrant liability as of December&nbsp;31, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="59%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="18%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="17%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	As of
<BR>
	December&nbsp;31,&nbsp;2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	As of
<BR>
	December&nbsp;31,&nbsp;2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected volatility
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	78.1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	74.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Remaining contractual term (in years)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.67
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.67
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Risk-free interest rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.54
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.65
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected dividend yield
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-15
</P>
<A NAME="eolPage112"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following tables present a reconciliation of the Company&#146;s financial liabilities
	measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December&nbsp;31, 2015, 2014 and 2013:
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Warrant liabilities (1)
</I>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="58%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Balance at beginning of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,004
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,088,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuances of convertible notes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	865,635
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,080,722
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cancellation of placement agent warrants (2)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(941,541
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of Representative&#146;s Warrant
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	403,696
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Increase in fair value (3)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	131,320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,563,080
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,007,295
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Conversion of convertible notes to common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5,665,883
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Balance at end of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	&nbsp;&nbsp;&nbsp;&nbsp;444,324
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	313,004
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,088,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Embedded derivatives liabilities (1)
</I>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended&nbsp;December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Balance at beginning of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,680,780
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuances of convertible notes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	537,607
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,075,985
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(Decrease) increase in fair value (3)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,337,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,604,795
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Conversion of convertible notes to common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,880,509
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Balance at end of period
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,680,780
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Prior to the closing of the Company&#146;s IPO on August&nbsp;1, 2014, the Company considered its convertible note related warrant liabilities and embedded derivatives liabilities as Level 3 financial instruments. The
	Company determined the fair value of these liabilities immediately prior to the Company&#146;s IPO and then reclassified the balances to additional paid-in capital on the closing of the IPO.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The Company reclassified the balance of the placement agent warrants to additional paid-in capital as a reduction of the offering costs upon their cancellation.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The change in the fair values of the warrant and embedded derivatives liabilities are recorded in other expenses in the statement of operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The key inputs into the Black-Scholes option pricing model are the per share value and the expected volatility of the Company&#146;s common
	stock. Significant changes in these inputs will directly increase or decrease the estimated fair value of the Company&#146;s warrant liability.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	4. Property, Equipment, and Leasehold Improvements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Property, equipment, and leasehold improvements, at cost, consist of:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Computer equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,691
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,691
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Furniture
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	434,697
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	434,697
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lab equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,631,016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,631,016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Leasehold improvements
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,821,677
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,813,520
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,907,081
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,898,924
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Less: accumulated depreciation and amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,288,113
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,750,769
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,618,968
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,148,155
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-16
</P>
<A NAME="eolPage113"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Depreciation expense was $537,344, $551,323 and $559,237 for the years ended December&nbsp;31,
	2015, 2014 and 2013, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	5. Accrued Expenses
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued expenses consist of the following:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="66%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued compensation costs
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,133,742
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,865,778
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued research and development service fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	590,307
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	202,183
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued professional fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	317,796
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	286,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued licensing fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	200,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	209,922
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	187,039
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,251,767
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,741,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	6. Senior Convertible Notes
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company issued approximately $15.0 million aggregate principal amount of its 8.00% Convertible Notes due May&nbsp;31,
	2015 (the &#147;Convertible Notes&#148;) from June 2013 through June 2014. On August&nbsp;1, 2014, in conjunction with the closing of the Company&#146;s IPO, the principal amount of the Convertible Notes, and all accrued and unpaid interest thereon,
	automatically converted into 5,109,988 shares of common stock. Upon the closing of the offering, the Company accelerated the amortization of the remaining debt discount balance to interest expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company recorded the costs directly related to the issuance of its Convertible Notes as debt issuance costs and amortized these costs to
	interest expense using the effective interest method of amortization until the completion of the Company&#146;s IPO. Upon the closing of the offering, the Company accelerated the amortization of the remaining balance to interest expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Each purchaser of the Convertible Notes also received a warrant which included an exercise price &#147;cap&#148; that was analogous to
	&#147;down round protection&#148; which precluded the Company from classifying the warrants in equity (the &#147;Note Warrants&#148;). The Convertible Notes also included embedded derivatives (i.e. penalty provisions) that required bifurcation. As
	such, the Company reflected both the values of the Note Warrants and the embedded derivatives as liabilities which were re-measured at each reporting period and immediately prior to the closing of the Company&#146;s IPO, and changes in fair value
	were recognized in the statement of operations. Upon the closing of the IPO, the Company reclassified the balances of the Note Warrant and embedded derivative liabilities to additional paid-in capital as the terms of the Note Warrants, including any
	penalty warrants, became fixed and the interest penalties were paid in the Company&#146;s common stock, and therefore both the Note Warrants and penalties were no longer considered a liability (see Note 3, &#147;Fair Value Measurements&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Upon the closing of the IPO and based on the terms of the Note Warrants, the Company determined the total number of shares of the
	Company&#146;s common stock underlying the Note Warrants to be 3,321,416 at an exercise price of $3.00 per share. The number of shares of common stock underlying the outstanding Note Warrants as of December&nbsp;31, 2015 and 2014 was 3,315,878 and
	3,321,416, respectively. The Note Warrants expire five years from the date of issuance.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	7. Net Loss Per Share of Common Stock
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted loss per share is the same as basic loss per share for all periods presented because the effects of potentially
	dilutive items were anti-dilutive given the Company&#146;s net loss. Basic loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-17
</P>
<A NAME="eolPage114"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth the computation of basic and diluted loss per share for common
	stockholders:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss applicable to common stockholders
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,120,964
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34,617,536
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23,620,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average shares of common stock outstanding
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,328,922
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,973,599
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,011,789
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss per share of common stock&#151;basic and diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3.86
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(23.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following potentially dilutive securities outstanding at December&nbsp;31, 2015 and 2014 have been
	excluded from the computation of diluted weighted average shares outstanding, as they would have been antidilutive given the Company&#146;s net loss:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preferred stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,554,874
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Options to purchase common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,313,755
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,089,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,221,652
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrants to purchase common stock (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,503,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,577,361
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	718,322
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,816,862
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,666,688
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,494,848
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The potential dilutive impact of the Company&#146;s Note Warrants (see Note 6 &#147;Senior Convertible Notes&#148;) were not included as of December&nbsp;31, 2013 as the underlying number of shares was not determinable
	at that time and would also have been antidilutive.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	8. Commitments and Contingencies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Operating Leases
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	December 2010, the Company entered into a non-cancellable operating lease for office space and laboratory facilities in Yonkers, New York expiring in December 2025. In December 2011, the Company entered into an amendment which extended the terms of
	the lease through December 2027. The lease provides for the option to renew for two additional five-year terms. The premises were occupied in June 2011. Monthly rent payments began the date the office and laboratory facilities were ready for
	occupancy. A security deposit in the amount of $54,865 was paid by the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2012, the Company entered into a
	non-cancellable operating lease for additional office space and laboratory facilities in the same building in Yonkers, New York expiring in December 2027. The lease provides for an option to renew for two additional five-year terms. A security
	deposit in the amount of $78,238 was paid by the Company. Future minimum lease payments are as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Year ending December 31:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	851,895
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2017
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	868,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2018
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	886,311
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2019
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	904,038
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2020
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	922,118
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Thereafter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,992,396
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,425,691
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Rent expense is recognized on the straight-line method over the terms of each lease. Rent expense for the
	years ended December&nbsp;31, 2015, 2014 and 2013, was approximately $873,000, $871,000 and $870,000, respectively.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-18
</P>
<A NAME="eolPage115"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	9. Capital Structure
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Common Stock
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of
	December&nbsp;31, 2015, the Company was authorized to issue 100,000,000 shares of common stock at $0.0001 par value per share.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Private
	Placement
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On June&nbsp;12, 2015, the Company closed a private placement of its securities with a group of institutional investors (the
	&#147;PIPE&#148;). Each investor received one share of common stock and a warrant to purchase one-half share of common stock at a price of $4.23 per common share purchased. The closing of the PIPE resulted in the issuance of an aggregate of
	4,728,128 common shares and warrants to purchase an additional 2,364,066 shares of common stock at an exercise price of $8.00 per full share, which expire three years form the date of issuance (the &#147;PIPE Warrants&#148;). The Company received
	net proceeds from the PIPE of $18.3 million, after deducting expenses payable by the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The placement agents in the PIPE received
	warrants to purchase 4% of the total number of shares of common stock sold in the PIPE (the &#147;Placement Agent Warrants&#148;), for a total of 189,126 shares of common stock underlying the Placement Agent Warrants. The Placement Warrants became
	exercisable upon issuance at an exercise price of $4.65 per share and expire on June&nbsp;11, 2020.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The common stock and accompanying
	PIPE Warrants and Placement Agent Warrants have been classified to stockholders&#146; equity in the Company&#146;s balance sheet.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Initial Public Offering
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In July 2014, the shareholders approved an amended certificate of incorporation that became effectively immediately upon the closing of the
	Company&#146;s IPO. The approved certificate increased the number of authorized shares of common stock to 100,000,000 shares.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On
	August&nbsp;1, 2014, the Company closed its IPO. Each Unit consisted of one share of common stock, one Class&nbsp;A Warrant to purchase one share of common stock at an exercise price of $4.80 per share and one Class B Warrant to purchase one-half
	share of common stock at an exercise price of $4.00 per full share. The closing of the IPO resulted in the sale of an aggregate of 6,880,333 Units at a public offering price of $6.00 per Unit, less underwriting discounts and commissions and the
	underwriter&#146;s expenses, including 880,333 Units issued upon the exercise by the underwriters of their option to purchase additional Units at the public offering price to cover over-allotments of the Company. The Company received net proceeds
	from the IPO of $35.0 million, after deducting underwriting discounts, commissions, and expenses payable by the Company. Following the IPO, the units separated and the shares of common stock, Class&nbsp;A Warrants and Class B Warrants began to trade
	separately. The common stock and accompanying Class&nbsp;A and Class B warrants were classified to stockholders&#146; equity in the Company&#146;s balance sheet.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On November&nbsp;2, 2015, the Company&#146;s Class B Warrants to purchase common stock expired in accordance with their terms. As of
	November&nbsp;2, 2015, holders of the Class B Warrants had exercised 4,812,328 Class B Warrants, resulting in the issuance of 2,406,164 shares of the Company&#146;s common stock and the receipt by the Company of approximately $9.6 million in gross
	proceeds. The 2,068,005 Class B Warrants that were not exercised prior to expiration have terminated and are no longer exercisable.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Representative&#146;s Warrant
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Maxim Group, LLC, the representative of the underwriters in the IPO, received the Representative&#146;s Warrant to purchase 3% of the total
	number of shares of common stock sold in the IPO, including those shares sold upon the exercise of the over-allotment, for a total of 206,410 shares of common stock underlying the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-19
</P>
<A NAME="eolPage116"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Representative&#146;s Warrant. The Representative&#146;s Warrant became exercisable at an exercise price of $7.50 per share beginning 180 days after the effective date of the Company&#146;s
	registration statement (January 24, 2015) and expires on August&nbsp;27, 2019. The Company classified the Representative&#146;s Warrant as a liability since it did not meet the requirements to be included in equity. The fair value of the
	Representative&#146;s Warrant will be re-measured at each reporting period and changes in fair value will be recognized in the statement of operations (see Note 3, &#147;Fair Value Measurements&#148;).
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Voting
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The holders of
	shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Dividends
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The holders of
	shares of common stock are entitled to receive dividends, if and when declared by the board of directors. As of December&nbsp;31, 2015, no dividends have been declared or paid on the Company&#146;s common stock since inception.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Reserved for Future Issuance
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has reserved for future issuance the following number of shares of common stock as of December&nbsp;31, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="66%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Options to purchase common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,313,755
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,089,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrants to purchase common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,503,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,577,361
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,816,862
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,666,688
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Convertible Preferred Stock
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Dividends
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On May&nbsp;28,
	2014, the board of directors declared a dividend to be paid in-kind to the holders of the Company&#146;s preferred stock in accordance with the Company&#146;s Fourth Amended and Restated Certificate of Incorporation, whereby each holder of shares of
	preferred stock will be entitled to a number of additional shares of the applicable series of preferred stock equal to the amount of the accrued and unpaid dividend on such holder&#146;s shares (the &#147;Dividend&#148;). The Company determined that
	605,645 shares of Series A preferred stock, 1,172,645 shares of Series B preferred stock, 1,379,388 shares of Series C preferred stock and 2,395 shares of Series C-1 preferred stock would be required to satisfy the Dividend.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company recorded the in-kind dividend payable and associated expense at fair value of the securities to be issued. The Company was able to
	assess the value of the preferred stock dividends in terms of its common stock to be issued upon conversion of the preferred stock on the closing of its IPO.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Conversion
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On
	August&nbsp;1, 2014, in conjunction with the closing of the Company&#146;s IPO, all outstanding shares of the Company&#146;s preferred stock, including the in-kind dividend payable, were automatically converted into 6,861,968 shares of its common
	stock.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-20
</P>
<A NAME="eolPage117"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	10. Stock Warrants
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2015 and 2014, the Company had warrants outstanding as shown in the table below.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="64%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="14%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="14%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Note Warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,315,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,321,416
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Class&nbsp;A Warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,880,333
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,880,333
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Class B Warrants (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,440,166
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PIPE Warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,364,066
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Representative&#146;s Warrant
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	206,410
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	206,410
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Placement Agent Warrants
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	189,126
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other warrants (2)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	547,294
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	729,036
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Warrants to purchase common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,503,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,577,361
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted-average exercise price per share
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.02
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.32
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The Class B Warrants expired pursuant to their terms on November&nbsp;2, 2015.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Other warrants are comprised of warrants issued prior to the Company&#146;s IPO, generally in exchange for services rendered to the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The fair value of each warrant to purchase shares of common stock issued for services rendered to the Company was estimated using the
	Black-Scholes option pricing model with the following weighted average assumptions:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fair value of underlying common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.27
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected volatility
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75.4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	72.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Remaining contractual term (in years)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Risk-free interest rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.68
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.65
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected dividend yield
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During 2015, the Company did not issue any warrants to purchase shares of common stock for services rendered
	to the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During 2014, the Company issued warrants to purchase 10,714 shares of common stock at a strike price of $5.25 per share
	for services rendered to the Company. The Company calculated the fair value of these warrants to be $26,354 which has been recognized as a component of general and administrative expenses in 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During 2013, the Company issued warrants to purchase 14,285 shares of common stock at a strike price of $7.00 per share for services rendered
	to the Company. The Company calculated the fair value of these warrants to be $22,149 which has been recognized as a component of general and administrative expenses in 2013.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes information regarding the Company&#146;s warrants outstanding and the corresponding exercise price at
	December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:51.70PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Exercise Prices
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Shares
<BR>
	Underlying
<BR>
	Outstanding
<BR>
	Warrants
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Expiration Date
</B>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-FAMILY:SYMBOL">
	&#163;
</FONT>
	$4.00
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,588,406
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	August&nbsp;31,&nbsp;2016&nbsp;&#150;&nbsp;September&nbsp;1,&nbsp;2021
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	$4.01 - $4.99
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,069,459
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	February 1, 2017 &#150; June 11, 2020
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	$5.00 - $9.99
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,656,900
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	December 10, 2016 &#150; June 27, 2021
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="FONT-FAMILY:SYMBOL">
	&#179;
</FONT>
	$10.00
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	188,342
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	August 31, 2016 &#150; January 5, 2022
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,503,107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-21
</P>
<A NAME="eolPage118"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	11. Stock Option and Incentive Plans
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Amended and Restated 2008 Equity Incentive Plan
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In July 2008, the Company adopted the 2008 Equity Incentive Plan (the &#147;Plan&#148;). On February&nbsp;26, 2013, the board of directors
	approved an amended and restated plan (the &#147;Amended Plan&#148;) to increase the number of shares of common stock available under the Amended Plan to 1,571,428 and, for new awards, to reduce the period that vested awards would remain exercisable
	upon termination of service from ten years to two years. The board of directors also approved an option exchange offer (the &#147;Exchange Offer&#148;) for eligible option holders with outstanding options with an exercise price in excess of $3.50
	per share. The offering period for the Exchange Offer commenced on March&nbsp;11, 2013 and expired on April&nbsp;9, 2013. Participation in the Exchange Offer was voluntary. Options to purchase 647,521 shares of the Company&#146;s common stock, held
	by a total of 26 participants, including 20 employees, were exchanged under the tender offer. The exchanged option grants were granted at an exercise price of $3.50 per share. The Company recorded expense associated with the modification with an
	immediate charge for the vested portion of option grants exchanged and additional charges as the remaining unvested portions become vested.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Upon the original adoption of the Plan, the number of shares of common stock reserved pursuant to the Plan was 214,285. On December&nbsp;12,
	2011, the Plan was amended to increase the number of shares of common stock available under the Plan to 900,000. The board of directors also increased the number of shares of common stock available under the Company&#146;s Amended Plan on
	February&nbsp;24, 2014 and April&nbsp;29, 2014 to 1,857,142 and 2,357,142, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of the closing of the Company&#146;s IPO,
	there will be no further grants made under the Amended Plan.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	2014 Omnibus Incentive Plan
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In April 2014, the Company&#146;s board of directors adopted the 2014 Omnibus Incentive Plan (the &#147;2014 Plan&#148;). The 2014 Plan was
	approved by the Company&#146;s shareholders on July&nbsp;3, 2014. The 2014 Plan allows for the granting of incentive and non-qualified stock options, restricted stock and stock unit awards, stock appreciation rights and other performance-based
	awards to the Company&#146;s employees, members of the board of directors and consultants of the Company. On July&nbsp;28, 2014, the effective date of the 2014 Plan, the number of shares of common stock reserved pursuant to the 2014 Plan was
	571,429. The 2014 Plan provides for an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2015 and continuing until the expiration of the 2014 Plan, equal to the lesser of
	(i)&nbsp;4% of the outstanding shares of common stock on December&nbsp;31 immediately preceding such date or (ii)&nbsp;a lesser amount determined by the Company&#146;s board of directors. Consistent with the provision for an annual increase, an
	additional 808,690 shares of common stock have been reserved under the 2014 Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company recognizes compensation expense for
	share-based compensation based on the fair value of the underlying instrument. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. A summary of stock option activity for the year
	ended December&nbsp;31, 2015, is summarized as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="49%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number of
<BR>
	Options
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted
<BR>
	Average
<BR>
	Exercise&nbsp;Price
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted
<BR>
	Average&nbsp;Remaining
<BR>
	Contractual Life
<BR>
	(in years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Aggregate
<BR>
	Intrinsic&nbsp;Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Options outstanding at December&nbsp;31, 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,089,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.95
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,353,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.64
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(75,197
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expired
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,605
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(28,520
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Options outstanding at December&nbsp;31, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,313,755
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.87
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.34
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,544,493
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vested and exercisable at December&nbsp;31, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,864,799
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.05
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,014,233
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-22
</P>
<A NAME="eolPage119"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Of the option grants outstanding to purchase 4,313,755 shares of common stock, grants to purchase
	667,870 shares of common stock were issued and are outstanding outside the Company&#146;s incentive plans.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The fair value of each option
	grant is estimated on the date of the grant using the Black-Scholes option-pricing model. The weighted average grant date fair value of options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 was $4.64, $3.95 and $3.50,
	respectively. Total compensation expense recognized amounted to $1,929,112, $1,940,179 and $2,309,569 for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. As of December&nbsp;31, 2015, the total remaining unrecognized
	compensation cost related to unvested stock options was $3,596,629 which will be recognized over a weighted average period of approximately 2.52 years.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following weighted average assumptions were used to compute the fair value of stock option grants:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="73%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Risk free interest rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.95
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.21
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected dividend yield
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected term (in years)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.96
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.22
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected volatility
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	74.36
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	76.3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	73.2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Expected volatility&#151;
</I>
	The Company estimated the expected volatility based on an average of the
	volatility of similar companies with publicly-traded equity securities. The companies were selected based on their enterprise value, risk profiles, position within the industry, and with historical information sufficient to meet the expected term of
	the associated award.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Expected term&#151;
</I>
	The Company based expected term on the midpoint of the vesting period and the contractual
	term of each respective option grant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Risk-free interest rate&#151;
</I>
	The Company estimated the risk-free interest rate in reference
	to yield on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Expected
	dividend yield&#151;
</I>
	The Company estimated the expected dividend yield based on consideration of its historical dividend experience and future dividend expectations. The Company has not historically declared or paid dividends to common
	stockholders. Moreover, it does not intend to pay dividends in the future, but instead expects to retain any earnings to invest in its continued growth.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	12. Retention Bonus Plan
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;24, 2014, the Company adopted the ContraFect Corporation Retention Bonus Plan (the &#147;Retention
	Plan&#148;). Under the Retention Plan, participants vested in and became eligible to receive awards equal to a fixed dollar amount (the &#147;Award Amount&#148;), upon the earliest to occur of any of the following events: (i)&nbsp;the IPO;
	(ii)&nbsp;a Change of Control (as defined in the Retention Plan); (iii)&nbsp;May&nbsp;31, 2015; and (iv)&nbsp;a participant&#146;s termination of employment due to death or Disability (as defined in the Retention Plan) (each such event, a
	&#147;Payment Event&#148;). In the event of an IPO or Change of Control, participants who were then employed by the Company were eligible to receive shares of common stock in an amount equal to 1.82 times each participant&#146;s Award Amount.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of June&nbsp;30, 2014, Award Amounts totaling $532,700 had been granted under the Retention Plan. Upon the closing of the Company&#146;s
	IPO, the Company recognized a total of $954,754 of expense associated with the vesting of the grants. On September&nbsp;11, 2014, the Company issued 133,109 shares of its common stock, net of shares withheld for tax obligations, in payment of the
	retention grants.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There are no outstanding Award Amounts as of December&nbsp;31, 2015 or December&nbsp;31, 2014 and the Company does not
	anticipate any further grants under the Retention Plan.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-23
</P>
<A NAME="eolPage120"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	13. 401k Savings Plan
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In 2010, the Company established a defined-contribution savings plan under Section&nbsp;401(k) of the Internal Revenue Code
	(the 401(k) Plan). The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre-tax basis The Company did not make any contributions to
	the 401(k) Plan through December&nbsp;31, 2014. During 2015, the Company established an employer matching program for participants in the 401(k) Plan. The Company incurred approximately $88,000 of expense for matching contributions to the 401(k)
	Plan during the year ended December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	14. Income Taxes
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has available approximately $91,586,000 and $96,074,000 of unused operating loss carryforwards for federal and
	state tax purposes, respectively, that may be applied against future taxable income. The net operating loss carryforwards will expire through the year 2035 if not utilized prior to that date. No provision for a deferred tax asset has been made for
	the tax benefits of the net operating loss carryforwards as the entire amount is offset by a valuation allowance. The valuation allowance increased by approximately $9,937,000 and $7,494,000 during the years 2015 and 2014, respectively, and was
	approximately $40,089,000 and $30,152,000 at December&nbsp;31, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Internal Revenue Code of 1986, as amended
	(the Code) provides for a limitation of the annual use of net operating losses and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes (as defined by the Code) that could limit the
	Company&#146;s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section&nbsp;382 of the Code has occurred, or whether there have been multiple ownership changes
	since the Company&#146;s formation, due to the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financing transactions. Accordingly, the
	Company&#146;s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full
	advantage of these carryforwards for federal or state income tax purposes.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s reserves related to taxes are based on a
	determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. For the three
	years ended December&nbsp;31, 2015, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company has not, as yet, conducted a study of research and development (R&amp;D) credit carryforwards. This study may
	result in an adjustment to the Company&#146;s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided
	against the Company&#146;s R&amp;D credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an
	adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#146;s uncertain tax positions are related to years that remain subject to examination by
	relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-24
</P>
<A NAME="eolPage121"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The principal components of the Company&#146;s deferred tax assets/liabilities for 2015 and 2014
	are as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="61%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred tax assets/liabilities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net operating loss carryovers
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,414,890
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	26,959,701
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	R&amp;D tax credits
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,469,756
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,224,288
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Share-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,922,680
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,649,073
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued compensation and severance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	147,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	409,234
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Depreciation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(496,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(690,981
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred rent
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	404,885
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	370,376
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	225,702
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	229,836
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40,088,761
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,151,527
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Valuation allowance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(40,088,761
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,151,527
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net deferred tax assets (liabilities)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A reconciliation of the statutory U.S. Federal rate to the company&#146;s effective tax rate is as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="66%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal income tax benefit at statutory rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(34.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	State income tax, net of federal benefit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5.49
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5.70
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Permanent item&#151;non-deductible interest
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14.59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other permanent items
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.99
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.83
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.01
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in valuation allowance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39.70
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24.89
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40.17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	R&amp;D tax credits
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(.99
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.21
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.48
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.10
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effective income tax (benefit) expense rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	15. Significant Agreements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Rockefeller University
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	License
	Agreements
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has entered into the following license agreements with The Rockefeller University:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	On July&nbsp;12, 2011, the Company entered into a license agreement for the worldwide, exclusive right to a patent covering the composition of matter for the lysin PlySS2 for the treatment and prevention of diseases
	caused by gram-positive bacteria (the &#147;CF-301 License&#148;). The Company rebranded PlySS2 as CF-301. The license gives the Company the right to exclusively develop, make, have made, use, import, lease, sell and offer for sale products that
	would otherwise infringe a claim of this patent application or patent.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	On June&nbsp;1, 2011, the Company entered into a license agreement for the exclusive rights to The Rockefeller University&#146;s interest in a joint patent application covering the method of delivering antibodies
	through the cell wall of gram-positive bacteria to the periplasmic space. This intellectual property was developed as a result of the sponsored research agreement between the Company and The Rockefeller University, and was jointly discovered and
	filed by the two parties.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
	On September&nbsp;23, 2010, the Company entered into a license agreement for the worldwide, exclusive right to develop, make, have made, use, import,
	lease, sell, and offer for sale products that would
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-25
</P>
<A NAME="eolPage122"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
	otherwise infringe a claim of the suite of patents and patent applications covering the composition of matter for eight individual lysin molecules for the treatment and prevention of diseases
	caused by gram-positive bacteria. The lysins in this suite have activity against Group B Streptococci, Staphylococcus aureus, Streptococcus pneumonia, Bacillus anthracis, Enterococcus faecalis and Enterococcus faecium.
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In consideration for the licenses, we paid Rockefeller license initiation fees in cash and stock and may be required to pay an annual
	maintenance fee, milestone payments and royalties on net sales from products to Rockefeller. We are allowed to grant sublicenses to third parties without prior approval, subject to certain conditions and the payment of a certain percentage of all
	payments we receive from sublicensees.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Each license agreement terminates upon the later of (i)&nbsp;the expiration or abandonment of the
	last licensed patent under the license agreement to expire or become abandoned, or (ii)&nbsp;10 years after the first commercial sale of the first licensed product. The Rockefeller University may terminate any license agreement in the event of a
	breach of such agreement by the Company or if the Company challenges the validity or enforceability of the underlying patent rights. The Company may terminate any license agreement at any time on 60 days&#146; notice.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Collaborative Research Agreements
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Beginning in October 2009, we entered into a research agreement with Rockefeller where we provided funding for the research. The initial
	agreement focused on producing and testing monoclonal antibodies against proteins of
<I>
	Staph aureus
</I>
	. On October&nbsp;24, 2011, we entered into a second research agreement with Rockefeller where we provide funding for the research, to identify
	lysins, enzymes or small molecules that will kill gram-negative bacteria, and identify and characterize lysins from Clostridia difficile to be engineered into gut commensal bacteria.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our current agreement runs through October&nbsp;31, 2016. Either party may terminate the agreement upon breach of the agreement, following 30
	days written notice and failure to cure such breach. Following the expiration or termination of the agreement, each party will have a non-exclusive license to use for internal research purposes all research results, including joint intellectual
	property. If Rockefeller or joint intellectual property develops from these programs, we will have the right-of-first refusal to negotiate to acquire a royalty-bearing license to utilize such intellectual property for commercial purposes.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Trellis Biosciences, LLC
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On
	January&nbsp;29, 2014, the Company entered into a license agreement with Trellis Biosciences, LLC (&#147;Trellis&#148;) that gives it exclusive rights to all Trellis mAbs in the field of influenza discovered from the Trellis CellSpot platform.
	Particularly, the license provides the Company with three fully human mAbs that bind, neutralize and protect animals from all strains of H1, H3 and B influenza, and that will also cross bind, neutralize and protect animals from all other seasonal or
	pandemic influenza strains that may arise (including H5N1 and H7N9).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In consideration for the license, the Company paid Trellis $200,000
	and issued 151,515 shares of Series C-1 preferred stock, contractually valued at $500,000. On October&nbsp;7, 2014, the Company issued 132,380 shares of its common stock in satisfaction of the $500,000 remaining due in stock as consideration for the
	license. The Company will also be required to make payments to Trellis upon the achievement of specified development and regulatory milestones and upon the achievement of future sales and for royalty on future net sales from products. The Company is
	allowed to grant sublicenses to third parties.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The license agreement terminates upon the earlier of (i)&nbsp;the Company&#146;s decision
	to terminate the agreement at will or for safety reasons, (ii)&nbsp;material breach by either party that is not cured within ninety (90)&nbsp;days, or (iii)&nbsp;either party&#146;s insolvency.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-26
</P>
<A NAME="eolPage123"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	MorphoSys AG
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2014, the Company and MorphoSys AG agreed to terminate their license agreement effective as of August&nbsp;15, 2014 and resolve all
	outstanding claims thereunder. On August&nbsp;11, 2014, the Company made the &#128;1,000,000 payment to MorphoSys AG pursuant to the agreed upon settlement.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Legal Contingencies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	From time to time,
	the Company may be involved in disputes and legal proceedings in the ordinary course of its business. These proceedings may include allegations of infringement of intellectual property, employment or other matters. The Company records a liability in
	its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss
	provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the
	financial statements not misleading. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the Company&#146;s financial statements. The Company currently has no legal proceedings ongoing that management
	estimates could have a material effect on the Company&#146;s financial statements.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	16. Related-Party Transactions
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company paid its non-employee directors fees for services as directors and consulting of approximately $630,000,
	$568,000 and $271,000 for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively, which were included in general and administrative expenses.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	17. Subsequent Events
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2016, the Company entered into a Sales Agreement with Cowen and Company, LLC (&#147;Cowen&#148;) to sell shares
	of the Company&#146;s common stock, with aggregate gross sales proceeds of up to $30 million, through an &#147;at the market&#148; equity offering program under which Cowen will act as sales agent. As of the date of this report, the Company has not
	sold any shares under the program.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	F-27
</P>
<A NAME="eolPage124"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SIGNATURES
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
	be signed on its behalf by the undersigned, thereunto duly authorized.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="6%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
<B>
	CONTRAFECT CORPORATION
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;J
<SMALL>
	ULIA
</SMALL>
	P. G
<SMALL>
	REGORY
</SMALL>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Julia P. Gregory
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<I>
	Chief Executive Officer
</I>
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below
	by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="44%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="18%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:33.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Signature
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:15.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Title
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:16.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Date
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;J
<SMALL>
	ULIA
</SMALL>
	P.
	G
<SMALL>
	REGORY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Julia P. Gregory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<I>
	(Principal Executive Officer)
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	March 15, 2016
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;M
<SMALL>
	ICHAEL
</SMALL>
	M
<SMALL>
	ESSINGER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Michael Messinger
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Vice President, Finance and
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Chief Accounting Officer
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<I>
	(Principal Financial Officer and Principal Accounting Officer
</I>
	)
<I>
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	March 15, 2016
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;S
<SMALL>
	OL
</SMALL>
	B
<SMALL>
	ARER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Sol Barer, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Lead Independent Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;I
<SMALL>
	SAAC
</SMALL>
	B
<SMALL>
	LECH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Isaac Blech
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;S
<SMALL>
	TEVE
</SMALL>
	G
<SMALL>
	ILMAN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Steve Gilman, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Chairman of the Board
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;D
<SMALL>
	AVID
</SMALL>
	N. L
<SMALL>
	OW
</SMALL>
	,
	J
<SMALL>
	R
</SMALL>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	David N. Low, Jr.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;M
<SMALL>
	ICHAEL
</SMALL>
	O
<SMALL>
	TTO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Michael Otto, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;R
<SMALL>
	OGER
</SMALL>
	P
<SMALL>
	OMERANTZ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Roger Pomerantz, M.D., F.A.C.P.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Vice Chairman of the Board
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;D
<SMALL>
	AVID
</SMALL>
	S
<SMALL>
	CHEINBERG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	David Scheinberg, M.D., Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;C
<SMALL>
	ARY
</SMALL>
	S
<SMALL>
	UCOFF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Cary Sucoff
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;L
<SMALL>
	AWRENCE
</SMALL>
	T
<SMALL>
	IAN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</SMALL>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Lawrence Tian
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	March 15, 2016
</TD>
</TR>
</TABLE>
<A NAME="eolPage125"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_SIGNATURES>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD WIDTH="33%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER">
<B>
	Incorporated by Reference
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:19.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:26.65PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	File No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:37.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filing Date
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:54.60PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filed/Furnished
<BR>
	Herewith
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;3.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amended and Restated Certificate of Incorporation
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;3.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Second Amended and Restated Bylaws
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	3.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	October&nbsp;29,&nbsp;2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Common Stock Certificate
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 3, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Class A Warrant Agreement, dated as of July 28, 2014, by and between the Company and American Stock Transfer &amp; Trust Company, LLC
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.5.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	October 29, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Specimen Class A Warrant Certificate
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.12
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	October 29, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.4
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Representative&#146;s Warrant, dated August 27, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	October 29, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.5
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Noteholder Warrant
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.7
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 3, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.6
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Specimen Unit Certificate
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.8
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.7
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Indenture
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-206786
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	September&nbsp;4,&nbsp;2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.8
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Investor Warrant
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	June 12, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.9
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Placement Agent Warrant
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	4.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	June 12, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	License Agreement, between The Rockefeller University and ContraFect Corporation, dated July 12, 2011
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Lease Agreement, between Hudson View Building #3 LLC and ContraFect Corporation, dated December&nbsp;1, 2010
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Lease Agreement, between Hudson View Building #3 LLC and ContraFect Corporation, dated January&nbsp;1, 2012
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.4#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Indemnification Agreement
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.4
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.5#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Employment Agreement by and between ContraFect Corporation and Julia P. Gregory dated April 29, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.6
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
<A NAME="eolPage126"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
</EFX_UNIDENTIFIED_TABLE>
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD WIDTH="36%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER">
<B>
	Incorporated by Reference
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:19.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:26.65PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	File No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:37.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filing Date
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:54.60PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filed/Furnished
<BR>
	Herewith
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.6#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Employment Agreement by and between ContraFect Corporation and Michael Wittekind, Ph.D. dated March 6, 2012
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.7
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.7#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Employment Agreement by and between ContraFect Corporation and Daniel E.&nbsp;Couto, dated March 21, 2011
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.8#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Separation and Consulting Agreement by and between ContraFect Corporation and Dr. Barry Kappel, dated April 15, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.9#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation Retention Bonus Plan
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.9
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.10#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation Retention Bonus Plan Award Agreement
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.10
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.11#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation Amended and Restated 2008 Equity Incentive Plan
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.11
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.12#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation Form of Stock Option Agreement
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.12
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.13#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation 2008 Equity Incentive Plan
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.13
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	April 18, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.14#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect Corporation 2014 Omnibus Incentive Plan
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	License Agreement, between Trellis Bioscience LLC and ContraFect Corporation, dated January 29, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.16
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to the Trellis License Agreement, dated June&nbsp;15, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	S-1/A
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	333-195378
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.16
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	July 1, 2014
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.17
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Securities Purchase Agreement between the Company and Benjamin Small, Birchview Fund, LLC, Broadfin Healthcare Master Fund, Ltd., Cormorant Global Healthcare Master Fund, LP, Jack W. Schuler, Matthew W. Strobeck, Oracle
	Institutional Partners, LP, Oracle Partners, LP, and Richard B. McCormick, dated June&nbsp;11, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	June&nbsp;12,&nbsp;2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
<A NAME="eolPage127"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
</EFX_UNIDENTIFIED_TABLE>
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER">
<B>
	Incorporated by Reference
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:19.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:26.65PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	File No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:37.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filing Date
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:54.60PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filed/Furnished
<BR>
	Herewith
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.18
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Registration Rights Agreement among the Company, Benjamin Small, Birchview Fund, LLC, Broadfin Healthcare Master Fund, Ltd., Cormorant Global Healthcare Master Fund, LP, Jack W. Schuler, Matthew W. Strobeck, Oracle
	Institutional Partners, LP, Oracle Partners, LP, and Richard B. McCormick and Brookline Group LLC, dated June 11, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	June&nbsp;12,&nbsp;2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.19#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	First Amendment to the Employment Agreement by and between ContraFect Corporation and Julia P. Gregory, dated August 10, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	8-K
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	August 13, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.20#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	First Amendment to Employment Agreement by and between the Company and Michael Wittekind, PhD., dated November 12, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10-Q
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	001-36577
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	10.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	November&nbsp;12,&nbsp;2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.21#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	First Amendment to Employment Agreement by and between the Company and Daniel E.&nbsp;Couto, dated November 2, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	23.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Consent of Ernst &amp; Young LLP
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;31.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;31.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Section 302 of the Sarbanes-Oxley Act of 2002
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;32.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	**
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;32.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	**
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.INS
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Instance Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
</TABLE>
<A NAME="eolPage128"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
</EFX_UNIDENTIFIED_TABLE>
<H5 ALIGN="LEFT">
<A HREF="#D109824D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="10%">
</TD>
<TD WIDTH="35%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER">
<B>
	Incorporated by Reference
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:19.10PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:26.65PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	File No.
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:25.30PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:37.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filing Date
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:54.60PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Filed/Furnished
<BR>
	Herewith
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.SCH
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Taxonomy Extension Schema Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.CAL
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Taxonomy Extension Calculation Linkbase Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.DEF
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Taxonomy Extension Definition Linkbase Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.LAB
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Taxonomy Extension Label Linkbase Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101.PRE
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	XBRL Taxonomy Extension Presentation Linkbase Document
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP>
	*
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	*
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Filed herewith.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	**
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Furnished herewith.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	#
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Indicates management contract or compensatory plan.
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_INDEX>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage129"></A>
<A NAME="D109824DEX31_HTM"></A>
<EFX_EXHIBIT_3>
<A NAME="FIS_EXHIBIT_3"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 3.1
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	AMENDED AND RESTATED
</B>
</P>
<EFX_CERTIFICATE_OF_INCORPORATION>
<A NAME="FIS_CERTIFICATE_OF_INCORPORATION"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATE OF INCORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	OF
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONTRAFECT
	CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	(originally incorporated on March&nbsp;5, 2008)
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	ContraFect Corporation (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the
	Delaware General Corporation Law (the &#147;DGCL&#148;), does hereby certify as follows:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A. The current name of the Corporation is
	ContraFect Corporation. The Corporation was originally incorporated under the name CONTRAFECT, INC. on March&nbsp;5, 2008. The original Certificate of Incorporation of the Corporation was amended, supplemented and restated by (a)&nbsp;that certain
	Certificate of Amendment of Certificate of Incorporation filed on March&nbsp;17, 2008, (b)&nbsp;that certain Certificate of Designation of Series &#147;A&#148; Preferred Shares filed on July&nbsp;1, 2009, (c)&nbsp;that certain Amended and Restated
	Certificate of Incorporation filed on February&nbsp;26, 2010, (d)&nbsp;that certain Second Amended and Restated Certificate of Incorporation filed on August&nbsp;2, 2010, (e)&nbsp;that certain Certificate of Amendment of Second Amended and Restated
	Certificate of Incorporation filed on September&nbsp;10, 2010, (f)&nbsp;that certain Third Amended and Restated Certificate of Incorporation filed on August&nbsp;25, 2011, (g)&nbsp;that certain Certificate of Amendment of Third Amended and Restated
	Certificate of Incorporation filed on June&nbsp;13, 2012, (h)&nbsp;that certain Fourth Amended and Restated Certificate of Incorporation filed on June&nbsp;11, 2013 and (i)&nbsp;that certain Fifth Amended and Restated Certificate of Incorporation
	filed on July&nbsp;25, 2014.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	B. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Sections 242 and
	245 of the DGCL proposing this Amended and Restated Certificate of Incorporation (this &#147;Certificate of Incorporation&#148;) and declaring its advisability. The stockholders of the Corporation duly approved and adopted this Certificate of
	Incorporation by written consent in accordance with Sections 228, 242 and 245 of the DGCL.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	C. This Certificate of Incorporation shall
	become effective upon its filing with the Secretary of State of the State of Delaware.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	D. Accordingly, the Corporation&#146;s certificate
	of incorporation, as previously amended and restated, is hereby further amended and restated in its entirety to read as follows:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FIRST:
	The name of the Corporation is ContraFect Corporation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	SECOND: The address of the registered office of the Corporation in the State of
	Delaware is located at 2711 Centerville Road, Suite 400, in the City of Wilmington, County of New Castle, 19808, and its registered agent is Corporation Service Company.
</P>
<A NAME="eolPage130"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	THIRD: The nature of the business or purposes to be conducted or promoted by the Corporation is
	to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 125,000,000 shares,
	consisting of (i)&nbsp;100,000,000 shares of Common Stock, $0.0001 par value per share (&#147;Common Stock&#148;), and (ii)&nbsp;25,000,000 shares of Preferred Stock, $0.0001 par value per share (&#147;Preferred Stock&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions
	thereof in respect of each class of capital stock of the Corporation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A.
<U>
	COMMON STOCK
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	General
</U>
	. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of
	the holders of the Preferred Stock of any series as may be designated by the Board of Directors of the Corporation (the &#147;Board of Directors&#148;) upon any issuance of the Preferred Stock of any series.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Voting
</U>
	. The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to
	one vote for each share thereof held by such holder;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as
	used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or more
	outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation.
	There shall be no cumulative voting.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The number of authorized shares of Common Stock may be increased or decreased (but not below the
	number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of the State of
	Delaware.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Dividends
</U>
	. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when
	determined by the Board of Directors and subject to any preferential dividend or other rights of any then outstanding Preferred Stock.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Liquidation
</U>
	. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject
	to any preferential or other rights of any then outstanding Preferred Stock.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage131"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	B.
<U>
	PREFERRED STOCK
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and
	in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors as hereinafter provided. Any shares of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except
	as otherwise provided by law.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred
	Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance
	with the General Corporation Law of the State of Delaware, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional
	or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such
	resolutions, all to the full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may
	provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares then outstanding) by the
	affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of
	the State of Delaware.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FIFTH: Except as otherwise provided herein, the Corporation reserves the right to amend, alter, change or repeal
	any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject to this reservation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	SIXTH: In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of the State of Delaware, and
	subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the By laws of the Corporation by the affirmative vote of a majority of the directors present at any regular or
	special meeting of the Board of Directors at which a quorum is present. The stockholders may not adopt, amend, alter or repeal the By laws of the Corporation, or adopt any provision inconsistent therewith, unless such action is approved, in addition
	to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of at least seventy five percent (75%)&nbsp;of the votes that all the stockholders would be entitled to cast in any annual election of directors
	or class of directors. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the
	holders of at least seventy five percent (75%)&nbsp;of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision
	inconsistent with, this Article SIXTH.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage132"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	SEVENTH: Except to the extent that the General Corporation Law of the State of Delaware prohibits
	the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a
	director, notwithstanding any provision of law imposing such liability. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any
	acts or omissions of such director occurring prior to such amendment or repeal. If the General Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the personal liability of directors, then the liability
	of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	EIGHTH: The Corporation shall provide indemnification as follows:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	Actions, Suits and Proceedings Other than by or in the Right of the Corporation
</U>
	. The Corporation shall indemnify each person who was
	or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the
	fact that he or she is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a
	similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) (all such persons being referred to hereafter as an &#147;Indemnitee&#148;), or by reason of any action alleged
	to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974),
	and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably
	believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or
	proceeding by judgment, order, settlement, conviction or upon a plea of
<U>
	nolo
</U>
<U>
	contendere
</U>
	or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably
	believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Actions or Suits by or in the Right of the Corporation
</U>
	. The Corporation shall indemnify any Indemnitee who was or is a party to or
	threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or
	officer of the Corporation, or is or was serving, or has agreed to serve, at the request
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage133"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with,
	another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146;
	fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and
	in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that no indemnification shall be made under this Section&nbsp;2 in respect of any claim, issue or matter as to which
	Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the
	adjudication of such liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses (including attorneys&#146; fees) which the Court of Chancery of Delaware or such other court
	shall deem proper.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Indemnification for Expenses of Successful Party
</U>
	. Notwithstanding any other provisions of this Article
	EIGHTH, to the extent that an Indemnitee has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Sections 1 and 2 of this Article EIGHTH, or in defense of any claim, issue or matter therein, or on
	appeal from any such action, suit or proceeding, Indemnitee shall be indemnified against all expenses (including attorneys&#146; fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith. Without limiting the
	foregoing, if any action, suit or proceeding is disposed of, on the merits or otherwise (including a disposition without prejudice), without (i)&nbsp;the disposition being adverse to Indemnitee, (ii)&nbsp;an adjudication that Indemnitee was liable
	to the Corporation, (iii)&nbsp;a plea of guilty or
<U>
	nolo
</U>
<U>
	contendere
</U>
	by Indemnitee, (iv)&nbsp;an adjudication that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
	interests of the Corporation, and (v)&nbsp;with respect to any criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe his or her conduct was unlawful, Indemnitee shall be considered for the purposes hereof to have been
	wholly successful with respect thereto.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Notification and Defense of Claim
</U>
	. As a condition precedent to an Indemnitee&#146;s
	right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought. With respect to any
	action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably
	acceptable to Indemnitee. After notice from the Corporation to Indemnitee of its election so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection
	with such action, suit, proceeding or investigation, other than as provided below in this Section&nbsp;4. Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but the
	fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i)&nbsp;the employment of counsel by Indemnitee has been authorized by the
	Corporation, (ii)&nbsp;counsel to Indemnitee shall have reasonably concluded that there may be a
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage134"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct
	of the defense of such action, suit, proceeding or investigation or (iii)&nbsp;the Corporation shall not in fact have employed counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases the fees and
	expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Article EIGHTH. The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any
	claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the conclusion provided for in clause (ii)&nbsp;above. The Corporation shall not be required to indemnify Indemnitee under this
	Article EIGHTH for any amounts paid in settlement of any action, suit, proceeding or investigation effected without its written consent. The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would impose
	any penalty or limitation on Indemnitee without Indemnitee&#146;s written consent. Neither the Corporation nor Indemnitee will unreasonably withhold or delay its consent to any proposed settlement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.
<U>
	Advance of Expenses
</U>
	. Subject to the provisions of Section&nbsp;6 of this Article EIGHTH, in the event of any threatened or pending
	action, suit, proceeding or investigation of which the Corporation receives notice under this Article EIGHTH, any expenses (including attorneys&#146; fees) incurred by or on behalf of an Indemnitee in defending an action, suit, proceeding or
	investigation or any appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that the payment of such expenses incurred by or on behalf of Indemnitee in advance of the
	final disposition of such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no
	further right to appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article EIGHTH; and
<U>
	provided
</U>
<U>
	further
</U>
	that no such advancement of expenses shall be made under this Article EIGHTH if it
	is determined (in the manner described in Section&nbsp;6 of this Article EIGHTH) that (i)&nbsp;Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or
	(ii)&nbsp;with respect to any criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such
	repayment.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	Procedure for Indemnification and Advancement of Expenses
</U>
	. In order to obtain indemnification or advancement of
	expenses pursuant to Section&nbsp;1, 2, 3 or 5 of this Article EIGHTH, an Indemnitee shall submit to the Corporation a written request. Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the
	Corporation of the written request of Indemnitee, unless (i)&nbsp;the Corporation has assumed the defense pursuant to Section&nbsp;4 of this Article EIGHTH (and none of the circumstances described in Section&nbsp;4 of this Article EIGHTH that would
	nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate counsel have occurred) or (ii)&nbsp;the Corporation determines within such 60 day period that Indemnitee did not meet the applicable standard of conduct set
	forth in Section&nbsp;1, 2 or 5 of this Article EIGHTH, as the case may be. Any such indemnification, unless ordered by a court, shall be made with respect to requests under Section&nbsp;1 or 2 of this Article EIGHTH only as authorized in the
	specific case upon a determination by the Corporation that the indemnification of Indemnitee is proper because
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage135"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indemnitee has met the applicable standard of conduct set forth in Section&nbsp;1 or 2 of this Article EIGHTH, as
	the case may be. Such determination shall be made in each instance (a)&nbsp;by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question
	(&#147;disinterested directors&#148;), whether or not a quorum, (b)&nbsp;by a committee of disinterested directors designated by majority vote of disinterested directors, whether or not a quorum, (c)&nbsp;if there are no disinterested directors, or
	if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular legal counsel to the Corporation) in a written opinion, or (d)&nbsp;by the stockholders of the Corporation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	Remedies
</U>
	. The right to indemnification or advancement of expenses as granted by this Article EIGHTH shall be enforceable by
	Indemnitee in any court of competent jurisdiction. Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the
	applicable standard of conduct, nor an actual determination by the Corporation pursuant to Section&nbsp;6 of this Article EIGHTH that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a
	presumption that Indemnitee has not met the applicable standard of conduct. In any suit brought by Indemnitee to enforce a right to indemnification, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an
	undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article EIGHTH. Indemnitee&#146;s expenses (including attorneys&#146; fees) reasonably
	incurred in connection with successfully establishing Indemnitee&#146;s right to indemnification, in whole or in part, in any such proceeding shall also be indemnified by the Corporation. Notwithstanding the foregoing, in any suit brought by
	Indemnitee to enforce a right to indemnification hereunder it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the General Corporation Law of the State of Delaware.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	Limitations
</U>
	. Notwithstanding anything to the contrary in this Article EIGHTH, except as set forth in Section&nbsp;7 of this Article
	EIGHTH, the Corporation shall not indemnify an Indemnitee pursuant to this Article EIGHTH in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board of Directors of the
	Corporation. Notwithstanding anything to the contrary in this Article EIGHTH, the Corporation shall not indemnify an Indemnitee to the extent such Indemnitee is reimbursed from the proceeds of insurance, and in the event the Corporation makes any
	indemnification payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification payments to the Corporation to the extent of such insurance reimbursement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	9.
<U>
	Subsequent Amendment
</U>
	. No amendment, termination or repeal of this Article EIGHTH or of the relevant provisions of the General
	Corporation Law of the State of Delaware or any other applicable laws shall adversely affect or diminish in any way the rights of any Indemnitee to indemnification under the provisions hereof with respect to any action, suit, proceeding or
	investigation arising out of or relating to any actions, transactions or facts occurring prior to the final adoption of such amendment, termination or repeal.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage136"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	10.
<U>
	Other Rights
</U>
	. The indemnification and advancement of expenses provided by this Article
	EIGHTH shall not be deemed exclusive of any other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or
	otherwise, both as to action in Indemnitee&#146;s official capacity and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure
	to the benefit of the estate, heirs, executors and administrators of Indemnitee. Nothing contained in this Article EIGHTH shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and
	directors providing indemnification rights and procedures different from those set forth in this Article EIGHTH. In addition, the Corporation may, to the extent authorized from time to time by its Board of Directors, grant indemnification rights to
	other employees or agents of the Corporation or other persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article EIGHTH.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	11.
<U>
	Partial Indemnification
</U>
	. If an Indemnitee is entitled under any provision of this Article EIGHTH to indemnification by the
	Corporation for some or a portion of the expenses (including attorneys&#146; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in
	settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless
	indemnify Indemnitee for the portion of such expenses (including attorneys&#146; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in
	settlement to which Indemnitee is entitled.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12.
<U>
	Insurance
</U>
	. The Corporation may purchase and maintain insurance, at its expense, to
	protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) against any expense, liability or loss incurred by him
	or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of
	Delaware.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	13.
<U>
	Savings Clause
</U>
	. If this Article EIGHTH or any portion hereof shall be invalidated on any ground by any court of
	competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including attorneys&#146; fees), liabilities, losses, judgments, fines (including excise taxes and penalties arising under the Employee
	Retirement Income Security Act of 1974) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including an action by or in the right of the Corporation, to the
	fullest extent permitted by any applicable portion of this Article EIGHTH that shall not have been invalidated and to the fullest extent permitted by applicable law.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage137"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	14.
<U>
	Definitions
</U>
	. Terms used herein and defined in Section&nbsp;145(h) and
	Section&nbsp;145(i) of the General Corporation Law of the State of Delaware shall have the respective meanings assigned to such terms in such Section&nbsp;145(h) and Section&nbsp;145(i).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	NINTH: This Article NINTH is inserted for the management of the business and for the conduct of the affairs of the Corporation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	General Powers
</U>
	. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Number of Directors; Election of Directors
</U>
	. Subject to the rights of holders of any series of Preferred Stock to elect
	directors, the number of directors of the Corporation shall be established by the Board of Directors. Election of directors need not be by written ballot, except as and to the extent provided in the By laws of the Corporation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Terms of Office
</U>
	. Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for
	a term ending on the date of the first annual meeting of stockholders following the annual meeting of stockholders at which such director was elected;
<U>
	provided
</U>
	that the term of each director shall continue until the election and qualification
	of his or her successor and be subject to his or her earlier death, resignation or removal.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Quorum
</U>
	. The greater of (a)&nbsp;a
	majority of the directors at any time in office and (b)&nbsp;one third of the number of directors fixed pursuant to Section&nbsp;2 of this Article NINTH shall constitute a quorum of the Board of Directors. If at any meeting of the Board of Directors
	there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.
<U>
	Action at Meeting
</U>
	. Every act or decision done or made by a majority of the directors present at a meeting duly held at which a quorum
	is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	Removal
</U>
	. Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only for
	cause and only by the affirmative vote of the holders of at least seventy five percent (75%)&nbsp;of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	Vacancies
</U>
	. Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly created directorship in the Board
	of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. A director elected to fill a
	vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the election and qualification of a successor and to such director&#146;s earlier death, resignation or removal.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage138"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	Stockholder Nominations and Introduction of Business, Etc
</U>
	. Advance notice of
	stockholder nominations for election of directors and other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the By laws of the Corporation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	9.
<U>
	Amendments to Article
</U>
	. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By laws of the
	Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy five percent (75%)&nbsp;of the votes which all the stockholders would be entitled to cast in any
	annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	TENTH: Stockholders of the Corporation may not take any action by written consent in lieu of a meeting. Notwithstanding any other provisions
	of law, this Certificate of Incorporation or the By laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least seventy five percent (75%)&nbsp;of the votes
	which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article TENTH.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	ELEVENTH: Special meetings of stockholders for any purpose or purposes may be called at any time by only the Board of Directors, the Chairman
	of the Board of Directors or the Chief Executive Officer of the Corporation, and may not be called by any other person or persons. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or
	purposes stated in the notice of meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the By laws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the
	affirmative vote of the holders of at least seventy five percent (75%)&nbsp;of the votes which all the stockholders would be entitled to cast in any annual election of directors or class of directors shall be required to amend or repeal, or to adopt
	any provision inconsistent with, this Article ELEVENTH.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, this Certificate of Incorporation, which restates, integrates
	and amends all previous certificates of incorporation of the Corporation, and which has been duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, has been executed by a duly authorized
	officer this 1st day of August, 2014.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="12%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="87%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	CONTRAFECT CORPORATION
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Julia Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Julia Gregory
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Chief Executive Officer
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
</EFX_CERTIFICATE_OF_INCORPORATION>
</EFX_EXHIBIT_3>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage139"></A>
<A NAME="D109824DEX107_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.7
</B>
</P>
<P STYLE="MARGIN-TOP:24PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	EMPLOYMENT AGREEMENT
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	by and between
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONTRAFECT CORPORATION
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	and
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	DANIEL E. COUTO
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	THIS EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;) is entered into on the latest date set forth on the signature pages hereto, by
	and between ContraFect Corporation, a Delaware corporation (&#147;Employer&#148;) and Daniel E. Couto, a resident of Massachusetts (&#147;Employee&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS, Employer is a biotech company engaged in the business of developing products for approval and sale;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS, Employee is a research scientist with knowledge and experience in the area of developing products in the biotech field for approval
	and sale;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS, Employer believes that the future services of Employee will be of substantial benefit to Employer and desires to
	assure itself of the continued availability of such services; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS, Employee desires to accept employment with Employer on the
	terms and subject to the conditions hereinafter stated.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	NOW, THEREFORE, for and in consideration of the premises above and the mutual
	promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	Employment and Duties of Employee
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a)
	Employer hereby employs Employee to serve Employer in the capacity of Vice President of Product Development. Employer shall have the power to determine the precise duties of Employee as they may change over time and as Employer&#146;s needs shall
	warrant. Employee agrees to devote Employee&#146;s full working time, attention, ability, skill and energies to the performance of Employee&#146;s duties
</P>
<A NAME="eolPage140"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	hereunder. Employee shall provide professional services on behalf of Employer in a manner and to an extent consistent with that established by Employer. Employee shall work at all
	locations/offices of Employer as requested by Employer, and upon Employer&#146;s request shall travel as needed to carry out his duties. Employee shall not provide like services for any other entity or person, whether for compensation or not, except
	as an employee of Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Employee shall comply with all bylaws, policies, procedures, standards and regulations of Employer now or
	hereafter promulgated. Employee shall participate in such continuing education as may be required under applicable ethical or licensing standards, laws, rules and regulations applying to Employee&#146;s profession or as may otherwise be required by
	Employer. Employee shall obtain and maintain all required licenses, credentials, approvals or other certifications to perform Employee&#146;s duties and services hereunder.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) Employee shall disclose in writing to Employer on the date hereof all financial interests or compensation arrangements of Employee (other
	than this Employment Agreement) and any member of Employee&#146;s Immediate Family (as hereinafter defined), including without limitation, any financial interests or compensation arrangements (as owner, employee, lessor, lessee, independent
	contractor, or otherwise) in any Biotech Venture (as hereinafter defined) (such financial interests and compensation arrangements hereinafter collectively referred to as &#147;Arrangements&#148;).
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(i) Biotech Venture shall mean and include without limitation, any entity or person that develops or sells, researches, or licenses scientific
	information or products for the therapy of human diseases.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(ii) Immediate Family shall mean Employee&#146;s spouse, parent, child,
	sibling, grandparent, and grandchild.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Employee shall not enter into any Arrangements with any Biotech Venture without the prior written
	consent of Employer. In the event that there is a change in any Arrangement, or if any member of Employee&#146;s Immediate Family enters into an Arrangement during the term of this Agreement, Employee shall immediately disclose such Arrangement to
	Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Hours and Place of Employment
</U>
	. Employee is expected to maintain a regular work week as assigned by the Employer for employees at his
	level performing such duties. Until such time as Employee moves to New York City, without the Employer&#146;s instruction to do so he shall work no less than three days per week at the Employer&#146;s offices in New York unless otherwise instructed
	by Employer. Employee, as a condition of his continued employment, shall relocate to New York on or by April&nbsp;15, 2011 so that he can be a full time employee working at Employer&#146;s offices.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage141"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Term of Employment
</U>
	. The initial term of employment (the &#147;Initial Term&#148;) of Employee&#146;s
	employment by Employer under this Agreement shall commence on March&nbsp;5, 2011 (the &#147;Commencement Date&#148;) and shall end three (3)&nbsp;years thereafter, unless earlier terminated as hereinafter provided. Unless either party elects to
	terminate this Agreement at the end of the Initial Term or any renewal term by giving the other party notice of such election at least ninety (90)&nbsp;days before the expiration of the Initial Term, this Agreement shall be deemed to have been
	renewed for an additional term of one (1)&nbsp;year commencing on the day after the expiration of the then current term and so on from year to year. Notwithstanding the foregoing, either party shall have the right to terminate this Agreement at any
	time for any reason or no reason upon thirty (30)&nbsp;days&#146; prior written notice. In the event that Employer or Employee gives notice to terminate pursuant to the foregoing sentence, Employer may elect to have Employee cease working
	immediately so long as Employer continues to pay Employee his base salary in accordance with the provisions of Section (4)(a)&nbsp;hereof for the entire thirty (30)&nbsp;day notice period. In the event Employer elects to have Employee immediately
	cease working during the thirty (30)&nbsp;days notice period as provided in the foregoing sentence and Employee finds alternative employment that is not in violation of any provision herein, Employee may accept and engage in the alternative
	employment and upon Employee&#146;s first date of employment with the alternative employer, Employer shall terminate the payment of Employee&#146;s base salary as provided in subsection 4(a). In the event that Employee is terminated by Employer
	without cause then in such event Employee shall be given a severance payment in the amount that is equal to twelve (12)&nbsp;months of his then base salary provided that Employee first signs a Severance and Release Agreement in a form prescribed by
	Employer. The aforesaid severance payment shall be paid over twelve (12)&nbsp;months and shall be subject to mitigation by Employee.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Compensation of
	Employee
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) As compensation for all services to be performed by Employee from and after the Commencement Date, Employer agrees to
	pay to Employee a base salary of Two Hundred Ten Thousand Dollars ($210,000.00) per annum. All such payments shall be prorated for any partial month or year and shall be payable in accordance with Employer&#146;s customary payroll practices for
	Employees. Federal income taxes, social security taxes and other customary employee payroll deductions shall be deducted from all amounts paid to Employee as compensation under this Employment Agreement. The Employer shall review Employee&#146;s
	performance after he has worked on a full time basis for six months at which time it will consider increasing his base salary to thereafter be $220,000. Employer will review Employee&#146;s performance annually at which time Employee&#146;s base
	salary may subsequently be changed.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage142"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Effective as of the Commencement Date Employer shall give Employee stock options for 100,000
	shares of common stock under its stock option plan which will provide, among other things, for vesting in three near equal annual increments at a $1.29 per share strike price. Such options shall have a duration of 10 years. The stock option plan
	provides, inter alia, that unvested options shall be forfeited in the event that Employee is no longer an employee as of the vesting date.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) The Employee also may qualify for a bonus based on the following criteria. During the first sixteen (16)&nbsp;months of this Agreement,
	(i)&nbsp;a bonus in the amount of 15% of the then base salary upon an IND application that is approved of by the CEO being filed with the FDA; and (ii)&nbsp;a bonus in the amount of 5% of the then base salary upon the delivery of material for
	toxicology. Each bonus, if any, shall be paid 50% in cash and 50% as options derived from The Company&#146;s Incentive stock option plan. Such options shall have a duration of 10 years and vest over a period of 3 years as described in 4(b) with an
	exercise price at the fair market value on the date of approval by the Board of Directors. Employer shall review Employee&#146;s performance annually with a view towards setting criteria for possible additional bonus arrangements.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) Employee shall be entitled to participate in such fringe benefit programs as Employer may offer to its senior employees generally,
	including family health and life insurance, at Employer&#146;s expense. The Employer&#146;s current health insurance plan is with Empire Blue Cross/Blue Shield and also includes optical and dental coverage. However, Employer may amend, decrease or
	discontinue any benefit program at any time without advance notice to or consent of the Employee, consistent with the manner in which Employer changes the benefit programs for other similarly situated employees of Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.
<U>
	Absences and Vacation
</U>
	. Paid time off for vacations and sick days shall be limited to an aggregate of seventeen (17 days) per annum during the term of
	this Agreement, which shall be in addition to legal holidays. Except as to sick days, time off shall be taken at a time reasonably convenient to Employer. In the event Employee&#146;s employment terminates prior to the end of the term hereof, such
	entitlement shall be prorated. Any unused time off at the end of any annual term of this Agreement shall not entitle Employee to payment therefor and may not be carried forward into any subsequent period of employment.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage143"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	Expenses
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) In addition to the compensation payable to Employee under Section&nbsp;4, Employer agrees to reimburse Employee for up to Twenty-Five
	Thousand Dollars ($25,000.00) of actual expenses incurred by Employee to transfer his household to New York City (permitted expenses hereunder include, but are not limited to, costs such as: contractual obligations for Employee&#146;s
	children&#146;s school term through June 2011, temporary housing needs for the time between Employee&#146;s home in Boston (March 31) and when Employee can occupy his new home in New York State, health care premium charges for Employee&#146;s Boston
	based health insurance plan for the period of March&nbsp;15 to April&nbsp;15, 2011) and an additional amount, up to $6,000 for Employee to take his family on up to three trips to New York in search of housing including the rental of a car. Such
	payments will be made subject to the submission of receipts for expenses. The amount of unused expenses, if any, will not be paid to Employee and may not be carried forward for use in future years. Such reimbursement shall be made upon presentation
	of receipts satisfactory to Employer for expenses actually incurred in connection with the foregoing.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	Termination Other Than For Cause
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) In the event of Employee&#146;s death, Employee&#146;s employment shall terminate immediately and Employee&#146;s estate shall be paid
	Employee&#146;s base salary and accrued bonus, if any, through the date on which such death occurred.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) If Employee becomes unable to
	perform the essential functions of Employee&#146;s duties (with reasonable accommodation, if requested) due to partial or total disability or incapacity resulting from a mental or physical illness or injury or any similar cause, Employer will
	continue the payment of Employee&#146;s base salary pursuant to Section&nbsp;4(a) for a period of two (2)&nbsp;weeks or for the duration of any accrued and unused vacation, whichever is longer, following the work day that Employee first is unable to
	perform the essential functions of Employee&#146;s duties due to such disability or incapacity. Thereafter, Employer shall have no obligation for the payment of Employee&#146;s base salary pursuant to Section&nbsp;4(a) to Employee during the
	continuance of such disability or incapacity. Notwithstanding anything to the contrary contained herein, Employee shall not be entitled to receive base salary pursuant to this subsection 8(b) for more than thirty (30)&nbsp;days, or such additional
	days if the Employee shall have accrued and unused vacation, in any consecutive twenty-four (24)&nbsp;month period. If Employee is unable to perform the essential functions of Employee&#146;s duties (with reasonable accommodation, if requested) due
	to partial or total disability or incapacity resulting from a mental or physical illness or any similar cause for the longer of a period of sixty (60)&nbsp;consecutive days or for a cumulative period of sixty (60)&nbsp;days during any twelve
	(12)&nbsp;month period or the maximum period of time required under the federal Family Medical Leave Act (&#147;FMLA&#148;) or other applicable law, Employer shall have the right to terminate this Agreement immediately after the expiration of the
	later of the sixtieth (60th)&nbsp;day of disability or exhaustion of available unpaid leave under FMLA or other applicable law, without the requirement of any further notice, in which event Employer shall have no further obligations or liabilities
	hereunder after the date of such termination.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage144"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	Termination For Cause
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Employee&#146;s employment under this Agreement shall be deemed to be terminated upon the occurrence of any of the following, at
	Employer&#146;s election, immediately upon Employer giving written notice of such termination to Employee:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(i) Employee&#146;s conviction
	of any felony or a crime involving moral turpitude.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(ii) Employee&#146;s failure or refusal to follow, in any material respect, the
	instructions of Employer or the bylaws, policies, standards or regulations of Employer, which from time to time may be established or changed, and such failure or refusal is not cured within fifteen (15)&nbsp;days of receiving written notice of such
	violation from Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iii) Employee&#146;s continued failure or refusal to faithfully and diligently perform, in any material
	respect, the usual and customary duties of Employee&#146;s employment hereunder, and such failure or refusal is not cured within fifteen (15)&nbsp;days of receiving written notice of such violation from Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iv) Employee&#146;s conduct is unprofessional, unethical, immoral or fraudulent and such conduct is not cured within fifteen (15)&nbsp;days
	of receiving written notice to cure such conduct from Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(v) Employee&#146;s conduct is detrimental to the reputation, character
	or standing of Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(vi) Unlawful use by Employee of narcotics or other controlled substances, or use of alcohol or other drugs in a
	manner Employer reasonably determines interferes with the performance of the essential functions of Employee&#146;s duties hereunder.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(xxii) Employee&#146;s failure or refusal to behave in a courteous, respectful and helpful manner toward third parties or co-workers and such
	behavior is not cured within ten (10)&nbsp;days of receiving notice to cure such behavior from Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(xiii) Any written notice under
	this Section&nbsp;9(a) shall specify the alleged violations in sufficient detail as to apprise Employee of the default or failure.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage145"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) In the event that Employer fails to pay Employee any installment of the base salary owed to
	Employee under Section&nbsp;4(a) or (b)&nbsp;when it is due and such non-payment is not cured within fifteen (15)&nbsp;days after Employee shall have notified Employer in writing of such non-payment, then Employee, provided that Employee is not in
	default with respect to any of Employee&#146;s obligations under this Agreement, shall have the option to terminate Employee&#146;s employment under this Agreement immediately upon Employee giving written notice of such termination to Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	9.
<U>
	Proprietary and Confidential Information
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a. Confidential Information. Employee acknowledges that, during the course of his service with Employer, he will have access to Confidential
	Information and materials not generally known outside Employer. For all purposes of this Agreement, &#147;Confidential Information&#148; means all information and materials (whether conceived or developed by Employee or others), marketing and other
	business plans, customers and customer information, data strategies, research, reports, copyrights and patents related to Employer. During the Term of this Agreement, Employee shall not, without the prior consent of Employer, communicate or divulge
	any Confidential Information or materials to anyone other than Employer and its partners, affiliates, employees, consultants and those designated by it except in the course of carrying out his duties or as required by law. Employee acknowledges that
	Confidential Information is and shall remain the property of Employer. The confidentiality obligations hereunder shall not apply to Confidential Information which: (i)&nbsp;is, or later becomes, public knowledge other than by breach of this
	Agreement; or (ii)&nbsp;is in the possession of Employee with the full right to disclose same prior to his receipt of it from Employer; or (iii)&nbsp;is independently received by Employee from a third party, with no restrictions of disclosure.
	Furthermore, Employee agrees not to use Confidential Information for any purposes other than to perform duties for Employer hereunder. Employee shall also execute Employer&#146;s standard Confidentiality Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b. Ownership of Patents and Intellectual Property. Employee agrees that any work prepared for Employer from the date of this Agreement until
	the expiration of his employment with Employer, which is eligible for copyright and patent protection under the laws of the United States or any other country and any proprietary know-how developed by Employee while rendering services for Employer,
	will vest in Employer. Employee hereby grants, transfers and assigns all right, title and interest in such work and all copyrights and patents in such work and all renewals and extensions thereof to Employer, and agrees to provide all assistance
	reasonably requested by Employer in the establishment, preservation and enforcement of Employer&#146;s copyright and patents in such work, such assistance to be provided at Employer&#146;s expense but without any additional
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage146"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	compensation to Employee if Employee is employed by Employer and for reasonable compensation and subject to his reasonable availability if he is not. If Employer cannot, after reasonable effort,
	secure Employee&#146;s signature on any documents needed do apply for or prosecute any patent, copyright or other right or protection relating to an invention, whether because of his physical or mental incapacity or for any other reason whatsoever,
	Employee hereby irrevocably designates and appoints Employer and its duly authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and in his name and stead for the purpose of executing and filing any such
	application or applications and taking all other lawfully permitted actions to further the prosecution and issuance of patents, copyrights, or similar protections thereon, with the same legal force and effect as if executed by him.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	c. Litigation. Employee agrees to render assistance and cooperation to Employer at its request regarding any matter, dispute or controversy
	with which Employer may become involved and of which Employee has useful knowledge, information or expertise. Such services will be without additional compensation if Employee is then employed by Employer and for reasonable compensation and subject
	to his reasonable availability if he is not. Following his employment, Employee shall not be required to cooperate other than as a fact witness. Employer agrees to pay all expenses reasonably incurred or to be incurred by Employee in connection with
	his cooperation.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	10. Covenants not to Compete.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a. Non-competition. Employee acknowledges that his duties hereunder and the services he will provide to Employer are of a special, unique,
	unusual and extraordinary character, which gives this Agreement particular value to Employer, and that the knowledge he will learn while working for Employer is such that it will necessarily be valuable to a competitor and almost impossible to keep
	confidential if Employee were to work for a competitor. Therefore, during the Term and for a period of one year after termination of his service to Employer, Employee will not, directly or indirectly, enter into, organize, control, engage in, be
	employed by, serve as a consultant to, be an officer or director of, or have any direct investment of more than 5% of the outstanding shares in, any business, person, partnership, association, firm, corporation, or other entity engaged in any
	business activity (including, but not limited to, research, development, manufacturing, selling, leasing, licensing or providing services) which is competitive with the business of Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b. Non-diversion. During the Term, and for a period of one year after the date of termination of Employee&#146;s employment with Employer,
	Employee will not divert or attempt to divert or take advantage of or attempt to take advantage of any actual or potential business or opportunities of Employer.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage147"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	c. Non-recruitment. Employee agrees that Employer has or will invest substantial time and effort
	in assembling its workforce. Accordingly, Employee agrees that during the Term and for a period of one year after the date of termination of Employee&#146;s employment with Employer Employee will not directly or indirectly (a)&nbsp;hire away any
	individuals who were employed by Employer during the one-year period prior to the date of termination of Employee&#146;s service with Employer, or (b)&nbsp;directly or indirectly, entice, solicit or seek to induce or influence any such employees to
	leave their service with Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	11. Remedies.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a. Employee acknowledges that the restrictions contained in Sections 9 and 10, in view of the nature of the business of Employer, are
	reasonable and necessary in order to protect the legitimate interests of Employer. Employee acknowledges that any violation of such restrictions would likely result in irreparable injuries to Employer, and Employee therefore acknowledges that, in
	the event of Employee&#146;s violation of any of these restrictions, Employer shall be entitled to seek from any court of competent jurisdiction preliminary and permanent injunctive relief without proving actual damage or immediate or irreparable
	harm and without posting any bond. In addition, Employer shall be entitled to seek damages and an equitable accounting of all earnings, profits and other benefits arising from such violation, which rights shall be cumulative and in addition to any
	other rights or remedies to which Employer may be entitled.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b. If the time, geographic, or other limitations specified in Sections 9 and
	10 above should be adjudged to exceed limitations permitted by applicable law in any proceeding, then the affected provisions shall be deemed reformed in such jurisdiction to the maximum time, geographic, product or service or other limitations
	permitted by applicable law. If Employee violates any of the restrictions contained in the foregoing Sections 9 and 10, the restrictive period shall be tolled, and shall not run, during the time of any said breach.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	c. In view of the difficulty of determining the amount of damages that may result to the parties hereto from the breach of the provision of
	Section&nbsp;9 or 10, it is the intent of the parties hereto that, in addition to monetary damages, any non-breaching party shall have the right to prevent any such breach in equity or otherwise, including without limitation prevention by means of
	injunctive relief. The prevailing party in any such action shall be entitled to an award of its reasonable attorney&#146;s fees and costs.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12.
	Non-disparagement. Employee and Employer mutually agree that, during the Term and for a period of five years thereafter, neither will directly or indirectly disparage the other.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage148"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	13.
<U>
	Entire Agreement; Amendments
</U>
	. This Agreement constitutes the entire agreement and understanding
	between Employer and Employee relating to the subject matter hereof, and shall not be amended or changed except by written instrument signed by each of the undersigned parties. There are no prior or contemporaneous oral or written understandings or
	agreements between the parties regarding Employee&#146;s employment by Employer or any other matter.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	14.
<U>
	No Waiver
</U>
	. Neither Employee nor Employer
	shall by any act, delay, indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any default in or breach of any of the terms and conditions hereof. No failure to exercise, nor any delay in
	exercising, on the part of Employee or Employer, any right, power or privilege hereunder shall operate as a waiver thereof. No single or partial exercise of any right, power or privilege hereunder shall preclude any other or further exercise thereof
	or the exercise of any other right, power or privilege.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	15. Waiver of jury trial. The parties hereto waive any and all rights to a trial by jury with
	respect to any action arising hereunder.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	16.
<U>
	Governing Law, Venue. Interpretation of Language
</U>
	. The parties agree that this Agreement shall be
	governed by the laws of the State of New York and that venue for an action between the parties that arises out of this Agreement shall be in New York county, State of New York. In the event an ambiguity or question of intent or interpretation
	arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	17.
<U>
	Resignation as Officer and Director
</U>
	. In the event that Employee&#146;s employment with Employer is terminated for any reason whatsoever, Employee
	agrees to immediately resign from any position Employee may hold as an officer or director of, or on behalf of, Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	18.
<U>
	Limitation on
	Authority
</U>
	. Without the express written consent of Employer, the Employee shall have no apparent or implied authority to:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) pledge
	the credit of Employer or any of its employees;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
<A NAME="eolPage149"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) bind the Employer under any contract, agreement, note, mortgage or otherwise; or
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) sell, mortgage, transfer or otherwise dispose of any assets of Employer.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	19.
<U>
	Notices
</U>
	. Any notices under this Agreement shall be given in writing in person or by registered or certified U.S. mail, postage prepaid, return
	receipt requested, or by facsimile with confirmation, to the parties at their respective addresses set forth below, and such notices shall be deemed given when received or three (3)&nbsp;days after placed in the mail in the manner provided above.
	Either party may change such party&#146;s address for notice by giving notice as provided herein.
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="64%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	(a)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	If to Employer:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	With a copy to:
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Dr. Robert Nowinski
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Seth I. Rubin, Esq.
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	ContraFect, Corp.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	East Tower, 15
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	th
</SUP>
	Floor
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	28 Wells Avenue
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	1425 Rxr Plaza
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Yonkers, NY 110701
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Uniondale, NY 11556-1425
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	(b)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	If to Employee:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Daniel Couto
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	70 Somerstown Rd.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Ossining, NY 10562
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	20.
<U>
	Prior Agreements
</U>
	. Employee represents to Employer that (a)&nbsp;there are no restrictions, agreements or
	understandings to which Employee is a party that would prevent or make unlawful Employee&#146;s execution of this Agreement or Employee&#146;s employment hereunder, (b)&nbsp;Employee&#146;s execution of this Agreement and Employee&#146;s employment
	hereunder shall not constitute a breach of any contract, agreement or understanding, oral or written, to which Employee is a party or by which Employee is bound, (c)&nbsp;Employee is free and able to execute this Agreement and to enter into
	employment by Employer, and (d)&nbsp;Employee shall not divulge to Employer any trade secrets or proprietary information that belongs to any other person or entity.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	21.
<U>
	No Assignment
</U>
	. This Agreement and the rights and obligations of both parties hereunder are personal in nature, and shall not be assignable by either
	party hereto, except by operation of law. Notwithstanding the foregoing, Employer may assign some or all of its rights hereunder to a successor in interest.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	11
</P>
<A NAME="eolPage150"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	22.
<U>
	Headings
</U>
	. Headings used in this Agreement are solely for the convenience of the parties and shall be
	given no effect in the construction or interpretation of this Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	23
<U>
	Miscellaneous
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original as against any
	party whose signature appears thereon, and all of which shall together constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all
	of the parties reflected hereon as the signatories.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Provisions Separable. The provisions of this Agreement are independent of and
	separable from each other, and no provision shall be affected or rendered invalid or unenforceable by virtue of the fact that for any reason any other or others of them may be invalid or unenforceable in whole or in part.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) Survival. Any provisions of this Agreement which, by their terms, are intended to survive the expiration or termination of this Agreement,
	including but not limited to the restrictive covenant and the provisions relating to non-solicitation, confidentiality, and both parties agree to forever waive any claim or defense, at law or in equity, asserting that such provision(s) terminated or
	otherwise became unenforceable as a result of the expiration or termination of this Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d)
<U>
	Section&nbsp;409A Compliance.
</U>
	Any payments under this Agreement that are deemed to be deferred compensation subject to the requirements of Section&nbsp;409A of the Internal Revenue Code are intended to comply with the requirements of section 409A. To this end, if at any time
	during the term of this Agreement, or upon its termination, the deferral of any payments or benefits otherwise payable is necessary to prevent any additional tax under Section&nbsp;409A, then Employer will defer such payments (without reduction in
	the amount ultimately paid or provided to Employee) until the earliest date that is permitted under Section&nbsp;409A. Any amounts so deferred will be paid promptly to Employee at the end of such deferral period.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	12
</P>
<A NAME="eolPage151"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed and delivered as
	of the day and year set forth below.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	CONTRAFECT CORPORATION
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/ Robert Nowinski
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Robert Nowinski, CEO
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16" COLSPAN="3">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	Dated: March&nbsp;21, 2011
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16" COLSPAN="3">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/ Daniel E. Couto
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Daniel E. Couto
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16" COLSPAN="3">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	Dated: March&nbsp;21, 2011
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	13
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage152"></A>
<A NAME="D109824DEX108_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.8
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
	EXECUTION VERSION
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	SEPARATION AND CONSULTING AGREEMENT
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This Separation and Consulting Agreement (the &#147;Agreement&#148;) is entered into by and between ContraFect Corporation (the
	&#147;Company&#148;) and Dr.&nbsp;Barry Kappel (&#147;Kappel&#148;), effective as of April&nbsp;15, 2015.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	Resignation from
	Employment
</U>
	. Effective as of April&nbsp;15, 2015, Kappel resigned from his employment with the Company, and thereby terminated his service in any position or office that he held as a consequence of his employment with the Company. For the
	avoidance of doubt, Kappel&#146;s last day of employment with the Company shall be April&nbsp;15, 2015 (the &#147;Employment Termination Date&#148;). The parties agree that they (in the Company&#146;s case, including its officers and directors) will
	refer to Kappel&#146;s termination of employment only in the manner set forth on
<U>
	Exhibit A
</U>
	, which shall be reflected in a Form 8-K. The Company agrees that no grounds exist to terminate Kappel for &#147;Cause&#148; as defined in the
	Employment Agreement (as defined below).
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Severance Compensation
</U>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a.
<U>
	Cash Compensation
</U>
	. Subject to Kappel&#146;s execution of this Agreement, the Company will provide Kappel with (i)&nbsp;a cash
	separation payment of $135,000, paid as a lump sum within ten business days following execution of this Agreement, and (ii)&nbsp;$330,750 in cash compensation, payable in twenty-four (24)&nbsp;substantially equal installments consistent with the
	Company&#146;s customary payroll practices, commencing on May&nbsp;15, 2015.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b.
<U>
	Equity Compensation
</U>
	. Effective as of April&nbsp;15,
	2015 (&#147;date of grant&#148;), Kappel will receive, a grant of fully vested and exercisable options to purchase shares of the Company&#146;s common stock with a grant date fair market value of $60,750, as determined by the Company in accordance
	with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 718, or any successor promulgation, and which shall have a stated exercise price equal to the closing per share price of the
	Company&#146;s common stock on the date of grant. These options shall remain exercisable until March&nbsp;30, 2016, after which date they shall expire to the extent unexercised. Such grant will be made on the same terms as previous grants, including
	the ability to cashless exercise.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	c.
<U>
	Benefit Continuation
</U>
	. If Kappel elects to receive continued healthcare coverage pursuant to
	the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#147;COBRA&#148;) in connection with the termination of Kappel&#146;s employment with the Company, the Company will pay the full premiums for such coverage (for Kappel and his eligible
	dependents) until the earlier of (i)&nbsp;the eighteen (18)&nbsp;month anniversary of the Employment Termination Date, or (ii)&nbsp;the date that Kappel and his covered dependents become eligible for healthcare coverage under a plan of Kappel&#146;s
	successor employer&#146;s plan(s).
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Payment of Earned but Unpaid Salary and Paid Time Off
</U>
	. In connection with the termination of
	Kappel&#146;s employment with the Company, the Company will pay Kappel any earned but unpaid base salary in a lump sum on the payroll date that falls on the Employment Termination Date. The Company will also pay Kappel salary for three
	(3)&nbsp;accrued but unused vacation days in a lump sum on the next payroll date following that which occurs on the Employment Termination Date. In lieu of payment for a fourth accrued but unused vacation day, Kappel will be entitled to retain his
	Company-issued iPad.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<A NAME="eolPage153"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Consulting Services
</U>
	. Kappel agrees, for the period from April&nbsp;15, 2015 to
	December&nbsp;31, 2015 (the &#147;Consulting Period&#148;), to perform consulting services for the Company and its affiliates as reasonably requested by the Company. Kappel&#146;s services shall be of an advisory nature and the Company shall not
	have any obligation to follow Kappel&#146;s advice. Kappel agrees to provide such services as reasonably requested by the Company but in no event for more than seventeen business days during the Consulting Period at such times and at such locations
	as may be reasonably requested by the Company&#146;s Chief Executive Officer and agreed to by Kappel, whose consent will not be unreasonably withheld. It is anticipated by the parties that Kappel&#146;s services shall be limited to no more than four
	days per month (two days in December). In connection with the provision of such consulting services, the Company will reimburse Kappel for any expenses reasonably incurred by him.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.
<U>
	Consulting Compensation
</U>
	. In exchange for Kappel&#146;s agreement to provide the consulting services contemplated hereunder, the
	Company will provide Kappel with the following treatment with regard to equity awards:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a. The vesting of Kappel&#146;s outstanding
	unvested options held as of the Employment Termination Date will accelerate in accordance with
<U>
	Exhibit B
</U>
	attached hereto. For the avoidance of doubt, such accelerated vesting will apply to each individual option grant until the earlier of
	(i)&nbsp;the date on which the entire grant is vested or (ii)&nbsp;December&nbsp;31, 2015. Such accelerated vesting is not intended to create entitlement to any options beyond those initially awarded in connection with each grant of options. Any
	options remaining unvested after December&nbsp;31, 2015 will be forfeited. Options granted prior to the consummation of the Company&#146;s initial public offering (specifically, those granted on April&nbsp;15, 2010,&nbsp;September&nbsp;1,
	2010,&nbsp;November&nbsp;1, 2010,&nbsp;February&nbsp;8, 2011,&nbsp;October&nbsp;3, 2011,&nbsp;February&nbsp;27, 2013,&nbsp;March&nbsp;21, 2014, and April&nbsp;29, 2014) will expire (to the extent vested on or prior to December&nbsp;31, 2015 after
	giving effect to this Agreement) on December&nbsp;31, 2017, with the exception of the options granted on April&nbsp;15, 2010 and September&nbsp;1, 2010, which will expire on April&nbsp;15, 2020 and September&nbsp;1, 2020, respectively. Options
	granted after the consummation of the Company&#146;s initial public offering (specifically, those granted on December&nbsp;4, 2014,&nbsp;February&nbsp;6, 2015, and those granted pursuant to Section&nbsp;2(b) above) will expire (to the extent vested
	on or prior to December&nbsp;31, 2015 after giving effect to this Agreement) on March&nbsp;30, 2016.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b. With respect to the consulting
	services contemplated hereunder, the Company will indemnify Kappel in respect of any liability he may incur, unless such liability is incurred due to Kappel&#146;s gross negligence or willful misconduct, as a result of his provision of the
	consulting services (including, without limitation, the payment of any reasonable attorneys&#146; fees and costs incurred by him). Kappel will be covered by the Company&#146;s applicable insurance policies with respect to the performance of any such
	services.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	Independent Contractor
</U>
	. During the Consulting Period, Kappel will not be an employee of the Company, but will have the
	relationship of an independent contractor to the Company. As an independent contractor, Kappel shall have no authority to represent, act on behalf of or bind
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage154"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	the Company. The parties agree that all income recognized by Kappel in respect of stock options vesting following
	the date hereof shall be self-employment income reportable on Form 1099. Kappel shall have the sole responsibility and obligation to report such self-employment income on Kappel&#146;s tax returns and to pay such taxes as are required by law, and,
	solely with respect to the income relating to such stock options, the Company shall have no right, responsibility or obligation to withhold income or payroll taxes under the United States Insurance Contributions Act or under state unemployment,
	disability or other laws or to pay employer payroll taxes thereon under such laws or to withhold special or general funds, assessments, or taxes generally collected by employers for the use and benefit of employees.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	Cooperation
</U>
	. Kappel agrees to render assistance and cooperation to the Company as the Company reasonably requests regarding any
	matter, dispute or controversy with which the Company may become involved and of which Kappel has or may have reason to have relevant knowledge, information or expertise. Such services will be without additional compensation if during the Consulting
	Period, and for reasonable compensation (including, without limitation, a per diem fee no less than the ratable base salary amount as was in effect prior to the Employment Termination Date) and subject to Kappel&#146;s reasonable availability if
	after the Consulting Period, provided, that in any event the Company will reimburse Kappel for any expenses reasonably incurred by him in connection with such cooperation. In no event will (i)&nbsp;Kappel have any obligation to cooperate if the
	Company is in breach of this Agreement (or any other agreement to which he is a party with the Company or its affiliates) and (ii)&nbsp;Kappel have an obligation to cooperate in any matter, dispute or controversy involving Kappel as an adverse party
	to the Company or its affiliates.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	Confidentiality
</U>
	. Kappel acknowledges that, during the Consulting Period he may have, and
	during his employment with the Company he has had, access to Confidential Information and materials not generally known outside the Company. For the purposes of this Agreement, &#147;Confidential Information&#148; shall mean all confidential and
	proprietary information and materials (whether conceived or developed by Kappel or others) of the Company, and Company marketing and other business plans, customers and customer information, data strategies, research, reports, copyrights and patents
	related to the Company. During the Consulting Period and thereafter, Kappel shall not, without the prior consent of the Company, communicate or divulge any Confidential Information or materials to anyone other than the Company and its partners or
	affiliates and those designated by the Company unless required by law. Kappel acknowledges that Confidential Information is and shall remain the property of the Company. The confidentiality obligations hereunder shall not apply to Company
	information that would be Confidential Information but which: (i)&nbsp;is, or later becomes, public knowledge other than by breach of this Agreement; (ii)&nbsp;is in the possession of Kappel with the full right to disclose prior to his receipt of
	such Confidential Information from the Company, as evidenced by written records; or (iii)&nbsp;is independently received by Kappel from a third party with no restrictions on disclosure. Furthermore, Kappel agrees not to use, without the
	Company&#146;s approval, Confidential Information for any purposes other than to perform duties for the Company under this Agreement. Kappel also hereby reaffirms his obligations under the Company&#146;s standard confidentiality agreement, executed
	by Kappel on February&nbsp;27, 2013.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage155"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	9.
<U>
	Ownership of Copyrights, Patents, and Intellectual Property
</U>
	. Kappel agrees that any
	work prepared for the Company during his employment therewith and during the Consulting Period which is eligible for copyright and patent protection under the laws of the United States or any other country, and any proprietary know how developed by
	Kappel while rendering services for the Company in any capacity, will vest in the Company. Kappel hereby grants, transfers, and assigns all rights, titles, interests, copyrights and patents in such work, and all renewals and extensions thereof, to
	the Company, and agrees to provide all assistance reasonably requested by the Company in the establishment, preservation and enforcement of the Company&#146;s copyrights and patents in such work. Such assistance will be provided at the
	Company&#146;s expense, but without any additional compensation to Kappel if during the Consulting Period, and for reasonable compensation (including, without limitation, a per diem fee no less than the ratable base salary amount as was in effect
	prior to the Employment Termination Date) and subject to Kappel&#146;s reasonable availability if after the Consulting Period. If the Company cannot, after reasonable effort, secure Kappel&#146;s signature on any documents needed to apply for or to
	prosecute any patent, copyright, or other right or protection relating to an invention, whether because of his physical or mental incapacity or for any other reason, Kappel hereby irrevocably designates and appoints the Company and its duly
	authorized officers and agents as his agent and attorney-in-fact, to act for and on his behalf and in his name and stead for the purpose of executing and filing any such application or applications and taking all other lawfully permitted actions to
	further the prosecution and issuance of patents, copyrights, or similar protections thereon with the same legal force and effect as if executed by him.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	10.
<U>
	Non-Competition
</U>
	. Kappel agrees that, during the Consulting Period and for a period of one year thereafter, he will not, directly or
	indirectly, enter into, organize, control, engage in, be employed by, serve as a consultant to, be an officer or director of, or have any direct or indirect investment in any business, person, partnership, association, firm, corporation, or other
	entity engaged in any business activity (including, but not limited to, research, development, manufacturing, selling, leasing, licensing or providing services) which is competitive with the business of the Company. For the sake of clarity, a
	business competitive with the Company&#146;s business is one that uses bacteriophages, bacteriophage lysins, endolysins or a derivative thereof for the treatment of human infections or the use of antibodies for the treatment of influenza.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	11.
<U>
	Non-Solicitation
</U>
	. Kappel agrees that, for a period of fifteen months after the Employment Termination Date, he will not divert,
	attempt to divert, take advantage of or attempt to take advantage of any actual or potential business or opportunities of the Company which Kappel became aware of as a result of his employment or consulting with the Company. Kappel further agrees
	that, during the Consulting Period and for a period of one year thereafter, he will not hire away any critical individuals who were employed by the Company during the Consulting Period or the one-year period thereafter, nor will Kappel directly or
	indirectly entice, solicit, or seek to induce or influence any such employees to leave their positions at the Company.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12.
<U>
	Non-Disparagement
</U>
	. Kappel and the Company agree that, during the Consulting Period and for a period of five years thereafter, neither will directly or indirectly disparage the other.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage156"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	13.
<U>
	Non-Disclosure
</U>
	. Kappel agrees that, during the Consulting Period and perpetually
	thereafter, he will not disclose, to any party, (i)&nbsp;the terms of this Agreement, including but not limited to the payments made to Kappel hereunder, or (ii)&nbsp;any information pertaining to the negotiation of this Agreement, provided that it
	will not be a breach of this Agreement if Kappel discloses the terms of this Agreement and information pertaining to its negotiation to his personal legal, financial and tax advisors and his family members.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	14.
<U>
	Remedies for Breach
</U>
	. In the event that Kappel willfully and materially breaches obligations under this Agreement, which have not
	been cured after a remedial period provided to Kappel by the Company of at least ten (10)&nbsp;business days, in addition to whatever other rights the Company may have, Kappel shall forfeit his right to receive any payments or benefits under this
	Agreement except with respect to the severance benefits described in Section&nbsp;2 hereof (which shall be provided in all instances other than willful and material breaches of any of Sections 8 through 13 hereof). In the event that the Company
	willfully and materially breaches obligations under this Agreement, which have not been cured after a remedial period provided to the Company by Kappel of at least ten (10)&nbsp;business days, Kappel may cease providing consulting services to the
	Company, although compensation therefor as described in the Agreement will be deemed earned in full and payable and no such breach will relieve the Company from any obligation under the Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	15.
<U>
	Non-Waiver of Breach
</U>
	. Either party may waive any breach of this Agreement by the other party, but no such waiver shall be deemed to
	have been given unless such waiver be in writing, signed by the waiving party and specifically designate the breach waived, nor shall any such waiver constitute a continuing waiver of similar or other breaches.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	16.
<U>
	Non-Assignment
</U>
	. Neither party may assign its obligations hereunder without the prior written consent of the other party.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	17.
<U>
	Release
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a.
<U>
	General Release
</U>
	. In consideration of the payments and benefits provided to Kappel under this Agreement, Kappel and each of his heirs, executors, administrators, representatives, agents, successors and assigns (collectively, the
	&#147;Releasors&#148;) hereby irrevocably and unconditionally waive, release and forever discharge the Company and its subsidiaries and affiliates and each of their respective current and former officers, employees, directors, partners, members,
	shareholders, representatives, attorneys and agents (collectively, the &#147;Released Parties&#148;) from any and all claims, demands, actions, causes of action, rights, judgments, obligations, damages, demands, accountings or liabilities of
	whatever kind or character, whether known or unknown, suspected or unsuspected (collectively, &#147;Claims&#148;), that the Releasors have or may have against the Released Parties that arise out of or are connected to (i)&nbsp;Kappel&#146;s
	relationship with the Company up to and including the dates of the execution of this Agreement, (ii)&nbsp;the Employment Agreement, dated as of October&nbsp;20, 2009, between the Company and Kappel (the &#147;Employment Agreement&#148;), or
	(iii)&nbsp;any event, condition, circumstance, conduct, occurrence, omission, transaction or obligation that occurred, existed or arose on or prior to the date hereof, including, with respect to both clauses (i)&nbsp;and (ii)&nbsp;of this
	Section&nbsp;17(a), without limitation: (1)&nbsp;any Claims under all federal, state and local statutes that employees or service
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage157"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	providers could bring employment or service-related claims under, including, without limitation, any antidiscrimination statute, wage and hour statute, leave statute, equal pay statute,
	whistleblower statute and any other federal, state, local or foreign law, rule or regulation, in each case that may legally be waived and released, and (2)&nbsp;any tort or contract Claims, including, without limitation, wrongful discharge, breach
	of contract, defamation, slander, libel, emotional distress, tortious conduct, invasion of privacy, wrongful or retaliatory discharge, violation of public policy, implied covenant of good faith and fair dealing, negligence, fraud, personal injury or
	sickness or any other harm. Kappel does not release, discharge or waive (A)&nbsp;any right Kappel may have to enforce this Agreement, (B)&nbsp;any Claims made under state workers&#146; compensation or unemployment laws, (C)&nbsp;Claims that cannot
	be waived by law, (D)&nbsp;Claims for vested benefits under the Company&#146;s employee benefit plans including equity compensation plans and grants thereunder to the extent vested or to be vested, or (E)&nbsp;Claims to indemnification,
	contribution, exculpation, directors and officers insurance or other insurance (e.g., executives and officers).
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b.
<U>
	Proceedings
</U>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	i.
<U>
	General Agreement Relating to Proceedings
</U>
	. Kappel has not filed, and except as provided in Section&nbsp;17(b)(ii) hereof,
	Kappel agrees not to initiate or cause to be initiated on his behalf, any complaint, charge, claim or proceeding against the Released Parties before any local, state or federal agency, court or other body relating to matters released pursuant to
	Section&nbsp;17 (each, individually, a &#147;Proceeding&#148;), and agrees not to participate voluntarily in any Proceeding. Kappel waives any right he may have to benefit in any manner from any relief (whether monetary or otherwise) arising out of
	any Proceeding.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	ii.
<U>
	Certain Administrative Proceedings
</U>
	. Section&nbsp;17(b)(i) hereof shall not preclude Kappel from filing a
	charge with or participating in any administrative investigation or proceeding by the Equal Employment Opportunity Commission or another Fair Employment Practices agency. Kappel is, however, waiving his right to recover money in connection with any
	such charge or investigation. Kappel is also waiving his right to recover money in connection with a charge filed by any other entity or individual, or by any federal, state or local agency.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	18.
<U>
	Section&nbsp;409A
</U>
	. This Agreement is intended to comply with Section&nbsp;409A of the Internal Revenue Code of 1986, as amended
	(&#147;Section 409A&#148;) or an exemption thereunder and shall be construed and administered in accordance with Section&nbsp;409A. Notwithstanding any other provision of this Agreement, payments and benefits provided under this Agreement may only
	be made upon an event and in a manner that complies with Section&nbsp;409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section&nbsp;409A either as separation pay due to an involuntary separation from
	service or as a short-term deferral shall be excluded from Section&nbsp;409A to the maximum extent possible. For purposes of Section&nbsp;409A, each installment payment provided under this Agreement shall be treated as a separate payment.
	Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section&nbsp;409A and in no event shall the Company be liable for all or any portion of any taxes,
	penalties, interest or other expenses that may be incurred by Kappel on account of non-compliance with Section&nbsp;409A. The parties agree that the treatment of equity compensation outstanding hereunder is not a material modification to
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage158"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	any such equity compensation. The parties further agree that the payment schedule for severance compensation payable hereunder would not result in a violation of Section&nbsp;409A (including the
	requirement that any compensation be subject to any six-month delay for specified employees), and the Company agrees to report such treatment consistent therewith.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	19.
<U>
	Severability
</U>
	. Provisions of this Agreement are severable. If any provision is held to be invalid or unenforceable it shall not
	affect the validity or enforceability of any other provision.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	20.
<U>
	Entire Agreement
</U>
	. This Agreement (and the applicable equity
	compensation arrangements referenced herein) represents the sole and entire agreement between the parties and, except as expressly stated herein, supersedes the Employment Agreement and all prior agreements, negotiations and discussions between
	Kappel and the Company, with respect to the subject matters contained herein.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	21.
<U>
	Governing Law
</U>
	. This Agreement shall be construed
	as a whole in accordance with its fair meaning and in accordance with the laws of the State of New York. The language in the Agreement shall not be construed for or against any particular party.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	22.
<U>
	Headings
</U>
	. The headings used herein are for reference only and shall not affect the construction of this Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	23.
<U>
	Disputes
</U>
	. The parties agree that any and all disputes, controversies or claims arising out of or relating to this Agreement, or
	breach thereof, shall be submitted to final and binding arbitration pursuant to the employment arbitration rules of the American Arbitration Association. The arbitration shall take place in the State of New York.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	24.
<U>
	Miscellaneous
</U>
	. Payments and benefits under this Agreement are not subject to mitigation or offset, except as expressly stated herein
	with respect to COBRA. This Agreement will be binding upon and inure to the benefit of the parties&#146; successors and heirs. This Agreement can be executed in counterparts, which together will constitute the binding agreement of the parties, and
	electronic copies shall have the effect of originals.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	[The remainder of this page is intentionally left blank.]
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage159"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed as of the day and
	year written below.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="43%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="43%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" COLSPAN="3">
<B>
	THE COMPANY
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Barry Kappel
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Julia P Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Dr. Barry Kappel
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Julia P Gregory
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Chief Executive Officer
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Date: April 15, 2015
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Date:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	April 15, 2015
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage160"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Exhibit A: Joint Statement
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:6%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On April&nbsp;15, 2015, Barry Kappel resigned from his position as Senior Vice President of Business Development of ContraFect Corporation to
	pursue other opportunities. He will serve as a consultant to ContraFect until December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage161"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Exhibit B: Schedule of Options
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="18%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="16%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:18.20PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
	Grant
<BR>
	Date
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
	Number
<BR>
	of&nbsp;Options
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Vesting Schedule
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
	Shares/Percentage
<BR>
	Vested as of
<BR>
	4-15-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Additional Shares
<BR>
	Originally Scheduled to
<BR>
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Vest&nbsp;by&nbsp;12-31-15
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Additional Shares that
<BR>
	Will Vest
	Under
<BR>
	Consulting
<BR>
	Agreement&nbsp;by&nbsp;12-31-15
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
	Total Vested
<BR>
	Shares/Percentage
<BR>
	Under Consulting
<BR>
	Agreement&nbsp;as&nbsp;of
<BR>
	12-31-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
	Shares
<BR>
	Forfeited
<BR>
	Under
<BR>
	Consulting
<BR>
	Agreement
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	2-27-13
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,714
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,285/75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	0
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	1,429/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,714/100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	1-1-13;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	7-1-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	annually
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	over next
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	three
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	years
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	3-21-14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,285
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,143/50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	0
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,571/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,714/75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,571/25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	2-24-14;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	8-24-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	annually
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	over next
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	three
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	years
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	4-29-14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,857
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,464/25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4,464/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4,464/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,392/75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,465/25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4-29-14;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4-29-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4-29-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	annually
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	4,464/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	over next
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	10-29-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	three
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	years
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	12-4-14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,000/25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	5,000/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	5,000/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,000/75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,000/25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	12-4-14;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	12-4-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	6-4-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	annually
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	5,000/25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	over next
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	12-4-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	three
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	years
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	2-6-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	1/16 on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,125/6.25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,875/43.75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,125/56.25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	each
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	6-30-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	on 5-15-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	calendar
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	quarter
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	end
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	9-30-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	on 6-30-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	through
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	2018
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25% on
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	12-31-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	on 8-15-15
</P>
<P STYLE="FONT-SIZE:6PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT" ALIGN="LEFT">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	on 9-30-15
</P>
<P STYLE="FONT-SIZE:6PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT" ALIGN="LEFT">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	on 11-15-15
</P>
<P STYLE="FONT-SIZE:6PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT" ALIGN="LEFT">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	3,125/6.25%
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	on 12-31-15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage162"></A>
<A NAME="D109824DEX1021_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_3"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.21
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Amendment No.&nbsp;1 to Employment Agreement with Daniel E. Couto
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This Amendment No.&nbsp;1 (the
<U>
	&#147;Amendment
</U>
	&#148;) is entered into by and between ContraFect Corporation (the &#147;
<U>
	Employer
</U>
	&#148;), and
	Daniel E. Couto, (the
<U>
	&#147;Employee
</U>
	&#148;), as of November&nbsp;2, 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS, pursuant to Section&nbsp;15 of the Employment
	Agreement, the Employer and the Employee desire to amend the Employment Agreement in accordance with the terms of this Amendment, as more fully set forth herein.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	THEREFORE, in consideration of the mutual agreements set forth below, the Employer and the Employee agree to amend the Employment Agreement as
	follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	1.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;4 of the Employment Agreement is amended by adding the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;You will be eligible for
	an annual incentive bonus of 30% of your annual base salary, subject to performance against mutually agreed-upon goals (effective January&nbsp;1, 2016, 70% corporate/30% individual). You will also be eligible for stock option grants on an annual
	basis.
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	2.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;7d of the Employment Agreement is amended to include:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;In the event that you are terminated
	by the Company without Cause, or in the event that you resign with Good Reason, as defined below, you will be given (i)&nbsp;a severance payment in the amount that is equal to twelve (12)&nbsp;months of your then-current base salary, (ii)&nbsp;a
	payment equal to twelve (12)&nbsp;months of bonus and (iii)&nbsp;a payment equal to twelve (12)&nbsp;months of applicable health insurance premiums (inclusive of dental and vision insurance) due under COBRA, provided that you first sign a Severance
	and Release Agreement in a form prescribed by the Company. These severance payments shall be paid over twelve (12)&nbsp;months as any regular paycheck.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;Good Reason&#148; shall mean the occurrence of any of the events or conditions as described here: (i)&nbsp;a material diminution of your authority,
	duties and responsibilities; (ii)&nbsp;a material reduction in your then-effective base salary, or (iii)&nbsp;the relocation of your principal place of employment to a location that is more than fifty (50)&nbsp;miles &#147;as the crow flies&#148;
	from Yonkers, New York. Employee must provide written notice (&#147;Notice of Good Reason&#148;) to Employer of the existence of a condition described in subsections (i)&nbsp;through (iii)&nbsp;above within 30 days of Employee&#146;s knowledge of
	the initial existence of the condition or such right is waived. The Notice of Good Reason shall fully set forth the facts comprising the event(s) or circumstance(s) giving rise to Good Reason.
</P>
<A NAME="eolPage163"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Employer shall have a period (the &#147;Good Reason Notice Period&#148;) of 30 days during which it may remedy
	the condition so that it shall not constitute Good Reason or inform Employee that it does not believe Good Reason exists. If Employee believes that the condition has not been cured, or that Good Reason exists notwithstanding Employer&#146;s belief
	that it does not, then Employee shall either abandon the contention that Good Reason exists or terminate employment within 30 days. If Employee continues to work beyond the 30
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	th
</SUP>
	day without
	resigning, Employee shall be deemed to have waived Good Reason for the event(s) or circumstance(s) set forth in the Notice of Good Reason. &#147;If there is a Change of Control Event and, within twelve (12)&nbsp;months of such Change of Control
	Event, you resign for Good Reason or you are terminated without Cause, you will receive the severance benefits as outlined above, and, in addition, your then-outstanding stock options and other equity awards, if any, will become immediately fully
	vested and exercisable. All such benefits are conditioned upon the execution of a Severance and Release Agreement in a form prescribed by the Company or its successors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;A &#147;Change of Control Event&#148; means any of the following: (i)&nbsp;any person, or persons acting as a group, or entity (except for a current
	stockholder) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company; (ii)&nbsp;a change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are
	Incumbent Directors. &#147;Incumbent Directors&#148; shall mean directors who either (a)&nbsp;are directors of the Company as of the date hereof, or (a)&nbsp;are elected, or nominated for election, to the Board with the affirmative votes of at least
	a majority of those directors whose election or nomination was not in connection with any transaction described in subsections (i), (iii)&nbsp;or (iv)&nbsp;or in connection with an actual or threatened proxy contest relating to the election of
	directors of the Company; (iii) a merger or consolidation with another entity where the voting securities of the Company outstanding immediately before the transaction constitute less than a majority of the voting power of the voting securities of
	the surviving entity outstanding immediately after the transaction, or (iv)&nbsp;the sale or disposition of all or substantially all of the Company&#146;s assets.&#148;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<U>
	Section&nbsp;409A
</U>
	. The Company and you intend, and this Amendment No.&nbsp;1 to the Employment Agreement shall be construed, that any amounts or
	benefits payable or provided under this Amendment and the Company&#146;s and your exercise of authority or discretion hereunder shall either be exempt from or comply with the provisions of Section&nbsp;409A of the Internal Revenue Code of 1986, as
	amended (&#147;the Code&#148;) and the treasury regulations relating thereto so as not to subject you to the payment of the tax, interest and any tax penalty which may be imposed under Code Section&nbsp;409A. The provisions of this Amendment shall
	be
</P>
<A NAME="eolPage164"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	interpreted and construed in a manner consistent with such intent. In the event that any provision of this
	Amendment would otherwise fail to satisfy the requirements of Section&nbsp;409A and the treasury regulations relating thereto, the Company and you agree to further amend this Amendment to maintain to the maximum extent practicable the original
	intent of the provision without violating the requirements of Code Section&nbsp;409A. Notwithstanding anything in this Amendment, you acknowledge and agree that the Company has not made any representations to you as to the tax treatment of any
	payments or benefits under this Amendment, and the Company does not guarantee the tax treatment of any payments or benefits under this Agreement, including without limitation pursuant to Section&nbsp;409A of the Code, federal, state, or local tax
	laws or regulations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	[Remainder of page intentionally left blank.]
</P>
<A NAME="eolPage165"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed and delivered as of the date first
	written above.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	EMPLOYER:
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Julia P Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Julia P Gregory
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	CEO
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	EMPLOYEE:
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Daniel E. Couto
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	Daniel E. Couto
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage166"></A>
<A NAME="D109824DEX231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We consent to the incorporation by reference in the Registration Statement (Form S-8 No.&nbsp;333-199046) pertaining to the ContraFect Corporation Amended and
	Restated 2008 Equity Incentive Plan and the ContraFect Corporation 2014 Omnibus Incentive Plan of our report dated March&nbsp;15, 2016, with respect to the financial statements of ContraFect Corporation included in this Annual Report (Form 10-K) for
	the year ended December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:54%; TEXT-INDENT:-2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Ernst&nbsp;&amp; Young LLP
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	MetroPark, New Jersey
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	March 15, 2016
</P>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage167"></A>
<A NAME="D109824DEX311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 31.1
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	I, Julia P. Gregory,
	certify that:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1. I have reviewed this Annual Report on Form 10-K of ContraFect Corporation;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
	make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
	respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
	defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
	registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
	financial reporting; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
	internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
	reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
	internal control over financial reporting.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Date: March 15, 2016
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Julia P. Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Julia P. Gregory
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Chief Executive Officer
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	(Principal Executive Officer)
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage168"></A>
<A NAME="D109824DEX312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 31.2
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	I, Michael Messinger,
	certify that:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1. I have reviewed this Annual Report on Form 10-K of ContraFect Corporation;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
	make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
	respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
	defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
	supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
	registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
	financial reporting; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
	internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
	reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
	internal control over financial reporting.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Date: March 15, 2016
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Michael Messinger
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Michael Messinger
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Vice President, Finance
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	(Principal Financial Officer)
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage169"></A>
<A NAME="D109824DEX321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 32.1
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In connection with this Annual Report on Form 10-K of ContraFect Corporation (the &#147;Company&#148;) for the year ended December&nbsp;31, 2015, as filed
	with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Julia P. Gregory, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that, to her knowledge on
	the date hereof:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of
	1934; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
	operations of the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Date: March 15, 2016
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Julia P. Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Julia P. Gregory
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chief Executive Officer
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(Principal Executive Officer)
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage170"></A>
<A NAME="D109824DEX322_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 32.2
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In connection with this Annual Report on Form 10-K of ContraFect Corporation (the &#147;Company&#148;) for the year ended December&nbsp;31, 2015, as filed
	with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Michael Messinger, Vice President, Finance of the Company, hereby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, that, to his knowledge on
	the date hereof:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of
	1934; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
	operations of the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Date: March 15, 2016
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Michael Messinger
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Michael Messinger
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vice President, Finance
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(Principal Financial Officer)
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
